Clinical Trials Card Agent — 2026-07-08

Conditions: PACVS, Long COVID/PASC, ME/CFS | Total: 622

Generated automatically. Data from ClinicalTrials.gov.


Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
NCT07388550
NOT_YET_RECRUITING • PHASE1 • Updated 2026-07-07 UPDATED
Conditions: Long COVID / PASC
AGENTS
Keytruda
Background: SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from an acute COVID-19 infection may continue to have symptoms that persist for months or years. These can include neurological symptoms, such as headaches, loss of taste or smell, dizziness, or trouble walking. Pembrolizumab is a drug approved to treat certain cancers. Researchers think this dru...
View on ClinicalTrials.gov →
General Phase 1 Small (<50 participants) Enrollment: Estimated Sponsor Type: Nih
Taurine Supplementation in Adolescents With Post-COVID Condition
NCT07682402
NOT_YET_RECRUITING • PHASE1 • Updated 2026-07-07 UPDATED
Conditions: Long COVID / PASC
AGENTS
Taurine
The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection. This condition, known as Long COVID (LC) or sometimes referred...
View on ClinicalTrials.gov →
Metabolic Neurological / Autonomic Phase 1 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
A Pilot rTMS Trial for Neuropsychiatric Symptoms of Long-COVID
NCT06586398
COMPLETED • NA • Updated 2026-07-06
Conditions: Long COVID / PASC
AGENTS
Rtms
This is a pilot randomized trial of rTMS for symptoms of fatigue and brain fog, and other neuropsychiatric symptoms of Long-COVID (Post-COVID, post-acute sequelae of COVID-19 infection, PASC). Twenty participants diagnosed with Long-COVID and recruited from the UCLA Long-COVID clinic will be randomized to receive active rTMS versus sham stimulation for 15 treatments followed by...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Balance Acceptance and Commitment Therapy for Long COVID
NCT06231238
ACTIVE_NOT_RECRUITING • NA • Updated 2026-07-02
Conditions: Long COVID / PASC
AGENTS
Balance Acceptance And Commitment Therapy
This randomised controlled trial aims to investigate the efficacy of a psychological intervention for long COVID (LC) / post-COVID-19 syndrome (PCS) called Balance Acceptance and Commitment Therapy (Balance ACT). The primary objective of this trial is to investigate whether Balance-ACT improves quality of life over treatment as usual (i.e., self-help leaflet) in people with PC...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Education of Medical Staff to Post Acute Covid susTained sYmptoms
NCT06082258
WITHDRAWN • NA • Updated 2026-07-01
Conditions: Long COVID / PASC
AGENTS
Training In The Management Of Functional DisordersReimbursement Of 3 Long Consultations
Evaluation of the effectiveness of a training and support intervention for general practitioners treating patients with persistent symptoms after a COVID-19 episode on the patients'quality of life at 3 months.
View on ClinicalTrials.gov →
General NA Enrollment: Actual Sponsor Type: Other
Dapagliflozin for Long COVID Syndrome
NCT06907251
NOT_YET_RECRUITING • PHASE3 • Updated 2026-07-01
Conditions: Long COVID / PASC
AGENTS
Dapagliflozin
This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.
View on ClinicalTrials.gov →
General Phase 3 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19
NCT06821087
COMPLETED • PHASE2 • Updated 2026-06-29
Conditions: Long COVID / PASC
AGENTS
Ketamine Only
Plain Language Summary: This study is a clinical trial to see if ketamine can help treat symptoms of Long COVID, especially fatigue and problems with thinking clearly (often called "brain fog"). Long COVID is a condition that affects people even after they have recovered from COVID-19, causing ongoing health issues like tiredness, memory problems, and difficulty concentrating....
View on ClinicalTrials.gov →
Neurological / Autonomic Anti-inflammatory Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Fluvoxamine for Long COVID-19
NCT05874037
COMPLETED • PHASE2 • Updated 2026-06-25
Conditions: Long COVID / PASC
AGENTS
Fluvoxamine
This clinical trial aims to test the effects of fluvoxamine as a treatment for Long COVID. Fluvoxamine is an FDA approved SSRI for Obsessive Compulsive Disorder (OCD), that has already had success in preventing hospitalization in patients with COVID-19 (STOP COVID and TOGETHER trials). This trial is testing whether fluoxamine helps to improve symptoms and the negative impacts o...
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Dietary Intervention to Mitigate Post-Acute COVID-19 Syndrome
NCT05977179
RECRUITING • NA • Updated 2026-06-23
Conditions: Long COVID / PASC
AGENTS
Dietary Intervention To Mitigate Post-Acute Covid-19 Syndrome
The primary objective of this study is to conduct a 16-week randomized controlled trial aimed at investigating the effectiveness of the Whole-Diet Approach when following a healthy US-style diet rich in anti-inflammatory properties. The study will focus on evaluating its impact on reducing symptoms related to Post-Acute Sequelae of SARS-CoV-2 Infection (PACS) in adults aged 50 ...
View on ClinicalTrials.gov →
Anti-inflammatory NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
PERCEIVE-Outreach: A Scalable, Risk-Based Model for Managing Persistent Cardiovascular Impact in Long COVID
NCT07661862
RECRUITING • NA • Updated 2026-06-22
Conditions: Long COVID / PASC
AGENTS
Perceive-Outreach Intervention
Some people who had COVID-19 continue to have symptoms for weeks, months, or even years after their infection. This is often called "Long COVID" or Post-Acute Sequelae of SARS-CoV-2 (PASC). For some people, Long COVID can affect the heart and lungs, making it harder to exercise or carry out daily activities. It can also affect mental health and quality of life. This study is t...
View on ClinicalTrials.gov →
General NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
Water-based Activity to Enhance Recovery in Long COVID-19
NCT06142253
RECRUITING • NA • Updated 2026-06-18
Conditions: Long COVID / PASC
AGENTS
Water+Ct
This two-year study will evaluate the feasibility and safety of an exercise + cognitive training program to improve neurological symptoms of long-COVID. This is a two-phased trial: 1) an exercise phase and 2) a cognitive training phase. The exercise phase will be an aquatic based exercise program. A combination exercise + memory training programs designed for persons with cogni...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Fed
A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID
NCT06974084
NOT_YET_RECRUITING • PHASE2 • Updated 2026-06-18
Conditions: Long COVID / PASC
AGENTS
MaravirocAtorvastatin, 10Mg, 20Mg, 40Mg
The IMPACT Long Covid Treatment clinical study (IMPACT-LC) is testing two repurposed and previously approved drugs, Maraviroc and Atorvastatin, for the treatment of non-hospitalized subjects with Long COVID. The main goals of the clinical study are to determine if this combination drug therapy can improve neurocognitive and physical functions in Long Covid patients, such as fat...
View on ClinicalTrials.gov →
Repurposed Neurological / Autonomic Phase 2 Large (200-999 participants) Enrollment: Estimated Sponsor Type: Industry
Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation
NCT05967052
TERMINATED • PHASE2 • Updated 2026-06-17
Conditions: ME/CFS
AGENTS
PregabalinIndependent Walking TrainingGradual Movement Therapy In The WardTelerehabilitationPsychotherapy
This is a single-center, prospective, randomized, double-blind (pharmacotherapy), placebo-controlled, and comprehensive rehabilitation phase II clinical trial to determine the usefulness of pregabalin in a new indication (post-COVID chronic fatigue syndrome). Patients will be randomized in a 1:1:1:1 ratio to pregabalin (75-300 mg daily in two divided doses), comprehensive reha...
View on ClinicalTrials.gov →
General Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Network
Effects of a Physical Rehabilitation Program on Long COVID
NCT07651371
COMPLETED • NA • Updated 2026-06-16
Conditions: Long COVID / PASC
AGENTS
Physical RehabilitationTreadmill ErgometerPulley
The objective of this clinical trial is to analyze the clinical, functional, and laboratory effects of a rehabilitation protocol designed for patients with long COVID; it may include any of the following: sex/gender, age groups, healthy volunteers. The main questions it aims to answer are: Does handgrip strength improve after the intervention? Does the 6-minute walk test impro...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
NCT05350774
ENROLLING_BY_INVITATION • PHASE2 • Updated 2026-06-12
Conditions: Unspecified / Overlap
AGENTS
Iv Normal SalineIv Immunoglobulin
Background: COVID-19 can cause problems in different parts of the body. For most people, it causes fevers or trouble breathing. Some people might not recover all the way. Researchers want to see if a treatment can help with people who have recovered from COVID-19 but still have symptoms ("Long COVID"). Objective: To learn if human immunoglobulin (IVIG) will help with neurolo...
View on ClinicalTrials.gov →
Immunomodulatory Anti-inflammatory Phase 2 Small (<50 participants) Enrollment: Estimated Sponsor Type: Nih
sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19
NCT07359482
RECRUITING • PHASE3 • Updated 2026-06-09
Conditions: Long COVID / PASC
AGENTS
Fluvoxamine
Fatigue, cognitive problems, post-exertional malaise (PEM) and postural orthostatic tachycardia syndrome (POTS) are common and debilitating symptoms after COVID-19. The pathophysiology of post-COVID is not well understood and there is no established biomedical treatment. Treatment options for post-COVID are thus much needed. A promising candidate intervention is fluvoxamine, a...
View on ClinicalTrials.gov →
Immunomodulatory Neurological / Autonomic Phase 3 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog
NCT06614309
RECRUITING • NA • Updated 2026-06-05
Conditions: Long COVID / PASC
AGENTS
Acute Progressive Carbon DioxideAcute Intermittent HypoxiaTraining: Progressive Carbon Dioxide RampingTraining: Intermittent Hypoxic Exposure
This study aims to assess the effects of both acute and chronic exposures to hypoxia and hypercapnia in patients with Long COVID syndrome.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID
NCT07627815
RECRUITING • PHASE2 • Updated 2026-06-04
Conditions: Long COVID / PASC
AGENTS
Paragon Novel Metabolic RegulatorDietary And Lifestyle Recommendations
This will be a six-week, randomized, parallel, two group, open-label design. Patients will be treated with Paragon Novel Metabolic Regulator (PNMR) + standard of care (SOC) or SOC alone for 6 weeks for the treatment of Long COVID. All patients will also be provided with with Dietary \& Lifestyle recommendations specifically designed to enhance immune system function and reduce ...
View on ClinicalTrials.gov →
Metabolic Immunomodulatory Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Industry
Diaphragmatic Breathing Exercises With KOTS Currents in Patients With Long COVID
NCT07621588
NOT_YET_RECRUITING • NA • Updated 2026-06-04
Conditions: Long COVID / PASC
AGENTS
Diaphragmatic Electrostimulation Using Kots CurrentsDiaphragmatic Breathing Exercises
This study will evaluate the effects of diaphragmatic breathing exercises combined with diaphragmatic electrostimulation using KOTS currents in patients with Long COVID. Participants will be randomly assigned to one of two groups. The control group will perform diaphragmatic breathing exercises, while the intervention group will perform diaphragmatic breathing exercises combine...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)
NCT06404099
COMPLETED • PHASE2 • Updated 2026-06-03
Conditions: Long COVID / PASC
AGENTS
ModafinilSolriamfetol
The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. For example, objectives, measures, and endpoints are generalized in the platform...
View on ClinicalTrials.gov →
General Phase 2 Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)
NCT06404112
COMPLETED • PHASE2 • Updated 2026-06-03
Conditions: Long COVID / PASC
AGENTS
MelatoninTailored Lighting (Tl) Active
The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. For example, objectives, measures, and endpoints are generalized in the platform...
View on ClinicalTrials.gov →
General Phase 2 Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Evaluating the Effects of a Fermented Diet on Microbiome Diversity in Individuals With Long COVID
NCT06560554
ENROLLING_BY_INVITATION • NA • Updated 2026-06-03
Conditions: Long COVID / PASC
AGENTS
Fermented Foods
The purpose of this study is to evaluate the effects of fermented foods on bacterial gut microbiome diversity of long-COVID subjects.
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)
NCT06305793
ACTIVE_NOT_RECRUITING • PHASE2 • Updated 2026-06-03
Conditions: Long COVID / PASC
AGENTS
IVIG (Intravenous Immunoglobulin)Coordinated Care
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for us...
View on ClinicalTrials.gov →
Immunomodulatory Neurological / Autonomic Phase 2 Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
NE3107 in Adults With Neurological Symptoms of Long COVID
NCT06847191
ACTIVE_NOT_RECRUITING • PHASE2 • Updated 2026-05-29
Conditions: Long COVID / PASC
AGENTS
Ne3107
Long COVID is a condition where debilitating symptoms can persist for months after a COVID-19 infection. This study aims to evaluate the effects of NE3107 on several neurological symptoms reported in people with Long COVID including difficulty concentrating or remembering things ("brain fog") and fatigue. Researchers will compare NE3107 to a placebo (a look-alike substance tha...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Large (200-999 participants) Enrollment: Actual Sponsor Type: Industry
A Study of Positive Emotions With Long COVID-19
NCT05676008
ACTIVE_NOT_RECRUITING • NA • Updated 2026-05-29
Conditions: Long COVID / PASC
AGENTS
Microdosing Of Mindfulness
This study is testing a new brief mindfulness practice for people suffering from long COVID-19 symptoms. People suffering from long COVID are particularly vulnerable to negative emotions, as they must also cope with the long-term uncertainty of physical and psychological stress beyond the acute infection. The goal of the study is to measure the ability of a brief mindfulness pr...
View on ClinicalTrials.gov →
General NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
Diagnostic and Clinical Management of Non-Obstructive Myocardial Ischemia in Patients With Long Covid-19 Syndrome and New Onset Chest Pain
NCT07559994
ACTIVE_NOT_RECRUITING • NA • Updated 2026-05-28
Conditions: Long COVID / PASC
AGENTS
Coronary Functional Test
Long Covid-19 INOCA is an investigator-initiated, prospective, randomized, sham-controlled, single center study. Its objective is to investigate the benefits of tailored medical therapy according to the results of the coronary functional testing (CFT) against the routine standard of care and the prevalence and endotypes of ischemia with non-obstructive coronary arteries (INOCA)...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Taurine Supplementation in Long COVID
NCT06721949
RECRUITING • PHASE2 • Updated 2026-05-27
Conditions: Long COVID / PASC
AGENTS
Taurine
The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection. This condition, known as Long COVID (LC) or sometimes referred...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
Brain-Training Treatment for Long COVID in Older Adults
NCT05705193
ACTIVE_NOT_RECRUITING • NA • Updated 2026-05-26
Conditions: Long COVID / PASC
AGENTS
Neuroflex
This research is being done to collect preliminary data on the potential of computerized "brain-training" exercises for treating Long COVID symptoms in older adults. The investigators hypothesize that computerized brain-training will be an acceptable and feasible intervention for treating Long COVID symptoms in older adults. The investigators also expect to provide initial evid...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)
NCT07076862
RECRUITING • EARLY_PHASE1 • Updated 2026-05-22
Conditions: Long COVID / PASC
AGENTS
A.1 - [¹⁸F]F-Arag Pet/CtA.2 - [¹⁸F]F-Arag Pet/CtB.1 - [¹⁸F]F-Arag Pet/CtB.2 - [¹⁸F]F-Arag Pet/Ct
This study uses total-body \[¹⁸F\]F-AraG PET/CT imaging to investigate immune activation and vascular changes in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Participants will undergo dynamic PET/CT imaging along with blood biomarker assessments and symptom evaluations. The study aims to characterize sites of immunological pertu...
View on ClinicalTrials.gov →
Immunomodulatory EARLY_Phase 1 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) to Improve Fatigue, Pain, and Quality of Life by Targeting Mitochondrial Dysfunction and Autonomic Nervous System Impairment
NCT07317401
NOT_YET_RECRUITING • NA • Updated 2026-05-22
Conditions: ME/CFS
AGENTS
Intermittent Hypoxia-Hyperoxia Treatment
This study is testing a new treatment for people with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and long-term symptoms after COVID-19. Both conditions cause extreme fatigue, muscle pain, "brain fog," and trouble concentrating, which often get worse after physical or mental activity. Currently, no effective treatments are available. The treatment being studied...
View on ClinicalTrials.gov →
Metabolic Mitochondrial Neurological / Autonomic Anti-inflammatory NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
AT1001 for the Treatment of Long COVID
NCT05747534
ACTIVE_NOT_RECRUITING • PHASE2 • Updated 2026-05-22
Conditions: Long COVID / PASC
AGENTS
Larazotide Acetate
The primary objective of this study is to evaluate the safety and efficacy of Larazotide (AT1001) versus placebo in children and adults 7 to ≤50 years of age who present with symptoms of Long COVID in the presence of SARS-CoV-2 antigenemia. AT1001 (n=100) or placebo (n=50) will be administered orally four times a day (QID) for 21 days.
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Fareon Open Label Device Clinical Trial
NCT07600320
NOT_YET_RECRUITING • NA • Updated 2026-05-20
Conditions: Unspecified / Overlap
AGENTS
Fareon Device
The purpose of this study is to assess the safety and feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to acquired brain injury, Long COVID, traumatic brain injury, myalgic encephalomyelitis (ME/CFS), and other neurodegenerative diagnoses including but not limited to Alzheimer's disease and to collect data on safety and efficacy to inform t...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction
NCT07597902
NOT_YET_RECRUITING • PHASE2 • Updated 2026-05-19
Conditions: Long COVID / PASC
AGENTS
ValacyclovirCelecoxibPaxlovid (Nirmatrelvir/Ritonavir)
The purpose of this research study is to test if the combination of three drugs, valacyclovir, celecoxib, and Paxlovid will decrease the symptoms of Long COVID in adults compared to a placebo (this does not contain the medications).
View on ClinicalTrials.gov →
Persistence / Antiviral Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
NCT07224490
RECRUITING • PHASE1 • Updated 2026-05-19
Conditions: Long COVID / PASC
AGENTS
Kisspeptin 112-121
The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin. This study will utilize the technique of frequent blood sampling (q10 minutes) to provide detailed neuroendocrine characteriz...
View on ClinicalTrials.gov →
General Phase 1 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Fatigability in Long COVID-19
NCT05699538
COMPLETED • NA • Updated 2026-05-18
Conditions: Long COVID / PASC
AGENTS
Minimal-Dose Home-Based Resistance Exercise
The overall goal of this project is to advance the understanding of underlying mechanisms impacting performance fatigability and perceived fatigability in Veterans with post-COVID-19 fatigue and explore the safety and feasibility of a home-based "minimal-dose" resistance exercise program in this population. The central hypothesis is that declines in force capacity, skeletal mus...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Fed
Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19
NCT06960928
RECRUITING • PHASE3 • Updated 2026-05-18
Conditions: Long COVID / PASC
AGENTS
Sirolimus (low-dose)
The study is conducted in New York, New York at The Cohen Center for Recovery from Complex Chronic Illness at Mount Sinai. This is an IND-exempt, off-label, multi-ascending, randomized, placebo-controlled clinical trial of sirolimus (also known as rapamycin) in adults with Long COVID. There are 2 arms: Sirolimus and Placebo. This study aims to evaluate the efficacy of Sirolim...
View on ClinicalTrials.gov →
Immunomodulatory Repurposed Phase 3 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Intermittent Fasting and a No-Sugar Diet for Long COVID Symptoms
NCT06214455
COMPLETED • NA • Updated 2026-05-14
Conditions: Long COVID / PASC
AGENTS
Low Sugar Diet And 10-12 Hour Eating WindowLow Sugar Diet, 8 Hour Eating Window And Fasting
This cross-over study will assess a no added sugar diet, a restricted daily eating window, and one or two full day water fasts to determine if there is an effect on self-reported symptoms of Long Covid (PASC).
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine Injury
NCT07567274
ENROLLING_BY_INVITATION • PHASE2 • Updated 2026-05-13
Conditions: Unspecified / Overlap
AGENTS
Dmso-Based Otic Solution With Betahistine, Dexamethasone, And LidocaineN-Acetylcysteine (NAC)
The goal of this clinical trial is to test a compounded dimethyl sulfoxide (DMSO)-based dual-route therapy for adults with refractory subjective tinnitus linked to long-COVID (post-acute sequelae of SARS-CoV-2) or post-COVID-19 vaccine injury. Participants have bothersome tinnitus that has not improved with at least two prior standard treatments. All participants will receive ...
View on ClinicalTrials.gov →
General Phase 2 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
A Study to Examine Anktiva for the Treatment of COVID-19.
NCT07123727
RECRUITING • PHASE2 • Updated 2026-05-13
Conditions: Long COVID / PASC
AGENTS
Anktiva
This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.
View on ClinicalTrials.gov →
General Phase 2 Small (<50 participants) Enrollment: Estimated Sponsor Type: Industry
Pain Relief With Integrative Medicine (PRIMe)?: Feasibility of Acupuncture for Long COVID
NCT06476496
COMPLETED • NA • Updated 2026-05-12
Conditions: Long COVID / PASC
AGENTS
Acupuncture
The goal of this preliminary study is to test methods and procedures to be used in a fully-powered trial to evaluate acupuncture treatment effectiveness. Specifically, we will test the feasibility of conducting a 2-arm randomized clinical trial for evaluating the effectiveness of acupuncture for pain in patients with long COVID. Researchers will compare pain intensity and impac...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
A Study to Assess Anktiva in Patients With Long Covid-19.
NCT07108036
RECRUITING • PHASE2 • Updated 2026-05-11
Conditions: Long COVID / PASC
AGENTS
N-803
This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.
View on ClinicalTrials.gov →
General Phase 2 Small (<50 participants) Enrollment: Estimated Sponsor Type: Industry
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
NCT06631287
RECRUITING • PHASE3 • Updated 2026-05-11
Conditions: Long COVID / PASC
AGENTS
Baricitinib
The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomarkers of inflammation and viral measures, in participants with Long COVID.
View on ClinicalTrials.gov →
Neurological / Autonomic Anti-inflammatory Phase 3 Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
NC Testing in LC & POTS
NCT05914649
RECRUITING • NA • Updated 2026-05-07
Conditions: Unspecified / Overlap
AGENTS
Iv Normal Saline
Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Post-Acute Sequelae of COVID (PASC, or "Long COVID") experience cognitive dysfunction. The investigators will test the hypothesis that 999 mL of IV saline will improve cognitive function in patients with POTS and Long COVID compared to placebo (50 mL of saline).
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
RCT of Mind-body in Long COVID and Myalgic Encephalomyelitis
NCT06933173
RECRUITING • NA • Updated 2026-05-07
Conditions: ME/CFS
AGENTS
Dynamic Neural Retraining System
We are studying the effect of a mind-body treatment for people with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) with or without Long COVID (LC). Our team recognizes that ME/CFS and Long COVID are serious, debilitating, biomedical conditions. ME/CFS can affect many different parts of the body, such as the nervous system, immune system, and metabolism. It is hypo...
View on ClinicalTrials.gov →
Metabolic Immunomodulatory NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
RECOVER-ENERGIZE Platform Protocol_Appendix A (Exercise Intolerance)
NCT06404060
ACTIVE_NOT_RECRUITING • NA • Updated 2026-05-07
Conditions: Long COVID / PASC
AGENTS
Personalized Cardiopulmonary Rehabilitation
This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes. This protocol is a prospective, multi-center, multi-arm, randomized, controlled pla...
View on ClinicalTrials.gov →
General NA Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Transcutaneous Vagus Nerve Stimulation as a Complementary Therapy to Exercise in Chronic Fatigue
NCT06170645
RECRUITING • NA • Updated 2026-05-06
Conditions: ME/CFS
AGENTS
Apa ProgramActive Transcutaneous Vns
Chronic fatigue is enhanced by adapted physical activity (APA) programs. Patients consulting on St Etienne hospital and suffering from fibromyalgia and long Covid benefit from a 4-6 week APA program, with 2 sessions per week. While most patients are improved by these exercise-training programs, for some the benefits remain very modest, and patients describe persistent fatigue. ...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Cognitive Muscular Therapy for Patients With Long-COVID and Breathing Pattern Disorder
NCT06503913
COMPLETED • NA • Updated 2026-05-06
Conditions: Long COVID / PASC
AGENTS
Cognitive Muscular TherapyBreathing Visualisation
The aim of the study is to test a treatment known as "Cognitive Muscular Therapy (CMT)" for reducing breathlessness and improving autonomic function in patients with long-COVID.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
RECOVER-ENERGIZE Platform Protocol_Appendix B (Structured Pacing (PEM))
NCT06404073
COMPLETED • NA • Updated 2026-05-06
Conditions: Long COVID / PASC
AGENTS
Structured Pacing
This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes. This protocol is a prospective, multi-center, multi-arm, randomized, controlled pla...
View on ClinicalTrials.gov →
General NA Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Intranasal Heparin Treatment to Reduce Transmission Among Household Contacts of COVID 19 Positive Adults and Children
NCT05204550
COMPLETED • PHASE2 • Updated 2026-05-05
Conditions: Long COVID / PASC
AGENTS
Unfractionated Heparin
Coronavirus-induced disease 2019 (COVID-19) is an infection caused by a virus whose full name is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This is a new and rapidly-spreading infectious disease which carries a significant risk of death, has brought massive economic impact globally and has proved hard to contain through public health measures. While we curren...
View on ClinicalTrials.gov →
General Phase 2 Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Digital Multimodal Rehabilitation for People With Post-acute COVID-19 Syndrome.
NCT05846126
COMPLETED • NA • Updated 2026-04-30
Conditions: Long COVID / PASC
AGENTS
Rehabcovid_TelematicRehabcovid_Immersivevr
Although most infected people survive the infection, many have persistent sequelae or symptoms, which cause disability or decreased quality of life. The World Health Organization has called on countries to prioritize the rehabilitation of the consequences of COVID-19 in both the medium and long term, as this chronicity is expected to impact the health public and the economy in ...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)
NCT05092516
ACTIVE_NOT_RECRUITING • NA • Updated 2026-04-30
Conditions: Long COVID / PASC
AGENTS
Active Tdcs
The main goal of this study is to improve dysexecutive symptoms (e.g., sustained attention, processing speed) in patients exhibiting post-acute sequelae of COVID-19 (PASC) through home-based transcranial direct current stimulation (tDCS), a noninvasive method that uses low intensity electric currents delivered to the brain through stimulation electrodes on the scalp.
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Long COVID-19 [11C]CPPC Study
NCT06223971
COMPLETED • EARLY_PHASE1 • Updated 2026-04-30
Conditions: Long COVID / PASC
AGENTS
[11C]Cppc Injection
The goal of this study is to evaluate the safety of using the \[5-cyano-N-(4-(4-\[11C\]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide\] (\[11C\]CPPC) radiotracer in positron emission tomography (PET) imaging of people with history of COVID-19 infection, with and without symptoms. The investigators are also interested to see whether use of this radiotracer re...
View on ClinicalTrials.gov →
General EARLY_Phase 1 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Pycnogenol® in Post-COVID-19 Condition
NCT05890534
COMPLETED • PHASE3 • Updated 2026-04-29
Conditions: Long COVID / PASC
AGENTS
Pycnogenol®
To determine the effect of Pycnogenol® versus placebo on patient-reported health status in people with post COVID-19 condition.
View on ClinicalTrials.gov →
General Phase 3 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Tele-exercise Training Program for Long COVID
NCT07553897
COMPLETED • NA • Updated 2026-04-28
Conditions: Long COVID / PASC
AGENTS
Telehealth Exercise Training Program
Patients with long coronavirus disease (COVID-19) experience multisystem symptoms and reduced quality of life (QOL). Proactive interventions are needed to enhance health outcomes.To investigate the effects of a 12-week tele-exercise training program on long COVID symptoms, cardiorespiratory fitness, and QOL.
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
NCT04510194
COMPLETED • PHASE3 • Updated 2026-04-24
Conditions: Long COVID / PASC
AGENTS
MetforminFluvoxamineIvermectin
1. The purpose of this trial is to conduct a 2x3 factorial randomized trials, which efficiently allows the parallel conduct of three randomized trials to understand whether metformin, ivermectin, or fluvoxamine, is superior to placebo for preventing Covid-19 disease progression in non-hospitalized adults with SARS- CoV-2 infection. 2. To understand if the active treatment arms ...
View on ClinicalTrials.gov →
General Phase 3 Very Large (1000+ participants) Enrollment: Actual Sponsor Type: Other
Harnessing Optimism and Perseverance in the Face of Long COVID-Español
NCT07216040
NOT_YET_RECRUITING • NA • Updated 2026-04-23
Conditions: Long COVID / PASC
AGENTS
Hope-Lc~Espanol
The Harnessing Optimism and Perseverance in the Face of Long COVID (HOPE-LC) program, created by Drs. Eric Watson and Amelia Hicks, is a group therapy model designed to foster resilience, adjustment, and coping skills for those living with chronic Long COVID. HOPE-LC\~Español provides a culturally and linguistically adapted version for Spanish-speaking individuals in Queens, de...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Prospective, Open-label Study of Seraph 100 in Patients With Prolonged COVID (PC)
NCT06637800
WITHDRAWN • NA • Updated 2026-04-20
Conditions: Long COVID / PASC
AGENTS
Seraph® 100 Microbind® Affinity Blood Filter
This study will use a prospective, open, single-arm design, in which a group of 100 patients with a diagnosis of prolonged COVID, previously selected according to inclusion and exclusion criteria, and who have undergone informed consent process and have signed the informed consent form, undergo two hemoperfusion procedures with the Seraph 100 filter, on consecutive days. They a...
View on ClinicalTrials.gov →
General NA Enrollment: Actual Sponsor Type: Industry
Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID
NCT06597396
ACTIVE_NOT_RECRUITING • PHASE2 • Updated 2026-04-20
Conditions: Long COVID / PASC
AGENTS
Abrocitinib
The primary purpose of this phase 2a study is to compare the efficacy of abrocitinib to placebo in improving severe fatigue in non-hospitalized adults with symptomatic Post-COVID Condition (PCC) (also called Long COVID). We are also interested in learning if abrocitinib is effective in improving overall health status in people suffering from severe fatigue from PCC. Eligible pa...
View on ClinicalTrials.gov →
General Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Long COVID Brain Fog: Cognitive Rehabilitation Trial
NCT06095297
RECRUITING • NA • Updated 2026-04-13
Conditions: Long COVID / PASC
AGENTS
Processing Speed TrainingIn-Lab Instrumental Activities Of Daily Living TrainingIn-Lab Brain Health TrainingTransfer PackageFollow Up Phone CallsVocational RehabilitationPeer MentoringReaction Time TrainingTrans-Auricular Vagus Nerve Stimulation: High IntensityTrans-Auricular Vagus Nerve Stimulation: Low Intensity
This study will compare two approaches to cognitive rehabilitation in adults with long COVID with persistent, mild to moderate, cognitive impairment. One approach will feature (A) web-based computer "games" that trains how quickly individuals process information that they receive through their senses; (B) in-lab training on everyday activities with important cognitive component...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19
NCT06871293
RECRUITING • NA • Updated 2026-04-13
Conditions: Long COVID / PASC
AGENTS
Functional And Cognitive Rehabilitation StrategyEvidence-Based Informational Support
This study aims to evaluate the impact of a functional and cognitive rehabilitation strategy compared to evidence-based informational messages, on functional capacity, cognitive abilities, quality of life, and disease progression in adults with chronic non-communicable diseases (NCDs) and Long Covid-19. Researchers will compare a structured rehabilitation program to informatio...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial
NCT06128967
COMPLETED • PHASE3 • Updated 2026-04-13
Conditions: Long COVID / PASC / ME/CFS
AGENTS
Fluvoxamine Maleate 100 MgMetformin
IRB approval date 14-APR-2024 and public at https://plataformabrasil.saude.gov.br/login.jsf since IURB approval Long COVID is a multi-systemic condition comprising often severe and persistent symptoms (longer than 12 weeks) that follow a known episode of COVID-19 and cannot be explained by another medical condition. This condition is observed in up to 15% of all individuals af...
View on ClinicalTrials.gov →
Immunomodulatory Anti-inflammatory Phase 3 Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)
NCT06766825
RECRUITING • PHASE2 • Updated 2026-04-03
Conditions: Long COVID / PASC
AGENTS
Plitidepsin 1.5 Mg/Day
The study aims to prove that plitidepsin could be an efficacious, safe, and well-tolerated therapy for PCC. To this end, we will perform a randomized, double-blind study comparing the clinical and laboratory benefits of plitidepsin vs. placebo in 90 subjects with moderate to severe functional disability. The study consists of an intervention period and a follow-up period, with ...
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study
NCT06928272
RECRUITING • PHASE3 • Updated 2026-04-03
Conditions: Long COVID / PASC
AGENTS
PirfenidoneUpadacitinib
The Long-Covid (LC)-Revitalize clinical study is testing repurposed drug treatments for Long Covid, involving adult participants from Brazil, Canada, Italy, Uganda, the United States, and Zambia. To qualify, participants must have had Covid-19 and experienced Long Covid symptoms for at least three months. The main goal of the study is to determine whether the drug treatments ca...
View on ClinicalTrials.gov →
Repurposed Anti-inflammatory Phase 3 Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
Improving Attention in Individuals With Long COVID-19
NCT06503874
COMPLETED • NA • Updated 2026-04-02
Conditions: Long COVID / PASC
AGENTS
Attention TrainingMusic Group
This study is to find out if the Attention Processing Training program is a potential treatment for brain fog symptoms, reported by people with Long-Covid. Also investigating the feasibility of completing this program virtually.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID
NCT06161688
ACTIVE_NOT_RECRUITING • PHASE2 • Updated 2026-04-02
Conditions: Long COVID / PASC
AGENTS
Ensitrelvir
Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID. This mechanism may be susceptible to antiviral therapy that blocks viral replication, which has the potential to alleviate long COVID symptoms. This trial will study the safety and efficacy of Ensitrelv...
View on ClinicalTrials.gov →
Persistence / Antiviral Anti-inflammatory Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)
NCT05855369
RECRUITING • PHASE2 • Updated 2026-04-02
Conditions: Long COVID / PASC
AGENTS
Trigeminal Nerve StimulationActive Smell Training
Persistent smell loss that can include diminished or distorted smell function is a common symptom of long COVID syndrome. There are limited treatment options for long COVID-related smell loss. This study aims to determine the efficacy of two at-home treatments, smell training and non-invasive trigeminal nerve stimulation. This study requires participants to conduct daily at-hom...
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Is Swimming a More Tolerable Form of Movement for Individuals With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome?
NCT07454395
SUSPENDED • NA • Updated 2026-03-30
Conditions: Long COVID / PASC / ME/CFS
AGENTS
SwimmingCycling
Individuals with ME/CFS experience profound exercise intolerance and post-exertional malaise. This remote (app-based) pilot study explores whether light, fully self-paced, swimming may be a tolerable form of movement for people with ME/CFS and related conditions, due to the distinct physiological effects of water immersion. The horizontal posture and hydrostatic pressure of wat...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
NCT06171152
SUSPENDED • EARLY_PHASE1 • Updated 2026-03-30
Conditions: Long COVID / PASC
AGENTS
Liraglutide Pen Injector [Saxenda]Medication Diary
This study is for people who have multiple sclerosis, acute leukemia (in remission), or long-COVID and a Body Mass Index over 27 and may struggle with cognitive issues such as remembering information, concentrating, or making decisions that affect everyday life. By doing this study, researchers hope to learn how liraglutide (Saxenda®), a weight loss drug, affects levels of a c...
View on ClinicalTrials.gov →
Neurological / Autonomic EARLY_Phase 1 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction
NCT05212610
COMPLETED • PHASE4 • Updated 2026-03-27
Conditions: Long COVID / PASC
AGENTS
Pfizer-Biontech Mrna Covid-19 VaccineModerna Mrna Covid-19 Vaccine
This study will evaluate the safety of administering an additional dose of an mRNA COVID-19 vaccine or mRNA bivalent COVID-19 booster vaccine to individuals who have had adverse reactions to a previous dose or administering an initial dose of an mRNA COVID-19 vaccine to individuals with a personal history of allergic reaction. In addition, this study will evaluate the safety of...
View on ClinicalTrials.gov →
General Phase 4 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms
NCT05965726
COMPLETED • PHASE2 • Updated 2026-03-27
Conditions: Long COVID / PASC
AGENTS
Paxlovid (Nirmatrelvir/Ritonavir)Ritonavir
This is an appendix of master protocol (NCT05595369) designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This sub-study is a prospective, multi-center, double-blind, randomized, controlled trial evaluating nirmatrelvir/ri...
View on ClinicalTrials.gov →
Immunomodulatory Persistence / Antiviral Anti-inflammatory Phase 2 Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Using Enhanced External Counterpulsation to Recover Cardiovascular Function for Patient of Chronic Diseases
NCT07492953
COMPLETED • NA • Updated 2026-03-25
Conditions: Long COVID / PASC
AGENTS
Enhanced External Counterpulsation
The goal of this clinical trial is to learn whether enhanced external counterpulsation (EECP) therapy can improve cardiopulmonary function and symptoms in adults with long COVID. It will also evaluate the safety and feasibility of two different EECP treatment schedules. The main questions it aims to answer are: * Does EECP therapy improve functional exercise capacity and card...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
DAOIB for the Treatment of Brain Fog
NCT05764538
RECRUITING • PHASE2 • Updated 2026-03-19
Conditions: Long COVID / PASC
AGENTS
Daoib
This is a 24-week open trial. We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB treatment will be beneficial in improving the cognitive function, mood symptoms, global functioning and quality of life...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
NCT06511050
RECRUITING • PHASE1 • Updated 2026-03-13
Conditions: Long COVID / PASC / ME/CFS
AGENTS
Lumbrokinase
This will be a pilot multi-arm clinical trial investigating the feasibility of Lumbrokinase (LK) as an intervention in three clinical cohorts: * Long Covid (LC) * Post-treatment Lyme disease syndrome (PTLDS) * Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
View on ClinicalTrials.gov →
General Phase 1 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Antiviral Clinical Trial for Long Covid-19
NCT06511063
RECRUITING • PHASE2 • Updated 2026-03-13
Conditions: Long COVID / PASC
AGENTS
Tenofovir Disoproxil/EmtricitabineSelzentry
The trial will test if two repurposed HIV antivirals can reduce symptom burden in adult participants with Long Covid compared to placebo. Viral infection and viral reactivation have been documented in Long Covid. Participants will be randomly allocated to receive antivirals, Truvada (tenofovir disoproxil/emtricitabine, TDF/FTC, Group 1) or Selzentry (Group 2), or a placebo (pi...
View on ClinicalTrials.gov →
Repurposed Persistence / Antiviral Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)
NCT06437223
COMPLETED • PHASE2 • Updated 2026-03-06
Conditions: Long COVID / PASC
AGENTS
Tonabersat
The primary objective of this study is to evaluate the safety and efficacy of Xiflam versus Placebo in patients who present with signs and symptoms of Long COVID. Xiflam (n=10) or placebo (n=5) will be administered orally once a day (QD) for 12 weeks.
View on ClinicalTrials.gov →
General Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Industry
Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hyperbaric Oxygen Therapy for the Treatment of Post COVID Condition
NCT06452095
RECRUITING • NA • Updated 2026-02-23
Conditions: Long COVID / PASC
AGENTS
Hyperbaric Oxygen Therapy (HBOT)
The RECLAIM study platform will be used to explore whether the use of Hyperbaric Oxygen therapy (HBOT) improves the symptoms of post covid cognitive dysfunction. Hyperbaric oxygen therapy is a well-established medical treatment. HBOT promotes healing by delivering a high concentration of oxygen into the body. This high level of oxygen has a number of known benefits, such as gr...
View on ClinicalTrials.gov →
Immunomodulatory Persistence / Antiviral Neurological / Autonomic Anti-inflammatory NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine
NCT05513560
COMPLETED • PHASE2 • Updated 2026-02-23
Conditions: Long COVID / PASC
AGENTS
IbudilastPentoxifylline
The researchers propose to develop a Canada-wide, adaptive randomized clinical platform trial to assess the effectiveness of various interventions in patients with lingering symptoms of COVID-19 ("Long COVID"). Participants will be randomized initially to 1 of 3 arms, including placebo (control) and 2 interventions. Because this is an adaptive trial, arms can be dropped if foun...
View on ClinicalTrials.gov →
General Phase 2 Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.
NCT05911906
COMPLETED • PHASE4 • Updated 2026-02-20
Conditions: Long COVID / PASC
AGENTS
Remdesivir
Following an infection with Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV2), one in ten people will experience persisting symptoms, or develop symptoms which can last for months and even years. These symptoms affect people in different ways and have been demonstrated to broadly impact physical, mental, and cognitive health. This is called Long COVID. Currently, ther...
View on ClinicalTrials.gov →
Persistence / Antiviral Neurological / Autonomic Phase 4 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
HOBSCOTCH for People With Post Acute COVID-19 Syndrome (PACS)
NCT06391489
ACTIVE_NOT_RECRUITING • NA • Updated 2026-02-20
Conditions: Long COVID / PASC
AGENTS
Hobscotch-Pacs
The goal of this pilot study is to assess the feasibility of adapting and delivering the existing home-based epilepsy self-management intervention, HOBSCOTCH, for people with Post Acute Covid Syndrome (PACS). The main questions it aims to answer are: Can the current HOBSCOTCH program be adapted for people with PACS? Will people with PACS experience improved quality of life s...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)
NCT06305806
COMPLETED • PHASE2 • Updated 2026-02-20
Conditions: Long COVID / PASC
AGENTS
IvabradineCoordinated Care
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for us...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
RECOVER-AUTONOMIC Platform Protocol
NCT06305780
COMPLETED • PHASE2 • Updated 2026-02-20
Conditions: Long COVID / PASC
AGENTS
IVIG (Intravenous Immunoglobulin)Ivabradine + Coordinated Care
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for us...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
A Fasting Pilot Study for Long COVID
NCT07418567
COMPLETED • NA • Updated 2026-02-18
Conditions: Long COVID / PASC
AGENTS
Prolonged Fasting
Background Long COVID (LC) is a chronic multisystemic condition which substantially impact the quality of life. Despite the staggering burden of LC, there is still no effective treatment. Because fasting promotes anti-inflammatory and antioxidant responses, which are involved in the pathophysiology of LC, we hypothesized that it might improve daily functioning and health-relat...
View on ClinicalTrials.gov →
Anti-inflammatory NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Mind Body Intervention for Long COVID-19
NCT06045338
RECRUITING • NA • Updated 2026-02-18
Conditions: Long COVID / PASC
AGENTS
Mind Body Intervention #1
The goal of this study is to determine if a mind-body intervention can help people suffering from symptoms associated with Long COVID. The study is a randomized trial examining the effectiveness of a mind body intervention in reducing somatic symptoms from Long COVID in participants as compared to usual care and an active control (second mind body intervention). The investigato...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction
NCT05445921
COMPLETED • PHASE1 • Updated 2026-02-12
Conditions: Unspecified / Overlap
AGENTS
Stellate Ganglion Block
Chronic olfactory dysfunction from the COVID-19 pandemic is a growing public health crisis with up to 1.2 million people in the Unites States affected. Olfactory dysfunction impacts one's quality of life significantly by decreasing the enjoyment of foods, creating environmental safety concerns, and affecting one's ability to perform certain jobs. Olfactory dysfunction is also a...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 1 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
A Trial of Shengmai Liquid for Long COVID Fatigue.
NCT06980636
RECRUITING • PHASE4 • Updated 2026-02-09
Conditions: Long COVID / PASC
AGENTS
Shengmai Liquid
The goal of this clinical trial is to learn if Shengmai liquid works to treat Long Covid fatigue. It will also learn about the safety of Shengmai liquid. The main questions it aims to answer are: * Dose the Shengmai liquid will reduce the level of fatigue in the participants and reduce the fatigue scale score of the participants? * Dose the Shengmai liquid will reduce the leve...
View on ClinicalTrials.gov →
General Phase 4 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Inspiratory Muscle Pressure and Diaphragmatic Strength in Women With Long COVID-19: A Pressure Biofeedback-Guided Training Study
NCT07397130
COMPLETED • NA • Updated 2026-02-09
Conditions: Long COVID / PASC
AGENTS
Pressure Biofeedback Unit
COVID-19 is an infectious disease that can cause long-term health problems even after the acute infection has resolved. Many people who have recovered from COVID-19 continue to experience breathing difficulties, fatigue, and reduced physical capacity. These ongoing problems are often related to decreased lung function and weakness of the breathing muscles, especially the diaphr...
View on ClinicalTrials.gov →
Anti-inflammatory NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Clinical Trial on a Natural Compound to Improve Chronic Inflammation After SARS-CoV-2 Infection
NCT07397910
NOT_YET_RECRUITING • NA • Updated 2026-02-09
Conditions: Long COVID / PASC
AGENTS
Experimental ProductPhysical ExerciseNo Physical Exercise
A controlled, randomized clinical trial is proposed to demonstrate the effectiveness of the experimental product in controlling hepato-pulmonary inflammation and neurovascular encephalic inflammation, which may constitute the etiopathogenic basis of persistent COVID. In addition, an individualized training program will be implemented for each participant in order to improve chr...
View on ClinicalTrials.gov →
Anti-inflammatory NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Stellate Ganglion Block for Long COVID Symptoms: A Randomized Controlled Trial
NCT07374562
RECRUITING • NA • Updated 2026-02-09
Conditions: Long COVID / PASC
AGENTS
Stellate Ganglion Block
This single-center, randomized, controlled, single-blind clinical trial evaluates whether a stellate ganglion block (SGB) using bupivacaine can improve persistent symptoms in adults with long COVID. Participants are assigned in a 1:1 ratio to receive either an ultrasound-guided right-sided SGB or a placebo saline injection delivered to the sternocleidomastoid muscle. After the ...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Humanity Neurotech Device Clinical Trial in Adults With Long COVID Cognitive Dysfunction
NCT06739668
COMPLETED • NA • Updated 2026-02-02
Conditions: Long COVID / PASC
AGENTS
Pascal Device
The purpose of this study is to assess the feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to PASC, and to collect data on safety and efficacy to inform the design of larger clinical studies. A prospective randomized controlled study of 30 participants with PASC and moderate to severe cognitive dysfunction. Total study duration will be 8 w...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
The COVID-RASi Trial (COVID-19)
NCT04591210
COMPLETED • PHASE3 • Updated 2026-01-28
Conditions: Long COVID / PASC
AGENTS
Angiotensin Converting Enzyme InhibitorAngiotensin Ii Receptor Blockers
The COVID-RASi study is an international randomized clinical trial that will evaluate the potential benefit of angiotensin modulators on clinical outcomes, in COVID-19 patients. The purpose of this study is to determine if renin-angiotensin system inhibitors (RASi), with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB), has a beneficial ...
View on ClinicalTrials.gov →
General Phase 3 Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome
NCT05697640
ACTIVE_NOT_RECRUITING • PHASE2 • Updated 2026-01-28
Conditions: ME/CFS
AGENTS
Vericiguat Oral Tablet
The goal of this clinical trial is to evaluate the therapeutic value of an approved drug (Vericiguat) in patients with post-COVID-19 syndrome, who suffer from profound tiredness or fatigue, regardless of bed rest.The main questions it aims to answer are: • Does Vericiguat relieve fatigue and/or other symptoms associated with post-COVID-19 syndrome? • What are the side effects o...
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Amantadine Therapy for Cognitive Impairment in Long COVID
NCT06055244
COMPLETED • PHASE2 • Updated 2026-01-27
Conditions: Long COVID / PASC
AGENTS
Amantadine
This study will look at the effects of amantadine on cognitive function in persons with Long COVID. It will also collect specimens to study possible causes of cognitive symptoms in Long COVID, and whether any lab tests can predict who will respond better to amantadine.
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
RECOVER-SLEEP: Platform Protocol
NCT06404086
COMPLETED • PHASE2 • Updated 2026-01-22
Conditions: Long COVID / PASC
AGENTS
ModafinilSolriamfetolMelatoninTailored Lighting (Tl) Active
The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. For example, objectives, measures, and endpoints are generalized in the platform...
View on ClinicalTrials.gov →
General Phase 2 Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
NCT07189936
RECRUITING • PHASE2 • Updated 2026-01-22
Conditions: Long COVID / PASC
AGENTS
To Measure Levels Of Circulating Monocyte/ T Cell Doublets At BaselineTo Measure Levels Of Circulating Monocyte/ T Cell Doublets After 28 Days Of 2 Hoba TreatmentTo Measure Splanchnic Venous Capacitance After 28 Days Of Treatment With 2HobaTo Measure Orthostatic Tachycardia After 28 Days Of Treatment With 2Hoba
Long COVID is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection. Approximately 7% of individuals who recover from SARS-Cov-2 infection develop Long COVID. Long COVID Postural Orthostatic Tachycardia Syndrome (LCPOTS) symptoms include fatigue, exercise intolerance, orthostatic intolerance, sy...
View on ClinicalTrials.gov →
Immunomodulatory Neurological / Autonomic Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
The Effect of Acupuncture Treatment on Cognitive Functions and Brain Networks for Long COVID
NCT07355751
NOT_YET_RECRUITING • NA • Updated 2026-01-21
Conditions: Long COVID / PASC
AGENTS
Acupuncture
Background of study: Long COVID(LC) is a prevalent sequalae of SARS-CoV-2 infection and can affect multiple organ systems. Cognitive dysfunction is one of the most common symptoms in LC with 22% prevalence. It can persist for years and significantly reduce patients' quality of life. Brain network is the neural basis underlying human cognitive processes. Diffusion tensor imagin...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome
NCT05421208
RECRUITING • NA • Updated 2026-01-20
Conditions: Long COVID / PASC
AGENTS
Effect On Inflammation After Chronic Pns Stimulation
The term post-acute COVID-19 syndrome or Long COVID is a disabling syndrome that persists beyond the 3-month convalescence period after COVID-19 infections. This syndrome affects mostly women (\~80%), present with chronic tachycardia and Orthostatic intolerance symptoms without any identifiable cause. In addition, non-specific symptoms such as fatigue, headache, and "brain fog...
View on ClinicalTrials.gov →
Immunomodulatory Neurological / Autonomic Anti-inflammatory NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Evaluating a Comprehensive Multimodal Outpatient Rehabilitation Program for PASC Program to Improve Functioning of Persons Suffering From Post-COVID-19 Syndrome: A Randomized Controlled Trial
NCT06156202
COMPLETED • NA • Updated 2026-01-20
Conditions: Long COVID / PASC
AGENTS
Comprehensive Rehabilitation
About 10-20% of persons who contract SARS CoV-2 will experience persistent post-acute sequelae of SARSCoV-2 infection (referred here as PASC). While treatments offered at emerging outpatient COVID recovery clinics are being informed by previous similar diseases, the need is great for a better understanding of the unique needs of this growing population and for tested, efficacio...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Immunoadsorption in Patients With Chronic Fatigue Syndrome Including Patients With Post-COVID-19 CFS
NCT05710770
COMPLETED • NA • Updated 2026-01-16
Conditions: ME/CFS
AGENTS
Immunoadsorption
The goal of this clinical trial is to learn about the effectiveness of repeated immunoadsorption intervention in patients with chronic fatigue syndrome (CFS) including patients with post-acute COVID-19 CFS (PACS-CFS). The main questions it aims to answer are: (1) Does repeated immunoadsorption relieve fatigue and/or other symptoms associated with CFS and PACS-CFS? (2) Is repea...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Long COVID-19 Intervention (COVIDL/MIQoL)
NCT06492590
COMPLETED • NA • Updated 2026-01-16
Conditions: Long COVID / PASC
AGENTS
Multicomponent Intervention
The goal of this clinical trial is to assess the effectiveness of a multicomponent intervention in individuals with Long COVID. The main questions it aims to answer are: * Does the intervention increase quality of life, mental well-being, resilience, and physical condition in individuals with Long COVID? * Does the intervention decrease anxiety, depressed mood, and fatigue in ...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Long COVID Diagnostic Reactivity Assesment Test
NCT07343856
ENROLLING_BY_INVITATION • NA • Updated 2026-01-15
Conditions: Long COVID / PASC
AGENTS
Electrodiagnostic Bioelectrical Assessment
This study is a diagnostic clinical investigation designed to evaluate bioelectrical response patterns assessed by electro-acupuncture-based medicament testing. The method is used to identify individual bioelectrical reactivity associated with the presence and persistence of pathological factors and to assess patient-specific responses to tested medicinal substances. The stud...
View on ClinicalTrials.gov →
Persistence / Antiviral NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Qigong for Post Acute Sequelae of COVID-19 Infection
NCT05675995
COMPLETED • NA • Updated 2026-01-13
Conditions: Long COVID / PASC
AGENTS
Qigong
The purpose of this study is to conduct a pilot feasibility study of a combination of external and internal qigong on health-related quality of life in individuals with prolonged symptoms following COVID-19 infection.
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome
NCT05926505
RECRUITING • PHASE2 • Updated 2026-01-08
Conditions: Long COVID / PASC
AGENTS
Anakinra 149 Mg/Ml Prefilled Syringe [Kineret]
The PRECISION is a proof-of-concept, phase II randomized clinical trial aiming to evaluate the efficacy and safety of anakinra in patients with Post-Acute COVID Syndrome (PACS) of the pro-inflammatory respiratory phenotype. Improvement is measured by a composite endpoint, namely, the "Score of PACS progression reversal"
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Diaphragmatic Breathing Exercises for Post-COVID-19 Diaphragmatic Dysfunction (DD)
NCT06330376
COMPLETED • NA • Updated 2026-01-08
Conditions: Long COVID / PASC
AGENTS
Specific Db Program/Diaphragmatic Manipulation Program
Diaphragm is the principal muscle of inspiration. Diaphragmatic dysfunction is seen in many conditions including following intubation, lung disease, prolonged ventilation, neuromuscular disease, phrenic nerve injury. The possible mechanisms of diaphragmatic dysfunction in patients with COVID19 are critical illness myopathy, ventilator-induced diaphragm dysfunction, iatrogenic p...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Long COVID Ultrasound Trial
NCT06189066
COMPLETED • NA • Updated 2026-01-07
Conditions: Long COVID / PASC
AGENTS
Splenic Ultrasound
The research objective is to assess the safety and potential efficacy of spleen ultrasound stimulation as an intervention for Long COVID in a pilot study. Specific Aims include: * Measure Long COVID disease activity before, during and after an 8-week course of spleen-directed daily ultrasound stimulation. * Measure molecular correlates of Long COVID disease activity before, d...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Industry
Vagal Approaches on Long COVID-19
NCT07190105
COMPLETED • NA • Updated 2026-01-07
Conditions: Long COVID / PASC
AGENTS
Sonocea Sonic Augmentation TechnologyTruvaga Electrical Vagus Nerve Stimulator
The purpose of this study is to explore whether two general wellness products, alone or combined, can support individuals experiencing Long COVID symptoms. Both wellness products stimulate the vagus nerve - a nerve that helps regulate stress, relaxation, mood, breathing, heart rate, inflammation, and digestion. The investigators will use a Fitbit to track participants' health ...
View on ClinicalTrials.gov →
Anti-inflammatory NA Large (200-999 participants) Enrollment: Actual Sponsor Type: Industry
Study of LAU-7b for the Treatment of Long COVID in Adults
NCT05999435
COMPLETED • PHASE2 • Updated 2026-01-06
Conditions: Long COVID / PASC
AGENTS
Lau-7B For 3 Cycles
ESSOR is a double-blind, placebo-controlled study of the orally-administered antiviral and inflammation-controlling LAU-7b for the treatment of adults with Long COVID and moderate to severe symptoms.
View on ClinicalTrials.gov →
Persistence / Antiviral Anti-inflammatory Phase 2 Large (200-999 participants) Enrollment: Actual Sponsor Type: Industry
Immunoadsorption in Autoimmune Long COVID
NCT07316127
RECRUITING • PHASE2 • Updated 2026-01-05
Conditions: Long COVID / PASC
AGENTS
Immunoadsorption
Some people continue to have serious symptoms long after COVID-19, such as extreme fatigue and feeling worse after activity. In some patients, this may happen because the immune system is attacking the body by mistake. This study will test a treatment called immunoadsorption, which filters the blood to remove harmful antibodies. People with long COVID who have these antibodies...
View on ClinicalTrials.gov →
Immunomodulatory Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Whole-Body Electrostimulation for Functional Recovery in Post-COVID Syndrome
NCT07312357
NOT_YET_RECRUITING • NA • Updated 2025-12-31
Conditions: Long COVID / PASC
AGENTS
Whole-Body Electromyostimulation Suit
Post-COVID syndrome is a condition that affects some people after recovering from the acute phase of COVID-19. Common symptoms include persistent fatigue, reduced physical capacity, and difficulties performing everyday activities, which can significantly impact quality of life and independence. At present, there is limited scientific evidence on effective rehabilitation strateg...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
The Long COVID Treatment Trial
NCT07128082
ACTIVE_NOT_RECRUITING • PHASE2 • Updated 2025-12-23
Conditions: Long COVID / PASC
AGENTS
Tirzepatide
The goal of this study is to determine whether a medicine called tirzepatide, also called Zepbound, can reduce symptoms of Long COVID. A randomized control trial will allow us to measure the effect of the treatment by having half of the participants take the medication and half take a placebo that has no medication. Participants will take the medication (or placebo) they are gi...
View on ClinicalTrials.gov →
General Phase 2 Very Large (1000+ participants) Enrollment: Actual Sponsor Type: Other
Study to Investigate the Health Benefits of a Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms
NCT06974058
COMPLETED • NA • Updated 2025-12-19
Conditions: Long COVID / PASC
AGENTS
Nasafytol®
This pragmatic clinical study aims to evaluate the efficacy and tolerance of a combined quercetin/curcumin supplement in adults experiencing mild to moderate symptoms of Long COVID-19. Participants will receive the combined quercetin/curcumin supplement for 2 months. The primary outcome is the improvement in overall symptom burden, while secondary outcomes include changes in qu...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Brain Stimulation in Long COVID
NCT07278206
RECRUITING • NA • Updated 2025-12-19
Conditions: Long COVID / PASC
AGENTS
Repetitive Transcranial Magnetic Stimulation
Cognitive problems and severe fatigue are two frequently occurring symptoms in long COVID, also known as Post-Covid Condition or Post-Acute Sequelae of COVID-19 (PASC), and their causes are currently unknown. Previous studies have shown reduced blood flow and increased inflammation in the brains of people with PASC. These brain processes are related to fatigue and cognitive pro...
View on ClinicalTrials.gov →
Neurological / Autonomic Anti-inflammatory NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Acupuncture and Chinese Herbal Medicine for Long COVID
NCT07285707
RECRUITING • NA • Updated 2025-12-16
Conditions: Long COVID / PASC
AGENTS
Acupuncture
List of the Hypothesis: Primary hypothesis: A flexible acupuncture and Chinese herbal medicine protocol will be feasible, acceptable, and useful for the treatment of long COVID. Secondary hypothesis: Long COVID patients receiving acupuncture treatment or acupuncture treatment and Chinese herbal supplements over an 8-week period will see improvements in their symptoms, functio...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
NCT04948203
ACTIVE_NOT_RECRUITING • PHASE2 • Updated 2025-12-15
Conditions: Long COVID / PASC
AGENTS
Sirolimus (low-dose)
The primary purpose of this study is to determine whether the drug sirolimus reduces the likelihood of developing of pulmonary fibrosis in patients who are hospitalized with COVID-19 pneumonia.
View on ClinicalTrials.gov →
Immunomodulatory Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Long COVID Immune Profiling
NCT06027255
RECRUITING • NA • Updated 2025-12-15
Conditions: Long COVID / PASC
AGENTS
Il-6CytokinesCompass 31
Parasympathetic nervous system (PNS) is part of the body's autonomic nervous system(PNS) protects body against inflammation. Study shows that reduced PNS function activity is associated with persistent inflammation. Preliminary data from the studies shows, that post-COVID-19 POTS patients have reduced parasympathetic (PNS) function. Given that the PNS protects against inflamma...
View on ClinicalTrials.gov →
Immunomodulatory Neurological / Autonomic Anti-inflammatory NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Neural Mechanisms of Fatigue in Post-Acute Sequela of SARS-CoV-2
NCT07278388
RECRUITING • NA • Updated 2025-12-12
Conditions: Long COVID / PASC
AGENTS
Physical Fatigue
This proposal aims to understand the neurobiological mechanisms of fatigue in individuals with Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). This knowledge will eventually provide candidate mechanisms to target with pharmacological intervention and inform rehabilitative care for those individuals suffering from symptoms of fatigue in PASC.
View on ClinicalTrials.gov →
General NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
Design and Validation of Innovative Strategies Based on Dual-Task Approach
NCT07254377
ACTIVE_NOT_RECRUITING • NA • Updated 2025-12-11
Conditions: Long COVID / PASC
AGENTS
Dual Task ExercisePhysical Therapy
People affected by Stroke, Multiple Sclerosis (MS), and Parkinson's disease (PD) share severe and complex disabilities. Widespread neuro-inflammatory processes represent an important pathogenetic component in all three conditions. The potential overlap with neurological complications of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has further contribut...
View on ClinicalTrials.gov →
Neurological / Autonomic Anti-inflammatory NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Modulation of the Brain Fog Scale by Eicosapentaenoic Acid Monoglycerides (MAG-EPA).
NCT06695910
RECRUITING • PHASE4 • Updated 2025-12-11
Conditions: Unspecified / Overlap
AGENTS
Monoglyceride Eicosapentaenoic AcidSunflower Oil
A growing body of studies shows that omega-3s act directly in molecular signaling pathways that reduce inflammation and are thought to have a positive effect on cognitive health. Brain fog is a term that has been popularized in the medical world in the wake of the COVID-19 pandemic. A significant proportion of patients with long COVID reported having cognitive sequelae that wer...
View on ClinicalTrials.gov →
Neurological / Autonomic Anti-inflammatory Phase 4 Small (<50 participants) Enrollment: Estimated Sponsor Type: Industry
Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19
NCT05619653
ACTIVE_NOT_RECRUITING • PHASE3 • Updated 2025-12-09
Conditions: Long COVID / PASC
AGENTS
PrednisoloneLosartan
Long COVID or Postacute sequelae of COVID-19 infection (PASC) are increasingly recognised complications, defined by lingering symptoms, not present prior to the infection, typically persisting for more than 4 weeks. Cardiac symptoms due to post-acute inflammatory cardiac involvement affect a broad segment of people, who were previously well and may have had only mild acute illn...
View on ClinicalTrials.gov →
Immunomodulatory Neurological / Autonomic Anti-inflammatory Phase 3 Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Physiology of Long COVID-19 and the Impact of Cardiopulmonary Rehabilitation on Quality-of-Life and Functional Capacity
NCT05566483
RECRUITING • NA • Updated 2025-12-04
Conditions: Long COVID / PASC
AGENTS
Exercise
The primary objectives of this study are to determine whether exercise training is an effective strategy for treatment of Long COVID and characterize the cardiorespiratory and autonomic physiology in these patients to precisely characterize mechanisms contributing to this syndrome.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms
NCT05595369
COMPLETED • PHASE2 • Updated 2025-12-02
Conditions: Long COVID / PASC
AGENTS
Paxlovid (Nirmatrelvir/Ritonavir)
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, double-blind, randomized, controlled platform trial with different interventio...
View on ClinicalTrials.gov →
Immunomodulatory Persistence / Antiviral Anti-inflammatory Phase 2 Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients
NCT07110714
RECRUITING • NA • Updated 2025-12-02
Conditions: Long COVID / PASC
AGENTS
Cold Water Hydrotherapy
This randomized controlled study evaluates the effects of cold water hydrotherapy in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to an usual care setting without hydrotherapy treatment.
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Industry
PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway
NCT05852873
ACTIVE_NOT_RECRUITING • PHASE3 • Updated 2025-11-21
Conditions: Long COVID / PASC
AGENTS
Paxlovid (Nirmatrelvir/Ritonavir)
The goal of this clinical trial is to compare treatment with oral Paxlovid (nirmatrelvir/ritonavir) and placebo for acute COVID-19 as an intervention to prevent long-COVID (post-COVID-19 condition) in adults aged 18-64 years old. The main question it aims to answer is: Does treatment with Paxlovid for acute COVID-19 reduce the prevalence of long-COVID compared to placebo. Pa...
View on ClinicalTrials.gov →
Persistence / Antiviral Phase 3 Very Large (1000+ participants) Enrollment: Estimated Sponsor Type: Other
RECOVER-ENERGIZE Platform Protocol
NCT06404047
COMPLETED • NA • Updated 2025-11-14
Conditions: Long COVID / PASC
AGENTS
Personalized Cardiopulmonary RehabilitationStructured Pacing
This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes. This protocol is a prospective, multi-center, multi-arm, randomized, controlled pla...
View on ClinicalTrials.gov →
General NA Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Sauna for Long Covid
NCT05931497
RECRUITING • NA • Updated 2025-11-13
Conditions: Long COVID / PASC
AGENTS
Whole Body Hyperthermia
Research suggests that Whole Body Hyperthermia in a sauna-like environment can reduce symptoms related to post-acute sequelae of SARS-CoV-2 (PASC), or Long Covid. The investigators aim to study the feasibility and treatment effect of this procedure for patients experiencing Long Covid symptoms.
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Stellate Ganglion Block for COVID-induced Parosmia
NCT06253806
COMPLETED • PHASE2 • Updated 2025-11-10
Conditions: Long COVID / PASC
AGENTS
Stellate Ganglion Block
Chronic olfactory dysfunction, both hyposmia and parosmia, from the COVID-19 pandemic is a growing public health crisis with up to 1.2 million people in the United States affected. Olfactory dysfunction impacts one's quality of life significantly by decreasing the enjoyment of foods, creating environmental safety concerns, and affecting one's ability to perform certain jobs. Ol...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)
NCT05877508
ACTIVE_NOT_RECRUITING • PHASE2 • Updated 2025-10-28
Conditions: Long COVID / PASC
AGENTS
Aer002
Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID. This mechanism may be able to be targeted by SARS-CoV-2 monoclonal antibodies (mAbs). This trial will study the safety and efficacy of AER002 to treat individuals with Long COVID in an adult population.
View on ClinicalTrials.gov →
Persistence / Antiviral Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS
NCT05918978
TERMINATED • PHASE2 • Updated 2025-10-23
Conditions: Long COVID / PASC
AGENTS
Efgartigimod
The OLE study aims to investigate the safety, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod in participants with post-COVID-19 postural orthostatic.
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Industry
Heat thErapy And mobiLity in COVID-19 Survivors
NCT06928116
RECRUITING • NA • Updated 2025-10-23
Conditions: Long COVID / PASC
AGENTS
Heat TherapyWalking
Post-acute sequelae of SARS-CoV-2 infection (PASC) is becoming a major risk factor for chronic diseases, with older adults and those with underlying health conditions at risk of developing persistent mobility limitations and disabilities. Although exercise intervention is a common strategy to restore functional capacity, it may not be feasible or enticing to many people with PA...
View on ClinicalTrials.gov →
Metabolic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
LIFT: Life Improvement Trial
NCT06366724
RECRUITING • PHASE2 • Updated 2025-10-22
Conditions: Long COVID / PASC / ME/CFS
AGENTS
PyridostigmineLow-Dose Naltrexone (LDN)
The LIFT will be conducted at Brigham and Women's Hospital (BWH) of Harvard Medical School, focusing on the effect of Pyridostigmine (Mestinon) and Low-Dose Naltrexone (LDN) in subjects aged 18-70 meeting the Canadian consensus criteria (CCC) for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) as well as having specifically Orthostatic Intolerance (OI). Long COVID (...
View on ClinicalTrials.gov →
Immunomodulatory Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Tele-Rehabilitative Exercise Training Program in Nurses With Long COVID
NCT06840873
COMPLETED • NA • Updated 2025-10-07
Conditions: Long COVID / PASC
AGENTS
Wearable DeviceHealthy Consulation
Long COVID can cause a decline in cardiorespiratory fitness, resulting in fatigue and negative impacts on individuals' quality of life (QoL), particularly in nurses who play a crucial role in public health. Combining with reduced cardiorespiratory fitness and suffering from a spectrum of long-COVID symptoms might substantially exaggertate fatigue, perceived stress, and reduce w...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Use of a Cysteine-rich Whey Protein Isolate in Post COVID-19 Cognitive Impairment
NCT07184398
COMPLETED • NA • Updated 2025-09-24
Conditions: Long COVID / PASC
AGENTS
Intervention With Consolidated Cysteine (Immunocal) 20 G Per DayCognitive Rehabilitation Workshops
Abstract Background: Post-COVID-19 cognitive impairment (PCCI), characterized by deficits in attention, memory, and executive functioning, remains a major challenge among patients with long COVID. Oxidative stress is a key contributor to this condition. Cysteine-rich whey protein isolate (CRWPI), such as Immunocal®, enhances intracellular glutathione production and may offer ne...
View on ClinicalTrials.gov →
Immunomodulatory Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition
NCT07184385
NOT_YET_RECRUITING • PHASE3 • Updated 2025-09-23
Conditions: Long COVID / PASC
AGENTS
Regenecyte
REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.
View on ClinicalTrials.gov →
General Phase 3 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Industry
Long COVID-19 Rehabilitation & Recovery Research Program
NCT05398692
TERMINATED • NA • Updated 2025-09-22
Conditions: Long COVID / PASC
AGENTS
On Site Exercise Rehabilitation
The purpose of the study is to assess the physiologic, immunologic, and mental health effects of an exercise and pulmonary rehabilitation program on patients with Long COVID-19 (LC).
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Effect of Hi-OxSR for the Treatment of Post COVID Condition
NCT06928506
RECRUITING • NA • Updated 2025-09-15
Conditions: Long COVID / PASC
AGENTS
Hi-Oxsr DeviceHi-Ox Device
The RECLAIM study platform will be used to explore whether the use of the Hi-OxSR device improves the symptoms of post covid cognitive dysfunction. Carbon dioxide (CO2) has been proposed as a potential treatment for persistent immune activation as there is evidence that CO2 has antioxidant, anti-inflammatory, and anti-cytokine effects. We conducted a pilot study assessing the o...
View on ClinicalTrials.gov →
Immunomodulatory Neurological / Autonomic Anti-inflammatory NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Tragus Stimulation for POTS Treatment
NCT07163130
NOT_YET_RECRUITING • NA • Updated 2025-09-09
Conditions: Unspecified / Overlap
AGENTS
Transcutaneous Auricular Vagus Nerve Stimulation
Postural Tachycardia Syndrome (POTS) is a form of dysautonomia characterized by an abnormal cardiovascular response to orthostatic challenges. Individuals afflicted with POTS typically exhibit a heart rate increase of more than 30 beats per minute (bpm) within 10 minutes of assuming an upright posture from a supine or sitting position. This abnormal response is often accompanie...
View on ClinicalTrials.gov →
Neurological / Autonomic Anti-inflammatory NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Transcranial Ultrasound Stimulation for Cognitive Function Modulation in Patients With Post COVID-19 Brain Fog
NCT07154199
RECRUITING • NA • Updated 2025-09-04
Conditions: Long COVID / PASC
AGENTS
Real Transcranial Ultrasound Stimulation
This study aims to investigate whether a specific brain region mediates the cognitive deficit in long COVID brain fog, and whether targeted modulation of this region can improve cognition. In observational study, the objective was to identify potential intervention targets for patients with long COVID brain fog. A total of 120 patients with long COVID were enrolled. Brain fog ...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Paxlovid for Treatment of Long Covid
NCT05576662
COMPLETED • PHASE2 • Updated 2025-09-04
Conditions: Long COVID / PASC
AGENTS
Paxlovid (Nirmatrelvir/Ritonavir)Ritonavir
The purpose of this study is to compare whether being treated with nirmatrelvir plus ritonavir for 15 days works better than being treated with placebo plus ritonavir to reduce severe symptoms of Long Covid. Participants will have 5 planned visits to the study clinic over 15 weeks and will take the drug (or placebo) for the first 15 days. This study uses the term post-acute s...
View on ClinicalTrials.gov →
Persistence / Antiviral Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Probiotic Use for Recovery Enhancement From Long COVID-19
NCT06643299
ACTIVE_NOT_RECRUITING • PHASE2 • Updated 2025-09-03
Conditions: Long COVID / PASC
AGENTS
Probiotic Agent
The goal of this clinical trial is to learn if probiotics can improve symptoms and quality of life in participants with Long COVID.
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid
NCT06234462
WITHDRAWN • PHASE2 • Updated 2025-08-26
Conditions: Long COVID / PASC
AGENTS
AmantadinePhysical, Occupational, Speech TherapyProvider CounselingMedications For Symptoms Management
Purpose: To decrease symptom burden, improve cognitive function, improve endurance, and decrease fatigue in subjects with post-acute sequelae of COVID-19 (PASC) or "long-hauler" COVID using amantadine. If amantadine use is determined to be efficacious in this population, the findings of this study will be used towards a subsequent randomized control trial.
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Enrollment: Actual Sponsor Type: Other
Synbiotic Therapy for NP-PASC
NCT06620406
COMPLETED • NA • Updated 2025-08-26
Conditions: Long COVID / PASC
AGENTS
Synbiotic Ivs-1Maltodextrin
Gut microbiome dysbiosis has been noted in patients with Post-acute sequelae (PASC) of Severe Acute Respiratory Syndrome-CoronaVirus -2 (SARS-CoV-2). A study performed at Columbia found that plasma levels of the short chain fatty acid (SCFA), butyric acid, remained lower in people with Neuropsychiatric PASC (NP-PASC) than in people with PASC after SAR-CoV-2 infection. Synbiotic...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Long-Covid-19 Alleviation Through Learning Mindfulness Study
NCT07140094
RECRUITING • NA • Updated 2025-08-24
Conditions: Long COVID / PASC
AGENTS
Structured Mindfulness Intervention
This research is being done to study a mindfulness intervention among people who have symptoms of Post-Acute Sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Mindfulness is defined as paying attention to the present moment with non-judgment and acceptance. Here the investigators are studying whether a mindfulness intervention can help reduce stress, reduce Lon...
View on ClinicalTrials.gov →
General NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
Effects of Immulina TM Supplements With PASC Patients
NCT05524532
COMPLETED • PHASE3 • Updated 2025-08-14
Conditions: Long COVID / PASC
AGENTS
Immulina Tm
This is a multi-site study that will try to determine the effects of Immulina ™, a natural dietary supplement, on blood chemicals associated with inflammation that are often increased in patients with long COVID (also called PASC).
View on ClinicalTrials.gov →
Anti-inflammatory Phase 3 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
The Use of Incentive Spirometry in Adult Patients Hospitalised in a Rehabilitation Center With Long-covid Syndrome
NCT05813873
ACTIVE_NOT_RECRUITING • NA • Updated 2025-08-14
Conditions: Long COVID / PASC
AGENTS
Triflow
The aim of this clinical trial is to investigate the efficacy of Triflow in the rehabilitation of patients with long covid syndrome hospitalised in a rehabilitation center. Participants will be divided into 2 groups and follow their exercise regime until the day they are discharged from the rehabilitation center. The intervention group will participate in a rehabilitation progr...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Vagus Nerve Stimulation to the Ear to Improve Symptoms in Post-COVID-19 and ME/CFS
NCT06968104
ACTIVE_NOT_RECRUITING • NA • Updated 2025-08-08
Conditions: Long COVID / PASC / ME/CFS
AGENTS
Transcutaneous Vagus Nerve Stimulation
This study is testing whether a gentle electrical stimulation of a nerve in the ear, called the vagus nerve, can help reduce fatigue and improve symptoms in people with Post-COVID Syndrome or Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The treatment, known as transcutaneous auricular vagus nerve stimulation (taVNS), is non-invasive and can be done at home using...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
tVNS in Long COVID-19
NCT06585254
RECRUITING • NA • Updated 2025-08-08
Conditions: Long COVID / PASC / ME/CFS
AGENTS
Transcutaneous Vagus Nerve Stimulator
A prior open label study has shown that transcutaneous vagus nerve stimulation \[tVNS\] can improve the health of some patients with postacute sequelae of SARS-CoV-2 infection (PASC), severely affected enough to also fulfill criteria for myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS). The purpose of this study is to compare two sets of stimulus parameters to dete...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Study to Evaluate Benefits & Safety of Endourage Formula C™ Oral Drops in People With Post-Acute COVID-19 Syndrome.
NCT04828668
COMPLETED • NA • Updated 2025-08-07
Conditions: Long COVID / PASC
AGENTS
Targeted Wellness Formula C™ Sublingual Drops - 1200Mg - 30 Ml
This study will explore the contribution of CBD oral drops in persons experiencing symptoms of Post Acute COVID Syndrome or "PACS".
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Industry
Long COVID-19 Syndrome Lifestyle Intervention Study
NCT05836402
COMPLETED • NA • Updated 2025-08-07
Conditions: Long COVID / PASC
AGENTS
Low Carbohydrate Diet Intervention
Rationale: Hyper-inflammatory responses seen in acute COVID-19 are also a feature of long covid, a condition of long-term consequences that are persisting or appearing after initial infection and recovery from acute COVID-19. Long-standing, often disabling symptoms are common in long covid and can be highly varied. Common symptoms include fatigue, brain fog, muscle and chest pa...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Does a Technology Enabled Multi-disciplinary Team-based Care Model for the Management of Long COVID and Other Fatiguing Illnesses Improve Clinical Care of Patients and Represent a Sustainable Approach Within a Federally Qualified Health Center?
NCT05167227
ACTIVE_NOT_RECRUITING • NA • Updated 2025-08-06
Conditions: Long COVID / PASC / ME/CFS
AGENTS
Extension For Community Healthcare Outcomes
The primary objective of the present research is to determine the effectiveness of Family Health Center of San Diego's Long COVID and Fatiguing Illness Recovery Program (LC\&FIRP) on clinician- and patient-level outcomes. LC\&FIRP is comprised of a teleECHO program focused on multi-specialty case-consultation and peer-to-peer sharing of emerging best practices to support manage...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)
NCT07021794
RECRUITING • PHASE2 • Updated 2025-08-05
Conditions: Long COVID / PASC
AGENTS
Sipavibart
This placebo-controlled, randomized, blinded, two-arm phase II study will test the safety and potential efficacy of the targeted mAb, Sipavibart (formerly AZD3152) in patients with Long COVID.
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial
NCT06156176
RECRUITING • NA • Updated 2025-08-01
Conditions: Long COVID / PASC
AGENTS
Covidex
Long COVID is a complex condition that affects approximately 1.4 million Canadians following SARS-CoV-2 infection. Fatigue is the most common symptom of Long COVID. This feasibility trial will evaluate a new rehabilitation program called COVIDEx for treating fatigue after COVID-19, and compare its effectiveness to the standard treatment currently used. The experimental treatmen...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Evaluation of the Effectiveness of Breathing Control Technique on Long COVID Symptoms at the Reunion University Hospital
NCT05851859
RECRUITING • NA • Updated 2025-07-30
Conditions: Long COVID / PASC
AGENTS
Cardiac Coherence
Despite the controversy, on October 6, 2021, the World Health Organization (WHO) recognized Long Coronavirus disease (COVID) by officially defining it: " symptoms appeared 3 months after the onset of the primary infection by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), persisting for at least 2 months and which cannot be explained by any other condition ". ...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
Cognitive Rehabilitation Therapy for COVID-19
NCT06086379
ENROLLING_BY_INVITATION • NA • Updated 2025-07-30
Conditions: Long COVID / PASC
AGENTS
Compensatory Cognitive Training For Covid-19
Cognitive dysfunction, psychiatric symptoms, functional impairment, and disability following COVID-19 negatively impact Veterans' community functioning and quality of life, contribute to significant human suffering, and are costly to VHA. Rehabilitation is a critical priority for Veterans with long COVID. One promising treatment to improve functioning in Veterans with post-COVI...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Fed
Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)
NCT07089719
NOT_YET_RECRUITING • PHASE2 • Updated 2025-07-28
Conditions: Unspecified / Overlap
AGENTS
Bevacizumab Injection
The aim of this research is to evaluate an innovative treatment, Bevacizumab, in patients suffering from respiratory complications related to COVID-19. These complications, particularly difficulty breathing (dyspnea) and impaired lung function, are common in some individuals after infection. The study seeks to determine whether Bevacizumab can improve breathing capacity by acti...
View on ClinicalTrials.gov →
General Phase 2 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Telerehabilitation Decision Support System: Pilot Testing Protocol
NCT07079787
NOT_YET_RECRUITING • NA • Updated 2025-07-23
Conditions: Long COVID / PASC
AGENTS
Telerehab Dss Pilot Test
This study follows the successfully completed HOLOBalance project which was funded by the EU Horizon 2020 scheme. TheHOLOBalance platform delivers exercises demonstrated via a hologram of the physiotherapist and corrected in real time by the hologram prompts based on performance monitoring via sensors. Further information is available at: https://holobalance.eu/. HOLOBalance wa...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms
NCT05965752
COMPLETED • NA • Updated 2025-07-18
Conditions: Long COVID / PASC
AGENTS
Brainhq/Active Comparator ActivityBrainhqPasc CoreTdcs-Active
This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating potential inte...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Double-Blind Randomized Placebo-Controlled Trial of a Proprietary Full Hemp Flower Formulation for Long COVID
NCT05467904
WITHDRAWN • NA • Updated 2025-07-17
Conditions: Long COVID / PASC
AGENTS
Xltranplus, Xltran
This is a double-blind, randomized, placebo-controlled single-center clinical trial to explore the safety and efficacy of a full cannabis flower formulation, rich in cannabinoids and terpenes formulation, Xltran Plus™ and Xltran™, both compared to placebo for the treatment of Long COVID patients with prolonged symptoms caused by COVID-19.
View on ClinicalTrials.gov →
General NA Enrollment: Actual Sponsor Type: Other
Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation
NCT06940609
RECRUITING • PHASE2 • Updated 2025-07-15
Conditions: Long COVID / PASC
AGENTS
Accelerated Intermittent Theta Burst Stimulation
The goal of this clinical trial is to test whether a type of rapid outpatient brain stimulation that uses magnetic fields, called accelerated intermittent theta burst stimulation (iTBS), can treat symptoms such as brain fog, depression, and anxiety in patients with Long COVID. The main questions it aims to answer are: * Is iTBS effective and feasible for reducing Long COVID sy...
View on ClinicalTrials.gov →
Neurological / Autonomic Anti-inflammatory Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Telerehabilitation of Balance Clinical and Economic Decision Support System
NCT06534164
NOT_YET_RECRUITING • NA • Updated 2025-07-10
Conditions: Long COVID / PASC
AGENTS
Full/High Tech Telerehabilitation Decision Support SystemBasic/Low Tech Telerehabilitation Decision Support SystemOtago Home Exercise ProgramVestibular Rehabilitation Program
This study follows the successfully completed HOLOBalance project which was funded by the EU Horizon 2020 scheme. TheHOLOBalance platform delivers exercises demonstrated via a hologram of the physiotherapist and corrected in real time by the hologram prompts based on performance monitoring via sensors. Further information is available at: https://holobalance.eu/. HOLOBalance wa...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
Feasibility of an Augmented Two-Day Step Test and Causal Modeling for Post-Exertional Symptom Exacerbation in Post Covid-19 Syndrome
NCT06933017
COMPLETED • NA • Updated 2025-07-08
Conditions: Long COVID / PASC
AGENTS
Portable Mask For Respiratory Gas AnalysisCardio-Pulmonary Exercise Test
This study aims to evaluate exercise capacity and identify causes of Post-Exertional Symptom Exacerbation (PESE) in individuals with Long COVID. The investigators will compare the effectiveness of the Two-Day 6-Minute Incremental Step Test (6MIST) and the Cardiopulmonary Exercise Test (CPET) in detecting PESE. Additionally, the investigators will assess metabolism, mitochondria...
View on ClinicalTrials.gov →
Metabolic Mitochondrial Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Nutritional Management of Post COVID-19 Cognitive Symptoms
NCT05705648
RECRUITING • NA • Updated 2025-07-08
Conditions: Long COVID / PASC
AGENTS
Medium Chain Triglyceride OilSafflower Oil
The goal of this clinical trial is to learn about in brain "fog" complaints associated with long-COVID in people aged 22-50-years. The main questions it aims to answer are: * the natural course of brain "fog" complaints * the effect, if any of supplemental dietary oil on brain "fog" complaints Participants will be asked to undergo some brain testing (X-rays and questions. Trea...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Effects os Physiotherapeutic Rehabilitation on Function Autonomic and Inflammatory in Patients With Long Covid
NCT07046208
NOT_YET_RECRUITING • NA • Updated 2025-07-01
Conditions: Long COVID / PASC
AGENTS
Physiothreapy Protocol
Introduction: Long COVID is characterized by persistent symptoms that persist for weeks or months after the acute phase of infection, with a significant impact on the cardiovascular and autonomic systems. Objectives: This study aims to evaluate the effects of a physiotherapeutic rehabilitation protocol on cardiovascular autonomic modulation and on inflammatory and cardiac bioma...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Investigating the Effectiveness of Vimida
NCT06251518
ACTIVE_NOT_RECRUITING • NA • Updated 2025-06-18
Conditions: Long COVID / PASC
AGENTS
Vimida
This randomized controlled trial (RCT) with 160 patients suffering from fatigue after COVID-19 infection aims to investigate the effectiveness of the unguided digital therapeutic vimida for reducing post-COVID-19 fatigue. Inclusion criteria are: male, female or non-binary, age ≥18 years, diagnosis of post-COVID-19 fatigue, ≥3 months since the last infection with COVID-19, fatig...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Industry
A Study Evaluating the Efficacy of the Vielight Neuro RX Gamma in the Treatment of Post COVID-19 Cognitive Impairment
NCT05857124
COMPLETED • PHASE1 • Updated 2025-06-15
Conditions: Long COVID / PASC
AGENTS
Vielight Neuro Rx Gamma Active Device
Some people who have been infected with the virus that causes COVID-19 can experience long-term effects from their infection, known as post COVID-19 conditions (PCC) or long COVID1. The medical circles often describe it as post-acute sequelae of Covid-19 (PASC). People with post-COVID conditions can have a wide range of symptoms that can last more than four weeks or even months...
View on ClinicalTrials.gov →
Metabolic Mitochondrial Neurological / Autonomic Phase 1 Small (<50 participants) Enrollment: Actual Sponsor Type: Industry
Attention, Memory and Quality of Life in Post-COVID-19 Adults
NCT07005921
NOT_YET_RECRUITING • NA • Updated 2025-06-12
Conditions: Long COVID / PASC
AGENTS
Qeeg-Neurofeedback
The pandemic has highlighted social, economic, educational, and political issues that have affected the health and quality of life of millions of Brazilians. Currently, attention and memory impairment remains predominant among the cognitive symptoms of Coronavirus observed in adults. The persistance of the reffered impairment after 12 weeks of COVID-19 is known as cognitive imp...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Effects of Auricular Vagus Nerve Stimulation Combined With Slow-paced Breathing on Individuals With Postural Orthostatic Tachycardia Syndrome.
NCT06996314
NOT_YET_RECRUITING • NA • Updated 2025-06-04
Conditions: Long COVID / PASC
AGENTS
Tvns + Slow-Paced BreathingTvns Without Breathing Training
This study investigates a non-pharmacological treatment approach for Postural Orthostatic Tachycardia Syndrome (POTS), a disorder of the autonomic nervous system characterized by an excessive increase in heart rate upon standing. POTS is commonly associated with symptoms such as dizziness, fatigue, cognitive difficulties, sleep disturbances, as well as anxiety and depression, w...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Effects of an Active Coping Program in Patients With Persistent Post-Covid Pain.
NCT05894629
COMPLETED • NA • Updated 2025-06-04
Conditions: Long COVID / PASC
AGENTS
Active Comparator: Usual Treatment
Justification: among the sequelae of Covid-19 in clinical practice we frequently find persistent neuromusculoskeletal pain. Previous studies carried out by this research group and in the scientific literature have shown that "Pain Neuroscience Education" (PNE) and Therapeutic Exercise (TE) constitute an effective care strategy in the treatment of persistent pain. Therefore, wit...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Exploring the Therapeutic Effects of Creatine Supplementation for Long COVID-19
NCT06992414
NOT_YET_RECRUITING • NA • Updated 2025-05-31
Conditions: Long COVID / PASC
AGENTS
Creatine Monohydrate
Individuals living with Long COVID often experiencing a degree of undue fatigue after physical or cognitive exertion secondary to the condition, timed post-exertional malaise 9PEM). This trial aims to explore the efficacy of creatine monohydrate in managing PEM
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS
NCT05633407
COMPLETED • PHASE2 • Updated 2025-05-23
Conditions: Unspecified / Overlap
AGENTS
Efgartigimod
The study aims to investigate the safety, tolerability, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod compared to placebo in participants with post-COVID-19 postural orthostatic tachycardia syndrome (POTS) (post-COVID-19 POTS).
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Industry
Effectiveness and Acceptability of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in People With Long COVID-19.
NCT06928480
RECRUITING • NA • Updated 2025-05-22
Conditions: Long COVID / PASC
AGENTS
Unified Protocol For The Transdiagnostic Treatment Of Emotional DisordersTreatment As Usual
This Randomized Controlled Trial (RCT) aims to assess the effectiveness and acceptability of the Unified Protocol (UP) in an online group format for the treatment of emotional disorders in adults. Participants will be 90 adults (45 in the control group and 45 in the experimental group) with diagnosis of long COVID and comorbid emotional disorders. Participants will be recruited...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Effect of Metabolic Modulation on a Post-acute COVID-19 Vaccination Syndrome (PACVS) Cohort
NCT06967428
NOT_YET_RECRUITING • PHASE2 • Updated 2025-05-13
Conditions: Long COVID / PASC
AGENTS
Combined Metabolic ModulatorRice Protein Powder With Vitamin C
The goal of this clinical trial is to evaluate whether metabolic modulation with a combined nutraceutical product can improve symptoms and metabolic health in adults diagnosed with post-acute Covid-19 vaccination syndrome (PACVS), a condition characterized by persistent fatigue and exercise intolerance attributed to Covid-19 vaccination and confirmed by laboratory testing. The...
View on ClinicalTrials.gov →
Metabolic Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
The Long COVID-19 Wearable Device Study
NCT05741112
RECRUITING • NA • Updated 2025-05-11
Conditions: Long COVID / PASC / ME/CFS
AGENTS
Wearable Device
To further characterize Long COVID-19 by collecting data from individuals who already own wearable devices or are provided with a wearable device along with basic and enhanced educational materials to determine if both can improve Long COVID-19 symptom management and post-exertional malaise.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Very Large (1000+ participants) Enrollment: Estimated Sponsor Type: Other
RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms
NCT05965739
COMPLETED • NA • Updated 2025-05-04
Conditions: Long COVID / PASC
AGENTS
Brainhq/Active Comparator ActivityBrainhqPasc CoreTdcs-Active
This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating potential inte...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Feasibility and Preliminary Efficacy of a Group-based Telerehabilitation Program in People With Post-COVID-19 Sequelae (TEPCO).
NCT06952127
COMPLETED • NA • Updated 2025-04-30
Conditions: Long COVID / PASC
AGENTS
Rehabilitation Program
The goal of this study pilot randomized controlled study is to evaluate the feasibility of the study procedures and to compare the preliminary efficacy of a rehabilitation program given in a "remote" (telerehabilitation) or "face-to-face" model for adult patients who had confirmed SARS-CoV-2 infection and still have symptoms after eight weeks of infection. The main question it ...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
The Effect of Smart Sensor Combined With APP for Individualized Precise Exercise Training in Long Covid-19
NCT05922865
COMPLETED • NA • Updated 2025-04-27
Conditions: Long COVID / PASC
AGENTS
Kneesup Smart Knee Assistive Device + Kneesup Care AppHealthy Consulation
The coronavirus (COVID -19) has rapidly turned into a global pandemic. For patients diagnosed with COVID-19, it caused severe damage in the upper respiratory system and systemic complications, including the cardiovascular, mental, nervous, and musculoskeletal system. Previous research has indicated that these subsequent sequelae can reduce quality of life. (A. W. Wong et al., 2...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
The Roles of Vitamin D and Microbiome in Children With Post-acute COVID-19 Syndromes (PACS) and Long COVID
NCT05633472
COMPLETED • NA • Updated 2025-04-17
Conditions: Long COVID / PASC
AGENTS
Vitamin D
A double-blind study to evaluate the role of human microbiome and vitamin D in the development of long COVID and PACS in children.
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy
NCT04904536
ACTIVE_NOT_RECRUITING • PHASE3 • Updated 2025-04-10
Conditions: Unspecified / Overlap
AGENTS
Atorvastatin
STRONGER is an international, investigator initiated and conducted, pragmatic clinical trial to determine whether 40mg atorvastatin daily can improve neurocognitive function in adults with long COVID neurological symptoms. The objective is to determine effectiveness of treatment with 40mg atorvastatin over 12 months on attenuating cognitive decline and neuroinflammatory biomark...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 3 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Physical Training in Patients With POTS After Covid-19
NCT05094622
ACTIVE_NOT_RECRUITING • NA • Updated 2025-04-06
Conditions: Long COVID / PASC
AGENTS
Physical Exercise Program
Covid-19 has the potential to affect physical, cognitive and psychological functions in multiple ways. It has been clear that a significant proportion of patients with Covid-19 develop long-term symptoms. The term post-acute Covid-19 syndrome (PACS) is now used to describe the wide range of prolonged symptoms following the infection. Patients may need specialized rehabilitation...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Developing an Integrative, Recovery-Based, Post-Acute COVID-19 Syndrome (PACS) Psychotherapeutic Intervention
NCT05453201
COMPLETED • NA • Updated 2025-04-02
Conditions: Long COVID / PASC
AGENTS
Long Covid Coping And Recovery (Lccr) Intervention
Post-Acute COVID-19 Syndrome (PACS), colloquially known as Long COVID, is a prevalent phenomenon that affects thousands of Veterans in VA care. VA patients suffering from Long COVID not only experience lingering physical symptoms following COVID-19 infection, but have increased mental health problems including sleep disorders, anxiety disorders, trauma and stress-related disord...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Fed
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
NCT05530317
RECRUITING • NA • Updated 2025-04-02
Conditions: Long COVID / PASC
AGENTS
Cardiac Rehabilitation
The goal of this proof-of-concept clinical trial is to determine whether cardiac rehabilitation improves exercise capacity and chronotropic (heart rate) response to exercise among people with Long COVID. The study will include individuals with confirmed SARS-CoV-2 infection, symptoms not present prior to COVID-19 that are persistent for at least 3 months after acute infection (...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Periodic Fasting for Treatment of Long Covid in Adults: a Pilot Study
NCT06522750
RECRUITING • NA • Updated 2025-03-30
Conditions: Long COVID / PASC
AGENTS
7-Day Ambulatory Caloric Restriction Intervention Using The Buchinger-Wilhelmi Method
Background: Long COVID, characterized by persistent symptoms following acute COVID-19 infection, has emerged as a significant public health concern. Symptoms range from fatigue, cognitive impairments, to respiratory difficulties, affecting patients\&#39; quality of life. Dietary interventions, particularly fasting, have historically been used to modulate immune responses and i...
View on ClinicalTrials.gov →
Metabolic Immunomodulatory Neurological / Autonomic Anti-inflammatory NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Symptom-based Rehabilitation Compared to Usual Care in Post-COVID - a Randomized Controlled Trial
NCT05172206
COMPLETED • NA • Updated 2025-03-28
Conditions: Long COVID / PASC
AGENTS
Symptom-Focused Rehabilitation
Inpatient, multimodal rehabilitation represents one of the most important interventions in the disease management of post/long COVID. Different professional societies, including the German Society of Pneumology and the European Respiratory Society, recommend rehabilitation intervention to reduce the sequelae of COVID-19. However, from the perspective of science and practice, th...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Cardiopulmonary Rehabilitation in Post-acute COVID-19 Syndrome
NCT05539950
WITHDRAWN • NA • Updated 2025-03-26
Conditions: Long COVID / PASC
AGENTS
Cardiopulmonary Rehabilitation
In 2022, though the optimized acute medical treatment of COVID-19 was determined, patients often experience the sequelae (also known as post-acute COVID-19 syndrome, the patients might develop cough, breathlessness, fatigue, weakness, impaired activities of daily livings etc.). Until now, there is no consensus for post-acute COVID-19 syndrome management. Previously, the cardiop...
View on ClinicalTrials.gov →
General NA Enrollment: Actual Sponsor Type: Other
Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome
NCT05682560
COMPLETED • PHASE2 • Updated 2025-03-24
Conditions: Long COVID / PASC
AGENTS
Regenecyte
REGENECYTE (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID.
View on ClinicalTrials.gov →
General Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Industry
A MHealth System for Patients with POTS
NCT06296914
COMPLETED • NA • Updated 2025-03-21
Conditions: Unspecified / Overlap
AGENTS
Potsapp
Postural Orthostatic Tachycardia Syndrome (POTS) affects approximately 500,000 - 3 million Americans. This number will only increase due to the large number of patients experiencing POTS due to "long COVID." POTS patients experience several symptoms, including tachycardia, palpitations, dizziness, and pre-syncope or syncope, among others. POTS can be very debilitating and not o...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID
NCT06883513
RECRUITING • NA • Updated 2025-03-19
Conditions: Long COVID / PASC
AGENTS
Osteopathic Manipulative Therapy Long-Covid ProtocolOsteopathic Manipulative Therapy Not Long-Covid Treatment Protocol
This study is investigating the effects of using an Osteopathic Manipulative Therapy (OMT) treatment protocol that was shown to statistically improve smell in individuals suffering from Long-COVID olfactory (smell) dysfunction in a small single-blinded pilot trial conducted during 2021. The questions this study is trying to answer are: 1. Does this OMT protocol improve other ...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Nitrite Supplementation in Long COVID Patients
NCT05618574
COMPLETED • PHASE2 • Updated 2025-03-19
Conditions: Long COVID / PASC
AGENTS
140 Ml Per Day Of Beet-It Nitrate Beverage
Potential benefits of a nitrate-rich juice supplement to improve skeletal muscle function and associated physical capacity will be studied in patients with Long COVID. Consenting patients with Long-COVID will be randomized to receive Beet-It nitrate beverage group versus a nitrate-depleted placebo beverage. Both groups will receive physical therapy at the long COVID Clinic at V...
View on ClinicalTrials.gov →
General Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Fed
NENCA Study on Neurological Complications of Long COVID-19 in Children and Adolescents; Neurophysiological, Electroencephalographic and Neuroradiological Investigation
NCT06876948
RECRUITING • NA • Updated 2025-03-14
Conditions: Long COVID / PASC
AGENTS
Psychological Tests, Eeg, Magnetic Resonance
The study seeks to investigate the neurological effects caused by Covid-19 in children and adolescents in the 6-16 age group. To do this, neuropsychological scales, an EEG and an MRI were used.
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID
NCT05638620
COMPLETED • PHASE1 • Updated 2025-03-13
Conditions: Long COVID / PASC
AGENTS
Stellate Ganglion Block With 0.5% Bupivacaine
The main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms.
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 1 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Telerehabilitation in People With Long COVID
NCT05205460
COMPLETED • NA • Updated 2025-03-11
Conditions: Long COVID / PASC
AGENTS
Home-Based Telerehabilitation
The aim of our study is to investigate the effectiveness of telerehabilitation in Post-COVID patients.
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Post-COVID-19 Chronic Fatigue Syndrome
NCT05642923
COMPLETED • PHASE4 • Updated 2025-03-10
Conditions: Long COVID / PASC
AGENTS
Synthetic Vitamin B1
Fatigue is recognized as one of the most commonly presented long-term complaints in individuals previously infected with SARS-CoV-2.
View on ClinicalTrials.gov →
General Phase 4 Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Effectiveness of Testofen Compared to Placebo on Long COVID Symptoms
NCT05795816
COMPLETED • PHASE3 • Updated 2025-03-10
Conditions: Long COVID / PASC
AGENTS
TestofenMicrocrystalline Cellulose
This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed Testofen (a specialised extract of Trigonella foenum-graecum (Fenugreek) seed) compared to placebo on post COVID-19 symptoms in otherwise healthy participants 18 years and over.
View on ClinicalTrials.gov →
General Phase 3 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Industry
Effects of L-ARGinine and Liposomal Vitamin C Supplementation On Physical Performance
NCT06865261
UNKNOWN • NA • Updated 2025-03-07
Conditions: Unspecified / Overlap
AGENTS
Bioarginina C
In older age, reduced mobility is associated with an increased risk of reduced quality of life, disability, institutionalisation, and death, as well as increased healthcare expenditures. Sarcopenia is a condition characterised by a reduction in muscle mass and strength and/or function. It is associated with several adverse outcomes, such as falls, increased risk of infection, d...
View on ClinicalTrials.gov →
Anti-inflammatory NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
A Web-based Platform to Improve Physical Function, Nutrition, and Mindfulness in Patients With Long COVID
NCT05422924
COMPLETED • NA • Updated 2025-03-06
Conditions: Long COVID / PASC
AGENTS
Web-Based Platform.
Patients with COVID-19 may experience prolonged physical and psychological symptoms after weeks or months of the infection. This may be caused by a combination of factors including poor nutrition, low physical activity, and lack of emotional support. Leading to poor overall health and low quality of life. This evidence indicated that people with long COVID-19 need a personalize...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction
NCT06597682
NOT_YET_RECRUITING • NA • Updated 2025-03-06
Conditions: Long COVID / PASC
AGENTS
PrednisoneBudesonide/FormoterolVitamin C Combined With Coenzyme Q10 Oral TreatmentMontelukast Tablets Oral Treatment
This study is a prospective, randomized controlled, basket trial. Patients diagnosed with Post-Acute Sequelae of SARS-CoV-2 Infection who meet the inclusion and exclusion criteria are recruited and divided into three symptom clusters: Inflammatory Cardiac involvement symptoms cluster, cough symptoms cluster and fatigue symptoms cluster. Each symptom cluster is randomly divided ...
View on ClinicalTrials.gov →
Immunomodulatory NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
Effect of Lithium Therapy on Long COVID Symptoms
NCT05618587
COMPLETED • PHASE2 • Updated 2025-03-05
Conditions: Long COVID / PASC
AGENTS
Lithium
This study will assess low-dose lithium's effects on several different symptoms experienced by long COVID patients.
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Brain and Gut Plasticity in Mild TBI or Post-acute COVID Syndrome Following Growth Hormone Therapy
NCT03554265
COMPLETED • PHASE3 • Updated 2025-03-05
Conditions: Long COVID / PASC
AGENTS
Somatropin
Patients with a history of mild traumatic brain injury (mTBI) or post acute sequelae of SARS-CoV-2 (PASC) and abnormal growth hormone secretion, as measured by glucagon stimulation test, will be treated with replacement growth hormone therapy for a period of 6 months (mTBI) or 9 months (PASC). Testing of cognition, exercise, fatigue, brain activation and morphology, body compos...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 3 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
CISCO-21 Prevent and Treat Long COVID-19.
NCT04900961
COMPLETED • NA • Updated 2025-02-25
Conditions: Long COVID / PASC
AGENTS
Resistance Exercise
Many people have long-lasting symptoms after COVID-19, such as breathlessness, fatigue and chest pain. So far, research studies of treatments for COVID-19 have focused on the life-threatening acute illness; few studies look at treatments to improve long-term health after COVID-19. COVID-19, particularly when this requires a hospital admission, can lead to weight loss and muscle...
View on ClinicalTrials.gov →
General NA Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Effectiveness of a Personalized In-home Telerehabilitation Program on Self-Care in Patients with Long COVID
NCT06822179
NOT_YET_RECRUITING • PHASE2 • Updated 2025-02-18
Conditions: Long COVID / PASC
AGENTS
Personalised Exercise Program
The goal of this clinical trial is to evaluate whether a 12-week tele-rehabilitation programme with monitoring via a mobile app produces medium-term improvements in self-management, fatigue and quality of life in patients affected by persistent COVID. The main questions it aims to answer are: * Will a multimodal program (exercise with education) improve the self-management ab...
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Group Psychotherapy in Long COVID
NCT06726772
COMPLETED • NA • Updated 2025-02-18
Conditions: Long COVID / PASC
AGENTS
Group Psychotherapy
The aim of the present study was to establish a single-arm group psychotherapy and to evaluate its clinical effectiveness in long COVID patients.
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Yogic Breathing and Guided Meditation for Long Covid Symptoms
NCT05139979
COMPLETED • NA • Updated 2025-02-06
Conditions: Long COVID / PASC
AGENTS
Breathing And Wellness WebinarRoutine Daily Activity
This study aims to assess the impact of brief digitally delivered breathing practice and guided meditation on post-Covid physical and mental symptoms in Long Covid Patients.
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Mental Intervention and Nicotinamide Riboside Supplementation in Long Covid
NCT05703074
ACTIVE_NOT_RECRUITING • PHASE2 • Updated 2025-02-05
Conditions: Long COVID / PASC
AGENTS
Nicotinamide RibosideMind-Body Reprocessing TherapyCare As Usual
Long COVID, also referred to as post-acute sequela of COVID-19 (PASC), is present in a substantial number of individuals, and treatment for this is warranted. Two different hypothetical models of Long COVID suggest attenuated mitochondrial energy production and functional brain alterations associated with psychosocial load, respectively, to be key mechanisms in the underlying p...
View on ClinicalTrials.gov →
Metabolic Mitochondrial Neurological / Autonomic Anti-inflammatory Phase 2 Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
REGAIN: RCT of Oxaloacetate for Fatigue in Long COVID
NCT05840237
COMPLETED • NA • Updated 2025-02-04
Conditions: Long COVID / PASC
AGENTS
Anhydrous Enol-Oxaloacetate, A "Medical Food"White Rice Flour
Following acute COVID-19, some patients develop a group of debilitating symptoms that include fatigue, orthostatic intolerance, difficulty with attention and concentration (often called "brain fog"), myalgias and disrupted sleep. The term Long COVID is used to describe these symptoms after the initial viral infection has passed. These symptoms are the same as those that define ...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Industry
REVERSE-Long COVID-19 With Baricitinib Study
NCT05858515
WITHDRAWN • PHASE3 • Updated 2025-01-31
Conditions: Long COVID / PASC
AGENTS
Baricitinib 4 Mg
REVERSE-LC is a phase 3 trial of baricitinib versus placebo in adults with neurocognitive impairment (a form of Alzheimer's Disease and Related Dementias or ADRD) or cardiopulmonary symptoms due to Long COVID.
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 3 Enrollment: Actual Sponsor Type: Other
Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial
NCT06792214
RECRUITING • PHASE4 • Updated 2025-01-24
Conditions: Unspecified / Overlap
AGENTS
Paxlovid (Nirmatrelvir/Ritonavir)Remdesivir
The DEFEND trial will be the world's first clinical trial to study the effectiveness of Paxlovid or Veklury in the prevention of cardiovascular post-acute sequelae of SARS-CoV-2 among hospitalized adults. Additionally, this pilot study will inform the design and conduct of a future full-scale multi-centre trial by testing the feasibility and accuracy of this study design.
View on ClinicalTrials.gov →
Persistence / Antiviral Phase 4 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Research of the Long-COVID-19 Syndrome in the Children
NCT05817006
COMPLETED • NA • Updated 2025-01-23
Conditions: Long COVID / PASC
AGENTS
Device
During the pandemic of the new coronavirus infection COVID-19 in the world community, in the Russian Federation, in particular in the Samara region throughout the pandemic period from the end of 2019, when the first outbreak of a new coronavirus infection occurred in Wuhan (Hubei Province) in the People's Republic of China, the main focus on prevention (development of modern va...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Cognitive Rehabilitation for Long COVID
NCT05676047
COMPLETED • NA • Updated 2025-01-23
Conditions: Long COVID / PASC
AGENTS
Cognitive Rehabilitation
The investigators are comparing two different methods for helping adults with Long Coronavirus (COVID) also known as Post-Coronavirus Syndrome or Post-Coronavirus Condition manage everyday cognitive challenges. Cognitive rehabilitation is a type of therapy that helps people who have challenges with everyday thinking because of a brain injury. One of the investigators on this pr...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions
NCT05592418
COMPLETED • PHASE2 • Updated 2025-01-22
Conditions: Long COVID / PASC
AGENTS
Rintatolimod
The purpose of this study is to assess the efficacy and safety of Ampligen® administered twice weekly by intravenous (IV) infusions in subjects experiencing the Post-COVID Condition of fatigue.
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Industry
Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2
NCT06316843
COMPLETED • PHASE2 • Updated 2025-01-22
Conditions: Long COVID / PASC
AGENTS
Valacyclovir Celecoxib Dose 1Valacyclovir Celecoxib Dose 2
To explore the safety and efficacy of daily doses of celecoxib + valacyclovir in the treatment of patients with prolonged symptoms caused by COVID-19.
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Optimising General Practice Long COVID Care - an Educational Intervention.
NCT06765421
NOT_YET_RECRUITING • NA • Updated 2025-01-09
Conditions: Long COVID / PASC
AGENTS
Intervention Group
This trial will evaluate the feasibility of a pilot educational intervention for GPs that aims to enhance care and care outcomes among patients with long COVID at six general practices in the Ireland East region. Our first objective is to conduct focus groups with key stakeholders (GPs, other health professionals, patients, families/carers) that will inform the contents of an ...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Effects of a Home-Based Exercise Intervention in Subjects with Long COVID
NCT06073002
ACTIVE_NOT_RECRUITING • NA • Updated 2024-12-11
Conditions: Long COVID / PASC
AGENTS
Home-Based Concurrent Exercise
The current Coronavirus Disease 2019 (COVID-19) pandemic is the most severe health crisis of the 21st century. This is not only due to the deaths caused by the disease. People that were affected by COVID-19 and supposedly recovered may suffer from long lasting sequelae. The presence of symptoms longer than 3 months after the infection with the Severe Acute Respiratory Syndrome ...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Narrative Intervention for Long COVID-19 (NICO)
NCT06091293
COMPLETED • NA • Updated 2024-12-10
Conditions: Long COVID / PASC
AGENTS
Narrative Intervention For Long Covid-19
This T1 proof of concept trial is designed to test the Narrative Intervention for Long COVID-19 intervention.
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Effects of Individual Tailored Physical Exercise in Patients With POTS After COVID-19 - a Randomized Controlled Study
NCT05877534
ENROLLING_BY_INVITATION • NA • Updated 2024-12-09
Conditions: Long COVID / PASC
AGENTS
Individual Tailored Exercise
Covid-19 has the potential to affect physical, cognitive and psychological functions in multiple ways. It has been clear that a significant proportion of patients with Covid-19 develop long-term symptoms. The term post COVID-19 condition (defined by WHO) is used to describe the wide range of prolonged symptoms following the infection. Patients may need specialized rehabilitatio...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Brain Research and Integrative Neuroscience Network for COVID-19
NCT06517706
RECRUITING • NA • Updated 2024-12-06
Conditions: Unspecified / Overlap
AGENTS
Combination Of TdcsCategorization Program
The aim of the experimental study is to investigate two interventions for the management of cognitive symptoms resulting from long COVID. Participants will be randomly assigned into two interventions. 1. Categorization Program (CP) training with active tDCS or 2. Categorization Program training with sham tDCS.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2
NCT05833217
RECRUITING • NA • Updated 2024-12-04
Conditions: Long COVID / PASC
AGENTS
Adipose Tissue BiopsySteady State Plasma Glucose (Sspg) Test
The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir for SARS-CoV-2 persistence. The results will not only determine whether obesity ...
View on ClinicalTrials.gov →
Persistence / Antiviral Anti-inflammatory NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
ImPROving Quality of LIFe in the Long COVID Patient
NCT05823896
COMPLETED • PHASE2 • Updated 2024-12-04
Conditions: Long COVID / PASC
AGENTS
Paxlovid (Nirmatrelvir/Ritonavir)
The purpose of this study is to investigate the efficacy of orally administered nirmatrelvir/ritonavir compared with placebo/ritonavir to improve quality of life in non-hospitalized adult participants suffering from post-acute COVID-19 syndrome.
View on ClinicalTrials.gov →
Neurological / Autonomic Anti-inflammatory Phase 2 Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study
NCT05096884
TERMINATED • EARLY_PHASE1 • Updated 2024-12-03
Conditions: Long COVID / PASC
AGENTS
Metoprolol Succinate
Most patients with acute COVID-19 (Coronavirus 19) recover within weeks, however a significant number of individuals will develop the post-acute COVID 19 syndrome (PASC). As of July 2021, the post COVID syndrome qualifies as a disability under the Americans with Disabilities Act. The symptoms which comprise this condition are highly variable and often extraordinarily debilitati...
View on ClinicalTrials.gov →
General EARLY_Phase 1 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Combined Pulmonary Rehabilitation and PMR for Long-Term COVID-19 Symptoms: A RCT
NCT06492577
COMPLETED • NA • Updated 2024-12-03
Conditions: Long COVID / PASC
AGENTS
Pulmonary Rehabilitation ProtocolProgressive Muscle Relaxation Protocol
Our study aimed to evaluate the effectiveness of a 21-day program combining pulmonary rehabilitation (PR) with progressive muscle relaxation (PMR) in patients experiencing long-term symptoms of COVID-19. Participants with persistent symptoms will be randomly assigned to either a PR group or a PR combined with PMR group. The PR program includes aerobic exercises, strength traini...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other Gov
A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.
NCT05668091
COMPLETED • PHASE2 • Updated 2024-12-02
Conditions: Long COVID / PASC
AGENTS
Paxlovid (Nirmatrelvir/Ritonavir)Ritonavir
This decentralized trial is a Phase 2, 1:1 randomized, double-blind, superiority, placebo-controlled study in an anticipated 100 non-hospitalized highly symptomatic adult participants with long COVID. It seeks to determine the efficacy, safety, and tolerability of 15 days of Paxlovid (nirmatrelvir/ritonavir), an anti-viral agent, compared with placebo plus ritonavir. The hypoth...
View on ClinicalTrials.gov →
Immunomodulatory Persistence / Antiviral Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Virtual Physical Rehabilitation for Patients Living with Long COVID
NCT05298878
COMPLETED • NA • Updated 2024-11-27
Conditions: Long COVID / PASC
AGENTS
Intervention Group: Virtual Home-Based Rehabilitation Plus Usual Outpatient Care
The purpose of this study is to investigate whether a timely, virtual home-based physical rehabilitation program for patients living with long COVID can improve functional mobility compared to usual care.
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.
NCT06441955
RECRUITING • PHASE4 • Updated 2024-11-27
Conditions: Long COVID / PASC
AGENTS
Paxlovid (Nirmatrelvir/Ritonavir)Physiological EvaluationModerna Covid-19 VaccineBiopsychologicalBehavioralGeneticMultidisciplinary Approach
Investigators are conducting a study on alternative treatments for patients who have received an current or previous positive COVID-19 diagnosis with mild-serve symptoms or undiagnosable condition after testing positive for severe acute COVID-19 infection and are experiencing long-haul symptoms. The symptoms of long COVID can include extreme tiredness (fatigue), shortness of br...
View on ClinicalTrials.gov →
Persistence / Antiviral Neurological / Autonomic Phase 4 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Network
A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection
NCT05472090
COMPLETED • PHASE2 • Updated 2024-11-26
Conditions: Long COVID / PASC
AGENTS
Tnx-102 Sl
This is a Phase 2, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken once daily at bedtime for the management of multi-site pain associated with Long COVID.
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Industry
Self-Management Interventions for Long COVID-19
NCT05268523
RECRUITING • NA • Updated 2024-11-25
Conditions: Long COVID / PASC
AGENTS
Mindfulness Skills Intervention
The purpose of this study is to investigate and compare the feasibility and efficacy of two group-based interventions (education vs. mindfulness) to help self-manage Long-COVID symptoms.
View on ClinicalTrials.gov →
General NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
Fascial Tissue Response to Manual Therapy: Implications in Long COVID-19
NCT06348186
UNKNOWN • NA • Updated 2024-11-20
Conditions: Long COVID / PASC
AGENTS
GuidebookGuidebook And Myofascial Reorganization® (Rmf).
According to the World Health Organization (WHO), as of mid-September 2022, more than 21 million Brazilians have recovered from COVID-19. However, post-infection symptoms continue to appear months after the end of the acute infection, a syndrome called long COVID. Therefore, the aim of this study is to investigate the responses of fascia-focused manual therapy in participants w...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Acupuncture for Post COVID-19 Condition (Long COVID) Neuropsychiatric Symptoms
NCT06633666
RECRUITING • NA • Updated 2024-11-13
Conditions: Long COVID / PASC
AGENTS
Acupuncture
In this study, a 12-week pragmatic, randomized, double-blinded clinical trial will be conducted to evaluate the efficacy of acupuncture for the treatment of long Covid neuropsychiatric symptoms and provide reference for clinical non-drug treatment.
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
VNS for Long-COVID-19
NCT05630040
COMPLETED • NA • Updated 2024-11-08
Conditions: Long COVID / PASC
AGENTS
Non-Invasive Vagus Nerve Stimulation
The goal of this proposed clinical case series is to evaluate the effect of a non-invasive vagus nerve stimulation paradigm on: 1) Symptom reporting via validated patient reported outcomes, and 2) objective clinical biomarkers of autonomic nervous system function. This will be a placebo controlled, randomized controlled trial with a crossover design built in. This study will a...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Cardiopulmonary Rehabilitation in Long COVID-19 Patients With Persistent Breathlessness and Fatigue
NCT05035628
COMPLETED • NA • Updated 2024-11-05
Conditions: Long COVID / PASC
AGENTS
Cardiopulmonary Exercise Training
The objective of this project is to assess the effects of a 2-month cardiopulmonary rehabilitation program on cardiorespiratory fitness in long COVID19 patients. Quality of life, functional capacity, functional respiratory capacity, inflammatory profile, coagulation markers, cognitive functions and brain O2 saturation will also be assessed before and after the exercise rehabili...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19
NCT05371288
WITHDRAWN • EARLY_PHASE1 • Updated 2024-11-05
Conditions: Long COVID / PASC
AGENTS
N-Acetylcysteine (NAC)
The purpose of this research study is to assess if glutathione, along with NAC (N-acetyl cysteine) and Alpha lipoic acid (ALA), can help reverse some of the COVID long-haul symptoms.Subjects will be randomized in to one of two groups. Depending on the group they are randomized in to, subjects will be taking either a combination of NAC, Alamax CR, and liposomal GSH or the same t...
View on ClinicalTrials.gov →
General EARLY_Phase 1 Enrollment: Actual Sponsor Type: Other
Stellate Ganglion Block With Lidocaine for the Treatment of COVID-19-Induced Parosmia
NCT06055270
UNKNOWN • PHASE3 • Updated 2024-10-23
Conditions: Unspecified / Overlap
AGENTS
Stellate Ganglion Block
Chronic olfactory dysfunction, both hyposmia and parosmia, from the COVID-19 pandemic is a growing public health crisis, affecting up to 1.2 million people in the United States. Olfactory dysfunction significantly impacts one's quality of life by decreasing the enjoyment of foods, creating environmental safety concerns, and affecting one's ability to perform specific jobs. Olfa...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 3 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Lithium Long COVID Dose-finding Study
NCT06108297
COMPLETED • PHASE1 • Updated 2024-10-22
Conditions: Long COVID / PASC
AGENTS
Lithium
This open-label study will assess if lithium dosages of 30-45mg/day are associated with greater symptomatic benefit than dosages of 10-15mg/day previously assessed among 50 patients with long COVID.
View on ClinicalTrials.gov →
General Phase 1 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Randomised Study to Investigate the Effectiveness of Acupuncture for the Relief of Long COVID-19 Related Fatigue
NCT05212688
COMPLETED • PHASE2 • Updated 2024-10-18
Conditions: Long COVID / PASC
AGENTS
Acupuncture
The Covid pandemic has left us with a significant number of people suffering from Long COVID, which is a clinical diagnosis of significant and varying ongoing symptoms at least 12 weeks following COVID-19 infection and characterised frequently by fatigue and breathlessness. Acupuncture has been shown to help breathlessness and fatigue in other conditions including in patients w...
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19
NCT06311435
RECRUITING • NA • Updated 2024-10-18
Conditions: Long COVID / PASC
AGENTS
Rna Biomarker Blood Test
The Primary objective of this study is to determine, using unblinded samples, if it is possible to develop an algorithm for the classification of specific blood RNA from patients with long COVID together and separately from the apparent health normal controls and other medical conditions that share the signs and symptoms of long COVID.
View on ClinicalTrials.gov →
General NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Industry
Uninterrupted and Interrupted Sitting in Long COVID-19
NCT05453175
COMPLETED • NA • Updated 2024-10-03
Conditions: Long COVID / PASC
AGENTS
Interrupting Sitting With Physical Activity
People who sit uninterrupted for prolonged periods time have been shown to have poorer cardiovascular health compared to those that regularly interrupt it (e.g. standing up and moving). Cognition and brain function has also been shown to be impaired following uninterrupted sitting. Research has shown that interrupting sitting with exercise improves cardiovascular health in heal...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients
NCT04482595
UNKNOWN • PHASE2 • Updated 2024-10-01
Conditions: Long COVID / PASC
AGENTS
Bio 300 Oral Suspension
This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the safety and efficacy of BIO 300 Oral Suspension (BIO 300) as a therapy to improve lung function in patients that were hospitalized for severe COVID-19-related illness and continue to experience post-acute respiratory complications associated with Long-COVID after discharge. Patients will be r...
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Industry
Pulmonary Rehabilitation for Long COVID (Post COVID-19 Condition)
NCT05244044
COMPLETED • NA • Updated 2024-10-01
Conditions: Long COVID / PASC
AGENTS
Pulmonary Rehabilitation In Primary Care
In the PuRe COVID study (a randomized, controlled, multicenter, pragmatic trial) the investigators aim to assess the effect of a pulmonary rehabilitation program in primary care on exercise capacity (6MWT) and daily life physical activity in patients with long COVID. 134 patients with long COVID, defined by self-reported persistent COVID related symptoms ≥6 weeks after COVID-1...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Effects of Cacao Flavonoids in Long COVID-19 Patients (FLALOC)
NCT06064838
COMPLETED • NA • Updated 2024-10-01
Conditions: Long COVID / PASC
AGENTS
Flavonoids
The study use a triple blind, placebo-controlled design enrolling male and female subjects between 30-70 yo to evaluate the effect of daily consumption of a cacao supplement on inflammation, endothelial damage, handgrip strength, fatigue scale and quality of life.
View on ClinicalTrials.gov →
Anti-inflammatory NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Pilot Study of Vitamin K2 (MK-7) and Vitamin D3 Supplementation and the Effects on PASC Symptomatology and Inflammatory Biomarkers
NCT05356936
COMPLETED • NA • Updated 2024-09-27
Conditions: Long COVID / PASC
AGENTS
Vitamin K2Vitamin D3
Participants are being asked to take part in this research study because they have had a previous diagnosis (at least 3 months ago) of COVID-19 and are experiencing persistent, recurrent or even new symptoms, i.e. post-acute sequelae of SARS-CoV-2 (PASC). The Investigators are interested in studying the effects of Vitamin K2 (MK-7) and Vitamin D3 supplementation on PASC symptom...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Feasibility Pilot Clinical Trial of Omega-3 Supplement vs. Placebo for Post Covid-19 Recovery Among Health Care Workers
NCT05121766
TERMINATED • PHASE1 • Updated 2024-09-19
Conditions: Long COVID / PASC
AGENTS
Omega-3
This is a two-arm, double blind randomized 12-week study to supplement omega-3 (Eicosapentaenoic acid - EPA + docosahexaenoic acid - DHA) among 100 adults (age 18+) who had coronavirus-19 (covid-19) and are experiencing possible after-effects from post-acute sequelae of covid-19 (also called post-covid syndrome or long covid syndrome).
View on ClinicalTrials.gov →
General Phase 1 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
The Impact of Chiropractic on Long COVID-19
NCT05693064
SUSPENDED • NA • Updated 2024-08-28
Conditions: Long COVID / PASC
AGENTS
Chiropractic Adjustments
The purpose of this waitlist-controlled, single-blind, one-way crossover, pilot trial is to evaluate the potential effects of \~8 weeks of chiropractic care on patient-reported fatigue and the autonomic nervous system in adults with long COVID. This study will allow us to estimate the standard deviation of the primary endpoint in our population with which a formal power calcula...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Treatment of COVID-19 Post-acute Cognitive Impairment Sequelae With tDCS
NCT05389592
COMPLETED • NA • Updated 2024-08-27
Conditions: Long COVID / PASC
AGENTS
Active Tdcs And Cognitive Training
After almost 2 years of pandemic, the consequences of the post-COVID syndrome, or PASC (Post Acute-Sequelae of Sars-CoV-2), have become a major challenge in the management of affected patients, generating costs for health services. and insecurity regarding treatments for the sequelae, given the complex and still poorly understood pathophysiology of COVID-19. This troubling sce...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Safety and Efficacy of Hyperbaric Oxygen Therapy for Long COVID Syndrome
NCT04842448
COMPLETED • PHASE2 • Updated 2024-08-22
Conditions: Long COVID / PASC
AGENTS
Hyperbaric Oxygen Therapy (HBOT)
Long COVID Syndrome (Long COVID), Post Acute COVID-19 Syndrome (PACS) or Post COVID-19 Syndrome (PCS) is defined as 'signs and symptoms that develop during or following an infection consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis'. 1 in 10 infected individuals may suffer persistent symptoms, and we are facing an emergi...
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Efficacy of Lactobacillus Paracasei PS23 for Patients With Post-COVID-19 Syndrome
NCT05813899
TERMINATED • NA • Updated 2024-08-15
Conditions: Long COVID / PASC
AGENTS
Ps23 Heat-Treated
To evaluate whether probiotics PS23 can improve the symptoms of patients with long COVID-19 ; also to evaluate the effects on blood cortisol and inflammation-related indicators in patients.
View on ClinicalTrials.gov →
Anti-inflammatory NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Effect of Red Beetroot Juice Intake in Adults With Long COVID-19
NCT06535165
COMPLETED • NA • Updated 2024-08-05
Conditions: Long COVID / PASC
AGENTS
Red Beetroot Juice
Red beetroot juice may have positive effects on multiple pathways involved in long COVID. The aim of this pilot study was to explore the impact of beetroot juice supplementation on physical function, gut microbiota, and systemic inflammation in adults with long-COVID
View on ClinicalTrials.gov →
Anti-inflammatory NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Resonance Breathing Training for Long Covid-related Myocardial Injury
NCT06379672
NOT_YET_RECRUITING • NA • Updated 2024-07-30
Conditions: Long COVID / PASC
AGENTS
Resonance Breathing
An investigation of the efficacy of resonance breathing training in the rehabilitation of patients with Long covid-related myocardial injury
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Addressing Cognitive Fog in Long-COVID-19 Patients
NCT05597722
TERMINATED • PHASE4 • Updated 2024-07-22
Conditions: Long COVID / PASC
AGENTS
Digital Cognitive Behavioral Intervention-RxwellAmphetamine-Dextroamphetamine
This study will assess two options to help patients better manage the cognitive fog and emotional distress that may be associated with having Long-COVID. Long-COVID is post-COVID conditions or symptoms lasting more than four weeks after infection. Clinicians from the UPMC Long-COVID Clinic leading this study are evaluating the utility of computer-based evaluation of COVID-relat...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 4 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Transcutaneous Electrical Nerve Stimulation (TENS) in Patients With Postacute Sequelae of Sars-CoV-2
NCT05200858
COMPLETED • NA • Updated 2024-07-16
Conditions: Long COVID / PASC
AGENTS
Tens - High-DoseTens - Low-Dose
The purpose of the pilot study is to examine acceptability and proof of concept effectiveness of a wireless TENS technology to address PASC associated FM. Sample size (n=30) is convenient and designed to explore acceptability and feasibility. Participants, who satisfy the inclusion and exclusion criteria and sign the informed consent form will be randomly assigned with ratio of...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial
NCT05690503
ACTIVE_NOT_RECRUITING • PHASE2 • Updated 2024-07-16
Conditions: Long COVID / PASC
AGENTS
Ci-581ACi-581B
Post-acute sequelae of SARS-CoV2 (PASC), colloquially known as "long-COVID," is thought to affect between 10-30% of all COVID-19 survivors. Patients with PASC also report worsening behavioral health symptoms over time that include new-onset depression, anxiety, and even suicidal behavior. The purpose of this randomized, double-blind, controlled trial is to test the efficacy of ...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Effectiveness and Safety of Mesenchymal Stem Cell Therapy in Long COVID Patients
NCT06492798
RECRUITING • PHASE1 • Updated 2024-07-09
Conditions: Long COVID / PASC
AGENTS
Umbilical Cord Mesenchymal Stem Cell
The goal of this clinical trial is to evaluate the effectiveness and safety of mesenchymal stem cell therapy in long-COVID patients. The main questions it aims to answer include: * whether umbilical cord mesenchymal stem cell therapy does benefit long-COVID patients * whether umbilical cord mesenchymal stem cell therapy is safe for long-COVID patients. Participants' demograph...
View on ClinicalTrials.gov →
General Phase 1 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Examining the Function of Cs4 on Post-COVID-19 Disorders
NCT06054438
COMPLETED • NA • Updated 2024-07-09
Conditions: Long COVID / PASC
AGENTS
Chinese Medicine Nutritional Supplement Cs4
Cordyceps is a medicinal Chinese medicine. The benefits of cordyceps-related therapeutic action have been studied due to its anti-inflammation and immunomodulation features. Thus, Cordyceps may have efficacy against health problems in the post-COVID era. the Cs4 is a Chinese medicine nutritional supplement fermented by Cordyceps. This Project conducts a two-stage waitlist-contr...
View on ClinicalTrials.gov →
Immunomodulatory Anti-inflammatory NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Pilot Randomized Study of RD-X19 Tx Device in Subjects With PCC (Long Covid) in the Outpatient Setting
NCT06113679
TERMINATED • NA • Updated 2024-07-05
Conditions: Long COVID / PASC
AGENTS
Rdx-19
Duration of Treatment: 7 days, 2 times per day. Following Randomization on Week 1 Day 1, Subjects will continue to have televisits and rate symptoms and upright activity weekly during a 5 week follow up. Subjects will be followed via in clinic visits at week 2/day 8 (+3/-0 days) and Week 6 / day 36, (+3/-3days). Subjects will receive a weekly televisit during Week 3 / day 15 (...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Industry
Enhancing COVID Rehabilitation With Technology
NCT05019963
ACTIVE_NOT_RECRUITING • NA • Updated 2024-07-03
Conditions: Long COVID / PASC
AGENTS
Nexj Connected Wellness
In March 2020, the World Health Organization (WHO) declared the novel coronavirus (COVID-19) a global pandemic. Ontario has confirmed more than 547,000 cases of COVID-19 since testing began. For many of these patients, symptoms resolve within 4 weeks of onset. However, it is becoming apparent that a significant number of individuals are experiencing symptoms that persist long a...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19:
NCT04695704
TERMINATED • PHASE3 • Updated 2024-07-03
Conditions: Long COVID / PASC
AGENTS
Montelukast
Recently, a new clinical presentation called "long covid" has been reported, for patients with symptoms lasting for more than 4 weeks from the onset of the disease. Typically, the symptoms comprise dyspnea, cough, headache, arthralgia, fever, abdominal pain, asthenia and skin manifestations This project aims to evaluate the efficacy of Montelukast in improving the quality of li...
View on ClinicalTrials.gov →
General Phase 3 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Cognitive Rehabilitation for People With Cognitive Covid19
NCT05731570
UNKNOWN • NA • Updated 2024-06-21
Conditions: Long COVID / PASC
AGENTS
Cognitive Rehabilitation
Cognitive impairment is increasingly recognised as a major component of long Covid, and is estimated to be present in 25-75% of affected individuals. This impairment impacts quality of life and the loss of functional ability has major consequences for affected people, their families and the wider economy given people's difficulty in returning to work. This study will focus on ...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Mindfulness in Post Acute Sequelae of SARS-CoV-2 Infection (PASC) Dysautonomia
NCT05566379
COMPLETED • NA • Updated 2024-06-14
Conditions: Long COVID / PASC
AGENTS
Mindfulness - Mindful Awareness Practices
The current pilot study will recruit participants experiencing new, returning, or ongoing symptoms related to COVID-19 illness for at least four weeks after being first infected with SARS-CoV-2. All participants will attend a virtual 6-week course entitled Mindful Awareness Practices (MAPs) created, hosted and led by expert facilitators from the Mindful Awareness Research Cente...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Effectiveness of Non-invasive Neuromodulation in Patients With Long-COVID
NCT06456502
UNKNOWN • NA • Updated 2024-06-13
Conditions: Long COVID / PASC
AGENTS
Non-Invasive Neuromodulation
Sleep quality and duration are critical to cognitive, emotional and physical well-being, and poor sleep quality has been associated with an increased risk of cognitive, psychological and cardiometabolic disorders. Several important physiological activities occur during sleep including a reduction in heart rate and blood pressure. In addition, sleep exerts important modulatory e...
View on ClinicalTrials.gov →
Metabolic Immunomodulatory Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
RCT Long COVID-19 Rehabilitation
NCT06085911
UNKNOWN • NA • Updated 2024-06-11
Conditions: Long COVID / PASC
AGENTS
One Day CourseIndividual Follow-Ups
The Coronavirus 2019 (COVID-19) pandemic has resulted in at least four million infections in Norway. The vast majority of cases are diagnosed and followed up in the community, but some with extensive symptoms and large degree of reduced function are referred to regional Covid-clinics. In total this patient group is placing an enormous burden on the already over stretched health...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Restoring Energy With Sub-symptom Threshold Optimized Rehabilitation Exercise for Long COVID
NCT06172803
COMPLETED • NA • Updated 2024-06-06
Conditions: Long COVID / PASC
AGENTS
Restoring Energy With Sub-Symptom Threshold Aerobic Rehabilitation ExerciseLight Stretching/Breathing Exercises
The overall goal of this study is to find out if rehabilitation exercise can help people who have long COVID. Participants will be randomized by chance to receive either aerobic exercise or breathing exercise (combined with stretches). Participants will be guided and supported in completing a tailored, 6-week home exercise program to be performed 5 - 6 days a week, prescribed a...
View on ClinicalTrials.gov →
Metabolic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Effects of Physiotherapy Via Telerehabilitation in Patients With COVID-19
NCT06251011
COMPLETED • NA • Updated 2024-06-05
Conditions: Long COVID / PASC
AGENTS
Exercise Training
This study aims to evaluate the effects of Physiotherapy Via Video Calls on Cardiopulmonary Functions, Physical Function, Cognitive Function, Activity Daily Livings, and Quality of Life in Patients With COVID-19.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Phase 2 Study of RSLV-132 in Subjects With Long COVID
NCT04944121
COMPLETED • PHASE2 • Updated 2024-05-29
Conditions: Long COVID / PASC
AGENTS
Rslv-132
The purpose of this study is to assess the efficacy (decrease in profound fatigue), safety and pharmacokinetics of RSLV-132 in subjects with long Corona Virus (COVID) syndome
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Industry
Efficacy of Photobiomodulation in the Rehabilitation of Olfactory Dysfunctions Induced by Long COVID-19
NCT06423495
UNKNOWN • NA • Updated 2024-05-21
Conditions: Long COVID / PASC
AGENTS
Low-Intensity Laser Treatment
On January 30, 2020, the WHO (World Health Organization) declared the new coronavirus pandemic as the sixth public health emergency of international concern. In February 2020, the virus was designated by the Coronavirus Study Group of the International Committee on Virus Taxonomy as severe acute respiratory syndrome coronavirus 2. Many reports have described the appearance of o...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome
NCT05497089
COMPLETED • PHASE2 • Updated 2024-05-17
Conditions: Long COVID / PASC
AGENTS
Temelimab 54Mg/Kg
This study is a Phase 2, 24-week, randomized, prospective, double-blind, multicenter study in patients experiencing neuropsychiatric symptoms and functional impairment in the course of PASC. The purpose of the study is to evaluate the efficacy and safety of Temelimab as a treatment for PASC neuropsychiatric symptoms in patients who had severe acute respiratory syndrome coronavi...
View on ClinicalTrials.gov →
General Phase 2 Large (200-999 participants) Enrollment: Actual Sponsor Type: Industry
Merging Yoga and Self-Management Skills for Symptoms of Long COVID
NCT05697042
COMPLETED • NA • Updated 2024-05-13
Conditions: Long COVID / PASC
AGENTS
My-Skills For Long Covid
Long COVID patients experience high symptom burden for many months after initial infection of the COVID-19 virus. This study will investigate a mobile intervention Merging Yoga and Self-Management Skills (MY-Skills Mobile) as a complementary therapy for fatigue, pain, mood and quality of life in long COVID patients at the UCHealth Center for Integrative Medicine. The study aim ...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
The Efficacy of Aerobic Exercise in the Rehabilitation of Patients With COVID-19-Related Myocardial Injury
NCT06404411
UNKNOWN • NA • Updated 2024-05-13
Conditions: Long COVID / PASC
AGENTS
Assigned InterventionsConventional Rehabilitation
A study of the efficacy of aerobic exercise based on cardiopulmonary exercise test in the rehabilitation of patients with COVID-19-related myocardial injury
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Prevention of Long Covid Syndrome
NCT05793736
COMPLETED • NA • Updated 2024-05-13
Conditions: Long COVID / PASC
AGENTS
Biofeedback TrainingTreatment As Usual
Biofeedback equipment is classified by the Food and Drug Administration (FDA) as medical device class II and this type of equipment/treatment has shown evidence regarding stress management in post-Covid-19 syndrome. The main objective of the study is to verify the feasibility of an HVR biofeedback training protocol in patients with long covid, and also to verify improvement in...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Nutrition and LOComotoric Rehabilitation in Long COVID-19
NCT05254301
COMPLETED • NA • Updated 2024-05-08
Conditions: Long COVID / PASC
AGENTS
Intervention Group
Long COVID is a new phenomenon, in which individuals who experienced a SARS-CoV-2 infection still experience one or more symptoms, such as exercise intolerance, fatigue and/or muscle pains in addition to other COVID-related symptoms, weeks to months after initial infection. The aim of this pilot-study is to learn about which complaints patients continue to experience after the...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Exercise Interventions in Post-acute Sequelae of Covid-19
NCT06065033
WITHDRAWN • NA • Updated 2024-05-08
Conditions: Long COVID / PASC
AGENTS
Exercise
The COVID-19 pandemic severely impacted the medical system both directly but also through incomplete recovery from the virus in the form of post-acute sequelae of COVID-19 (PASC). PASC affects at least 9.6 million individuals as of May 2022 and continues to affect many more. PASC is a multisystem disorder often presenting with mental fog, dyspnea on exertion, and fatigue among ...
View on ClinicalTrials.gov →
Immunomodulatory NA Enrollment: Actual Sponsor Type: Other
Electro-acupuncture for Long Covid Neuropsychiatric Symptoms
NCT05890508
UNKNOWN • NA • Updated 2024-05-07
Conditions: Long COVID / PASC
AGENTS
Acupuncture
In this study, a 16-week randomized, sham-controlled, double-blinded clinical trial will be conducted to to investigate the efficacy and safety of electro-acupuncture compared to sham acupuncture for treatment of long covid neuropsychiatric symptoms.
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Digital Cognition Study During Long-COVID
NCT06391970
UNKNOWN • NA • Updated 2024-04-30
Conditions: Long COVID / PASC
AGENTS
Cognitive Screening
The persistence of the COVID-19 disease symptoms, such as extreme fatigue, shortness of breath, cardiovascular complications, depression and anxiety, pain, brain fog, loss of taste/smell, headaches as well as loss of memory has been evoked in many studies. This project aims at approaching the persistent symptomatology on cognition, more than 1 year after the infection. When we...
View on ClinicalTrials.gov →
Persistence / Antiviral Neurological / Autonomic NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other Gov
tDCS in the Management of Post-COVID Disorders
NCT06074848
UNKNOWN • PHASE2 • Updated 2024-04-24
Conditions: Long COVID / PASC
AGENTS
Transcranial Direct Current StimulationMotor TrainingCognitive Training
Different physical and mental morbidities such as pain, fatigue, depressed mood and cognitive impairment can be triggered by coronavirus infection. Transcranial direct current stimulation (tDCS), an easy-to-apply, non-pharmacological and safe technique, has been used to attenuate these symptoms caused by other diseases, and, therefore, it is expected that it can also attenuate ...
View on ClinicalTrials.gov →
Immunomodulatory Neurological / Autonomic Anti-inflammatory Phase 2 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Multi-systemic Rehabilitative Interventions in Long COVID-19 Patients in Two Different Settings: a Randomized Controlled Trial
NCT06379737
COMPLETED • NA • Updated 2024-04-23
Conditions: Long COVID / PASC
AGENTS
Multi-Systemic Rehabilitation
Objective: This study aimed to evaluate the effectiveness of a multisystem rehabilitation program for Long Covid patients in two different settings. Design: Randomized controlled trial. Settings: Health resort and home-based. Participants: 72 Long Covid patients. Interventions: Patients were randomly assigned into two groups: Group A (n=36) received health resort intervention,...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Effect of Virtual Reality in Patients With Long Covid-19
NCT06374446
UNKNOWN • NA • Updated 2024-04-18
Conditions: Long COVID / PASC
AGENTS
Classical TreatmentVirtual Reality Combined With Classical TreatmentVirtual Reality
SARS-CoV-2 was first detected in Wuhan, Hubei Province, China, in late 2019. It is a highly contagious virus that has been reported to occur in humans and is said to cause pneumonia. Covid-19 infection is transmitted through droplets during coughing and sneezing and through contact with the mouth, nose or eyes after contaminated hands. The most obvious symptoms of Covid-19 sym...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Effect of Probiotic Strain Lactobacillus Paracasei PS23 on Brain Fog in People With Long COVID
NCT06348212
UNKNOWN • NA • Updated 2024-04-04
Conditions: Long COVID / PASC
AGENTS
Lactobacillus Paracasei Ps23Microcrystalline Cellulose
The goal of this clinical trial is to test whether the intervention of probiotics supplement can improve symptoms of long covid syndrome. Participants will be given probiotics or placebo capsules for two month. Symptom questionnaires, cognitive function, eeg and fecal sample are recorded/collected before and after the supplement. Researchers will compare the probiotic group a...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other Gov
Efficacy of a Dietary Supplementation in Reducing Hospital Admissions for COVID-19. Randomized Clinical Trial
NCT04751669
COMPLETED • NA • Updated 2024-03-25
Conditions: Long COVID / PASC
AGENTS
Vitamin And Trace Elements
A double-blind, placebo-controlled, randomized clinical trial to assess efficacy of micronutrient dietary supplementation in reducing hospital admissions for COVID-19 and incidence of Long Covid. We want to assess the need for hospital admission for severe acute respiratory syndrome Corona Virus-2 (SARS-CoV-2) infection in outpatients diagnosed of COVID-19 disease, taking a mi...
View on ClinicalTrials.gov →
General NA Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.
NCT05601180
COMPLETED • NA • Updated 2024-03-19
Conditions: Long COVID / PASC
AGENTS
Respicure®Standard Of Care
Interventional, Prospective, National, Multicentre, Randomised, Open-label, Controlled Clinical Study Comparing Two Parallel Groups, One Control Arm (Standard Treatment) Versus Intervention Arm (Standard Treatment + Study Product) Evaluating the Efficacy of Respicure® 0.38% /0.38% (Resveratrol / Quercetin) Phytotherapy Product From BEKER Laboratories as an add-on Treatment in t...
View on ClinicalTrials.gov →
General NA Large (200-999 participants) Enrollment: Actual Sponsor Type: Industry
Exercise for Health in Patients With Post-acute Sequelae of COVID-19
NCT05848518
COMPLETED • NA • Updated 2024-03-19
Conditions: Long COVID / PASC
AGENTS
Rehabilitation Program
Background: Many patients with COVID-19 present the so-called post-acute sequelae of COVID-19 such as fatigue, post-stress discomfort, dyspnea, headache, pain mental impairment, incapacity to perform daily physical tasks ant exercise intolerance. This study aims to investigate the effects of different exercise programs on physical and mental fitness, physical condition and biom...
View on ClinicalTrials.gov →
Immunomodulatory Anti-inflammatory NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
The Use of Photobiomodulation in the Treatment of Oral Complaints of Long COVID-19.A Randomized Controlled Trial.
NCT05760092
COMPLETED • PHASE2 • Updated 2024-03-12
Conditions: Long COVID / PASC
AGENTS
Institutional Standard Treatment For Xerostomia And Long CovidPhotobiomodulation Therapy
Coronavirus (COVID-19) is a newly emerging zoonotic agent that emerged in December 2019 in China (2019-nCoV) as a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV -2). Long COVID-19, or Post-Covid Syndrome or Long-term COVID-19, is a post-viral syndrome that persists after the acute infection has resolved. The most frequent symptoms of Lonf-term COVID are fatigue and d...
View on ClinicalTrials.gov →
General Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Sulfureous Water Therapy in Viral Respiratory Diseases
NCT06294756
COMPLETED • NA • Updated 2024-03-06
Conditions: Long COVID / PASC
AGENTS
Inhalation Of Sulfurous Thermal WaterInhalation Of Sterile Distilled Non-Pyrogenic Water
The goal of this double-blind, interventional, randomized case-control, pilot trial is to evaluate the effects of active sulfurous (STW) versus placebo (SDW) inhalations on blood test parameters, serum inflammatory cytokines, spirometry data, as well as qualitative and quantitative changes in the nasal microbiome of subjects affected by long Covid. The main questions it aims t...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
High-definition Transcranial Direct Current Stimulation and Chlorella Pyrenoidosa to Reduce Cardiovascular Risk
NCT06255600
UNKNOWN • NA • Updated 2024-03-05
Conditions: Long COVID / PASC
AGENTS
High Definition-Transcranial Direct Current StimulationChlorella Pyrenoidosa
Recent investigations have shown that of the patients who were affected by SARCov2 have remained with persistent symptoms in a high proportion. In these considerations, the literature has suggested nomenclatures such as "post-COVID-19" and "chronic COVID-19", "long -COVID" and Post-Covid Syndrome for patients recovered from SARCov2 reporting persistent symptoms and signs for we...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Effect of Metformin in Reducing Fatigue in Long COVID in Adolescents
NCT06147050
UNKNOWN • PHASE3 • Updated 2024-03-04
Conditions: Long COVID / PASC
AGENTS
Metformin
Long Covid is a multisystem condition comprising often severe symptoms that follow a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Long COVID often manifests as fatigue and neurocognitive impairment (also referred to as 'brain fog'). Based on two systematic reviews of Covid-19 cases in neonates, children and adolescents under 19 years of age, fatigue c...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 3 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Treatment of Post-COVID-19 With Hyperbaric Oxygen Therapy: a Randomized, Controlled Trial
NCT06267300
UNKNOWN • PHASE3 • Updated 2024-02-28
Conditions: Long COVID / PASC
AGENTS
Hyperbaric Oxygen Therapy (HBOT)
The goal of this clinical try is to investigate the effect of hyperbaric oxygen therapy (HBOT) on symptoms, quality of life and absence of work through sickness in patients with post-COVID on short- and mid-term, as well as to identify biochemical mechanisms of action. The main questions it aims to answer are: * What is the clinical relevance of improvements of symptoms and q...
View on ClinicalTrials.gov →
General Phase 3 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Pre-probiotic Supplementation for Post-covid Fatigue Syndrome
NCT06013072
COMPLETED • NA • Updated 2024-02-06
Conditions: Long COVID / PASC
AGENTS
Dietary Supplement: Experimental
The goal of this randomized controlled double-blind parallel-group interventional trial is to evaluate the effects of of dietary supplementation with a pre-probiotic on patient- and clinician-reported outcomes, and brain tissue metabolism in patients with post-covid fatigue syndrome.
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Study on the Effect of Incentive Spirometer-based Respiratory Training on the Long COVID-19
NCT06231225
NOT_YET_RECRUITING • NA • Updated 2024-01-30
Conditions: Long COVID / PASC
AGENTS
Incentive Spirometer Respiratory Training
The COVID-19 pandemic has emerged as the most significant public health crisis of the 21st century. As of the end of January 2023, global confirmed cases have exceeded 670 million, with a domestic cumulative total of 10.24 million cases, including occurrences of reinfection. Beyond acute symptoms following infection, patients and society face the challenge of long-term complica...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Hyperbaric Oxygen for Long COVID-19 Pulmonary Sequela
NCT04905888
WITHDRAWN • PHASE2 • Updated 2024-01-23
Conditions: Long COVID / PASC
AGENTS
Hyperbaric Oxygen Therapy (HBOT)
This is a pilot study in 24 subjects where half will be randomized to 10 treatments with hyperbaric oxygen (HBO). It will primarily study pulmonary sequelae with imaging and physiological measurements (low dose chest computer tomography (CT), Ventilation/perfusion with magnetic resonance imaging (VA/Q MRI), cardiopulmonary exercise testing with pulse oximetry (SpO2) and spirome...
View on ClinicalTrials.gov →
General Phase 2 Enrollment: Actual Sponsor Type: Other
Vagus Nerve Stimulation as Treatment for Long Covid
NCT05608629
COMPLETED • NA • Updated 2024-01-08
Conditions: Long COVID / PASC / ME/CFS
AGENTS
Transcutaneous Non-Invasive Vagus Nerve Stimulation
Many patients do not recover following Covid infection. The resulting illness is called Long Covid. Because there is no agreed upon treatment for this ailment, the research team has decided to do an open label pilot study using non-invasive, transcutaneous stimulation of the auricular branch of the vagus nerve. Inclusion criteria required the patient to fulfill criteria for hav...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Vagus Nerve Stimulation for Post-COVID Syndrome
NCT05679505
COMPLETED • NA • Updated 2024-01-05
Conditions: Long COVID / PASC
AGENTS
Auricular Transcutaneous Vagus Nerve Stimulation
The aim of this study is to increase parasympathetic activity and decrease the severity of symptoms by providing vagal stimulation with the t-VNS method in order to suppress the increased sympathetic activity in patients with prolonged Covid symptoms.The main question\[s\] it aims to answer are: Question 1:Is left ear transcutaneous vagus nerve stimulation effective in suppres...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
IMMUNERECOV CONTRIBUTES TO IMPROVEMENT OF RESPIRATORY AND IMMUNOLOGICAL RESPONSE IN POST-COVID-19 PATIENTS.
NCT06166030
UNKNOWN • PHASE3 • Updated 2023-12-12
Conditions: Long COVID / PASC
AGENTS
Nutritional Blend (Immunerecov).
Background: COVID-19 left consequences in different organs from months to years requiring different types of rehabilitation. In fact, a severe loss in the lung function, and in the respiratory and peripheral muscle strength is commonly observed in post-COVID-19 patients. Objectives: Thus, the present study investigated whether 30 days of supplementation with a nutritional blend...
View on ClinicalTrials.gov →
Immunomodulatory Anti-inflammatory Phase 3 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Effect of Inhaled Hydroxy Gas on Long COVID Symptoms
NCT06159296
UNKNOWN • NA • Updated 2023-12-06
Conditions: Long COVID / PASC
AGENTS
Hydroxy Gas
The goal of this clinical trial is to see if several weeks of self-administered, home-based, treatment involving breathing hydroxy gas (a mixture of hydrogen and oxygen) for at least 2 hours a day for 3 weeks, will relieve symptoms in patients suffering from Long COVID. The main question it aims to answer is whether inhaling hydroxy gas might be a useful treatment option to hel...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Effect of Kinesio Tape Versus Diaphragmatic Breathing Exercise In Post COVID-19
NCT05770193
COMPLETED • NA • Updated 2023-12-05
Conditions: Long COVID / PASC
AGENTS
Pursed Lip BreathingCognitive Behavior TherapyDiaphragmatic Breathing ExerciseKinesio Tape
According to WHO, current evidence suggests some people experience a variety of long-term effects after they recover from their initial illness. These effects are collectively known as post COVID-19 condition or "long COVID. While most people who develop COVID-19 fully recover, some people develop effects like fatigue, breathlessness, functional activities and cognitive dysfunc...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Stem Cell Study for Long COVID-19 Neurological Symptoms
NCT06156241
UNKNOWN • PHASE1 • Updated 2023-12-05
Conditions: Long COVID / PASC
AGENTS
Stem Cell
The purpose of this research study is to test the safety and benefit of a human cord blood derived stem cell infusion as a treatment for individuals with post COVID-19 neurological problems. Participants in the study will have 6 clinic visits over a 12 to 14 mo. period with each visit lasting 2 to 6 hours. Participants will receive 1 stem cell infusion at study visit #3. Partic...
View on ClinicalTrials.gov →
General Phase 1 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Enhanced External Counterpulsation to Treat Long COVID-19 Fatigue
NCT05668039
UNKNOWN • NA • Updated 2023-11-30
Conditions: Long COVID / PASC
AGENTS
Enhanced External Counterpulsation
The goal of this double blind, outcome-assessor blind, randomized controlled trial, is to compare the effectiveness of external encounter counterpulsation (EECP) versus sham procedure in participants with long COVID-19 fatigue. The main question\[s\] it aims to answer are: * Whether EECP improves fatigue score * Whether EECP improves quality of life, six-minute walk test, and...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other Gov
Inspiratory Muscle Training in People With Long COVID-19- A Pilot Investigation.
NCT06091358
UNKNOWN • NA • Updated 2023-11-30
Conditions: Long COVID / PASC
AGENTS
Pro2
This pilot investigation will recruit people with Long COVID to participate in a 4 week individualized inspiratory muscle training intervention with pre and post spirometry testing and additional functional outcomes to assess the effectiveness of the intervention.
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Ivabradine for Long-Term Effects of COVID-19 With POTS Cohort
NCT05481177
UNKNOWN • PHASE4 • Updated 2023-11-29
Conditions: Long COVID / PASC
AGENTS
Ivabradine
The purpose of the study is three-fold. The primary aim is to identify the proportion of Long-Haul COVID (LHC) and non-LHC volunteers with relevant symptoms actually have postural orthostatic tachycardia syndrome (POTS). The second is to determine benefit of ivabradine treatment. Ivabradine is a drug approved to treat tachycardia in persons with heart failure. The third is to c...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 4 Large (200-999 participants) Enrollment: Estimated Sponsor Type: Fed
Efficacy of Two Therapeutic Exercise Modalities for Patients With Persistent COVID
NCT06142240
UNKNOWN • NA • Updated 2023-11-21
Conditions: Long COVID / PASC
AGENTS
Exercise Programe
Symptoms of long-standing sequelae and complications of COVID-19, termed Long COVID19 or persistent COVID, have been reported worldwide. However, the etiology underlying the prolonged or fluctuating symptomatology is limited and there is no uniform and widely accepted definition.Patients describe persistent COVID as a fluctuating disease with variable and persistent symptoms.Mo...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-19
NCT05719012
WITHDRAWN • PHASE2 • Updated 2023-11-21
Conditions: Long COVID / PASC
AGENTS
Uc-Mscs
To explore the efficacy and safety of Umbilical cord mesenchymal stem cells in the treatment of long COVID-19
View on ClinicalTrials.gov →
General Phase 2 Enrollment: Actual Sponsor Type: Other
WHO COVID-19 - Evaluation of the Efficacy of Probiotics to Reduce the Occurrence of Long COVID
NCT05080244
COMPLETED • NA • Updated 2023-11-07
Conditions: Long COVID / PASC
AGENTS
Probiotics
Probiotics may be considered as an option of treatment for long COVID since they have anti-viral effect, trigger immunomodulation and have low side-effects. This randomized controlled trial aims to reduce the number of patients with long COVID by 25% 90 days after the COVID-19 diagnosis by taking probiotics in a symptomatic population, self-caring at home. During the acute phas...
View on ClinicalTrials.gov →
Immunomodulatory NA Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
FMT for Post-acute COVID-19 Syndrome
NCT05556733
UNKNOWN • NA • Updated 2023-10-31
Conditions: Long COVID / PASC
AGENTS
Faecal Microbiota Transplantation
In recovered COVID-19 patients, emerging global data have reported the presence of long COVID, that is, at least one symptom that an alternative diagnosis cannot explain has been persistent for four or more weeks after the initial infection. We demonstrated previously that almost 80% of recovered COVID-19 patients in Hong Kong suffer from Long COVID for more than 6 months, affe...
View on ClinicalTrials.gov →
Immunomodulatory NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
A Practical RCT of TCM in the Treatment of LCOVID and Analysis of Syndrome Types and Medication Characteristics.
NCT06095258
UNKNOWN • PHASE2 • Updated 2023-10-26
Conditions: Long COVID / PASC
AGENTS
Traditional Chinese Medicine TreatmentWestern Medicine Treatment
This is a multi-center, outcome assessor-blinded, practical randomized controlled trial, aiming to compare the actual clinical effectiveness of individualized traditional Chinese medicine and conventional Western medicine in the treatment of long COVID. Totally 162 patients with long COVID recruited into the study will be randomly assigned to the traditional Chinese medicine t...
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Magnesium and Vitamin D Combination for Post-COVID Syndrome
NCT05630339
COMPLETED • NA • Updated 2023-09-28
Conditions: Long COVID / PASC
AGENTS
Magnesium ChlorideVitamin D
The goal of this double-blind randomized controlled clinical trial is to determine the efficacy of the administration of magnesium chloride + vitamin D as an adjuvant in the treatment of post-Coronavirus Disease (COVID) syndrome. The participants will be integrated: a) Intervention group that will receive 1 g of magnesium chloride (equivalent to 300 mg of elemental magnesium) ...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other Gov
Non-pharmacological and TCM-based Treatment for Long COVID Symptoms
NCT06042777
UNKNOWN • NA • Updated 2023-09-21
Conditions: Long COVID / PASC
AGENTS
Acupuncture And Tcm-Based Lifestyle Management
Cognitive impairment is one of the commonly reported Long COVID symptoms, mainly in terms of memory, attention, and executive function. The cognitive symptoms of Long COVID are similar to "brain fog" or "chemo brain", manifested as low energy, disorientation, difficulties in attention and communication which are common conditions in cancer patients after chemotherapy. Given the...
View on ClinicalTrials.gov →
Metabolic Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)
NCT04880161
COMPLETED • PHASE1 • Updated 2023-09-21
Conditions: Long COVID / PASC
AGENTS
Ampion
This is a phase I study to evaluate the safety and efficacy of inhaled Ampion on patients with prolonged respiratory symptoms due to COVID-19 (Long COVID).
View on ClinicalTrials.gov →
General Phase 1 Small (<50 participants) Enrollment: Actual Sponsor Type: Industry
Connecting Breath and Mind for CYP With Long COVID
NCT05705154
UNKNOWN • NA • Updated 2023-09-08
Conditions: Long COVID / PASC
AGENTS
Psychology Interventions
Recruitment target: Phase I: Co-design of intervention: 5 to 15 CYP aged between 12-18 years of age referred to the pan-London long COVID MDT. Phase II: Randomised pilot: 40 patients (12-18 years) will be recruited from a potential pool of 214 patients referred to the pan-London long COVID MDT. Methods: Phase I: Co-design Design and setting The intervention will be co-designe...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Effects of Exercise Training on Patients With Long COVID-19
NCT05961462
COMPLETED • NA • Updated 2023-09-06
Conditions: Long COVID / PASC
AGENTS
Exercise Training
Effects of Exercise training on Patients With Long COVID-19, is a single-center, randomized, controlled trial designed to evaluate the effects of 4- week aerobic exercise administered to patients with long COVID-19 symptoms. The main outcome is cardiopulmonary fitness and long COVID-19 symptom improvement. Quality of life, depression, anxiety, insomnia status and perceived stre...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
A Pilot Study of a PhysiOthErapy-based Tailored Intervention for Long COVID (COVID-19)
NCT05040893
UNKNOWN • NA • Updated 2023-08-29
Conditions: Long COVID / PASC
AGENTS
Physiotherapy
The purpose of this study is to determine the benefits and feasibility of physiotherapy in the recovery of ongoing symptoms after COVID-19 illness. Long COVID Syndrome (Long COVID) is defined by persistent symptoms (including breathlessness, chest pain and fatigue) after COVID-19 illness that continue for more than 12 weeks and cannot be explained by another diagnosis. The goal...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Effect of Plasmapheresis on Clinical Improvement and Biological Parameters of Patients With Long-haul COVID
NCT05543590
WITHDRAWN • NA • Updated 2023-08-14
Conditions: Long COVID / PASC
AGENTS
PlasmapheresisBlood CollectionStool SamplesPet ScanCycle Ergometer Stress TestMedical Consultations
Many patients infected with SARS-Cov-2 present in the months following infection with non-specific symptoms such as non-resolving fatigue, cognitive disorders, dyspnea, headaches, myalgias, sleep disorders, anosmia/ ageusia and post exertion malaise. The persistence of these symptoms is called "post covid syndrome" or "long Covid". According to the literature, the pathophysiol...
View on ClinicalTrials.gov →
Immunomodulatory Persistence / Antiviral Neurological / Autonomic NA Enrollment: Actual Sponsor Type: Other
Feasibility of Personalised Health Behaviour Coaching to Support Symptoms and Activities of Daily Living in Those With Long COVID-19.
NCT05752331
COMPLETED • NA • Updated 2023-08-04
Conditions: Long COVID / PASC
AGENTS
Physical Activity Behavioural Modification
This pilot RCT aims to assess whether a simple PA behavioural modification intervention can be delivered safely and feasibly to individuals with Long COVID suffering long standing symptoms with concerns regarding their ability to perform activities of daily living. Participants will be randomised to receive an 8-week physical activity behavioural modification intervention alon...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Investigation of the Use of a Probiotic Supplement in People With Long COVID
NCT05975034
UNKNOWN • NA • Updated 2023-08-03
Conditions: Long COVID / PASC
AGENTS
Probiotic
This study is a double-blinded randomised trial to assess the efficacy of a probiotic supplement in alleviating symptoms in people with Long COVID.
View on ClinicalTrials.gov →
General NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
Telerehabilitation for Post COVID-19 Condition
NCT05973136
COMPLETED • NA • Updated 2023-08-02
Conditions: Long COVID / PASC / ME/CFS
AGENTS
Telerehabilitation Program Based On Cardiorespiratory Principles
Telerehabilitation is a great alternative to offering care during a global pandemic. 85% of patients with COVID-19 report persistent symptoms up to 8 months after the infection. There are no clear recommendations for post-covid rehabilitation. The aims of the study are (1) to test the logistic aspect of implanting a hybrid rehabilitation program and (2) to evaluate the acceptab...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Feasibility Study of Adhera® Fatigue Digital Program for Patients With Long COVID-related Fatigue
NCT05631171
COMPLETED • NA • Updated 2023-07-20
Conditions: Long COVID / PASC
AGENTS
Adhera® Fatigue Digital Program
Adhera® Fatigue Digital Program (or AFDP) is a digital health program based on behavioral and emotional change techniques that provides personalized physical and emotional self-management support for patients with long COVID-related fatigue. The digital health solution is designed to be used for 3 months, and includes a mobile application and a smartwatch. This is a clinical s...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Industry
Effectiveness of a Psychological Intervention on Mental Health and Sleep.
NCT05951803
UNKNOWN • NA • Updated 2023-07-19
Conditions: Unspecified / Overlap
AGENTS
Brief Behavioral Intervention In Insomnia
Background: The COVID-19 pandemic represented a global public health problem that brought considerable consequences to the physical and mental health of the entire population. Objective: To compare the effectiveness of the brief behavioral intervention for insomnia by teleconsultation (BBII-TC) with the brief behavioral intervention for face-to-face insomnia (BBII) on symptoms ...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other Gov
Exercise and Post-COVID/ Long-COVID: Effects of Different Training Modalities on Various Parameters in People Affected by the Sequelae of COVID-19
NCT05204511
COMPLETED • NA • Updated 2023-07-19
Conditions: Long COVID / PASC
AGENTS
Endurance TrainingConcurrent Training
The current COVID-19 pandemic is the most severe health crisis of the 21st century. This is not only due to the deaths caused by the disease. People that were affected by COVID-19 and supposedly recovered may suffer from long lasting sequelae. The presence of symptoms longer than 3 months after the infection with SARS-CoV-2 is referred to as Post-COVID-19 Syndrome or Long COVID...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Safety, Efficacy, and Dosing of VIX001 in Patients With Neurological Symptoms of Post Acute COVID-19 Syndrome (PACS).
NCT05947617
UNKNOWN • PHASE1 • Updated 2023-07-17
Conditions: Long COVID / PASC
AGENTS
Vix001
The study, identified as VIX001-PACS-01, is a Phase 1, open-label, dose-escalation trial evaluating the safety, tolerability, preliminary efficacy, and dose effect of VIX001, an amniotic fluid product, in patients with Post-Acute COVID-19 Syndrome (PACS) and cognitive impairment. Conducted at the University of Miami Hospital and Clinics, the trial aims to enroll up to nine part...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 1 Small (<50 participants) Enrollment: Estimated Sponsor Type: Industry
Multimodal Investigation of Post COVID-19 in Females
NCT05225220
COMPLETED • NA • Updated 2023-07-07
Conditions: Long COVID / PASC
AGENTS
Parasym Device
The purpose of this study is to investigate the effects of transcutaneous vagus nerve stimulation (t-VNS) on Long Covid symptoms in females and to identify factors influencing susceptibility and recovery-particularly in the cognitive domain, as over 80% of long-haulers experience "brain fog".
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Multimodal Long Covid19
NCT05932797
UNKNOWN • NA • Updated 2023-07-06
Conditions: Long COVID / PASC
AGENTS
Multimodal Intervention In Long Covid19
Due to the COVID-19 pandemic, the world has seen the need to identify groups of patients who experience various effects in the medium and long term after recovering from the initial illness. These medium- and long-term effects are collectively known as the post-COVID-19 condition, Long-COVID, or prolonged COVID. Current evidence indicates, with conservative estimates, that betw...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Cognitive-behavioral Therapy for Mental Disorder in COVID-19 Survivors
NCT05815693
UNKNOWN • NA • Updated 2023-06-29
Conditions: Long COVID / PASC
AGENTS
Mindfulness-Based Stress Reduction
The consequences of the Intensive Care Unit and the Covid-19 disease are still uncertain. However, many studies are bringing out often psychological and dramatic consequences for many COVID-survivor patients. Among the ex-covid patients discharged from our Intensive Care Unit and with at least one covid-related psychological consequence, we want to evaluate the effectiveness f...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
The Efficacy and Safety of a Chinese Herbal Medicine for Long COVID Associated Fatigue
NCT05684952
UNKNOWN • PHASE2 • Updated 2023-06-28
Conditions: Long COVID / PASC
AGENTS
Shenlingcao Oral Liquid
This is a randomized, double-blinded, placebo-controlled clinical trial to determine the efficacy and safety of a Chinese herbal medicine (Shenlingcao oral liquid) for treating long COVID associated fatigue.
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Vagus Stimulation in Female Long COVID Patients.
NCT05918965
UNKNOWN • NA • Updated 2023-06-26
Conditions: Long COVID / PASC
AGENTS
Transcutaneous Electrical Vagal Neurostimulation
The aim of the present pilot study is to investigate the acceptance, feasibility and implementation of the vagus nerv stimulation in Long COVID patients. Additionally, the effects on parameters of the autonomic nervous system as well as on symptoms of Long COVID will be described in a pre/post comparison. For this purpose, a total of 45 female Long COVID patients will particip...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Effectiveness of Transcranial Direct Current in Patients With Persistent COVID-19 With Headaches and Chronic Pain.
NCT05780450
UNKNOWN • NA • Updated 2023-06-13
Conditions: Long COVID / PASC
AGENTS
Transcranial Direct Current Therapy
This study aims to verify the efficacy / effectiveness of treatment with transcranial direct therapy (TDCS) in patients with Persistent Covid who present headaches, migraines and chronic pain, such as arthralgias and myalgias. Transcranial Direct Therapy is used in the field of Physiotherapy and Rehabilitation, with results that prove to be effective for the treatment of patie...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Treatment of Long COVID Symptoms Utilizing Autologous Stem Cells Following COVID-19 Infection
NCT05669261
UNKNOWN • PHASE1 • Updated 2023-06-09
Conditions: Long COVID / PASC
AGENTS
Adipose Tissue HarvestAtcell
The project is described as a Phase 1 Clinical Safety Study intended to provide preliminary assessments of the safety, tolerability, and secondarily to be vigilant for signals of amelioration of symptoms associated with Post-Acute Sequelae of SARS-CoV-2 infection
View on ClinicalTrials.gov →
General Phase 1 Small (<50 participants) Enrollment: Estimated Sponsor Type: Industry
Plasma Exchange Therapy for Post- COVID-19 Condition: A Pilot, Randomized Double-Blind Study
NCT05445674
COMPLETED • PHASE2 • Updated 2023-06-07
Conditions: Long COVID / PASC
AGENTS
Plasma Exchange Procedure
PAX is a prospective, randomized (1:1), double-blind, placebo-controlled study, that have as a objective to evaluate the safety and tolerability of plasma exchange (PE) in patients with Post Acute Covid-19 Syndrome (PCC) comparing to sham plasma exchange. The participants will be randomized in two arms: (1) 6 sessions of PE (Plasma Exchange) with human serum albumin 5% or (2) 6...
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Physiotherapy for Persistent Function by Superficial Neuromodulation
NCT05681455
UNKNOWN • NA • Updated 2023-06-06
Conditions: Long COVID / PASC
AGENTS
Neuromodulation Nesa Nxsignal® Device
Objectives: To evaluate pressure pain thresholds, fatigue scales, quality of life and sleep quality, in women with Persistent Covid (PC), pre- and post-treatment using electrotherapy and in a placebo group of PC patients. Relevance: This trial can be a tool for patients affected by CP who present pain and fatigue problems, insomnia or signs of imbalance of their Autonomic Ne...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
VSL#3® vs Placebo in the Treatment of Fatigue and Other Symptoms in Long Covid (DELong#3)
NCT05874089
UNKNOWN • NA • Updated 2023-05-24
Conditions: Long COVID / PASC
AGENTS
Vsl#3®
This study aims to evaluate the effectiveness of VSL#3® in reducing Fatigue and other symptoms in Long Covid Syndrome compared to placebo.
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Post Covid-19 Dysautonomia Rehabilitation Randomized Controlled Trial
NCT05855356
UNKNOWN • NA • Updated 2023-05-11
Conditions: Long COVID / PASC
AGENTS
RehabilitationStandard Of Care
Dysautonomia in post-covid-19 condition appears to affect a significant number of patients, with reports raising the incidence up to 61%, having an overlap with myalgic encephalomyelitis/ chronic fatigue syndrome. Quality of life and daily function is significantly impacted and conservative management interventions, despite the lack of high quality evidence up to now, are neede...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Amygdala Insula Retraining in the Management of Long COVID Symptoms
NCT05851846
UNKNOWN • NA • Updated 2023-05-10
Conditions: Long COVID / PASC
AGENTS
Amygdala Insula Retraining
The goal of the study is to compare a mind body intervention against usual care in patients with fatigue with long COVID. Our research questions include 1. Is the mind body intervention additive to usual care in long COVID 2. Can the mind body intervention change laboratory markers, heart rate variability and dysautonomia.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Fed
Osteopathy and Physiotherapy Compared to Physiotherapy Alone on Fatigue and Functional Status in Long COVID
NCT05012826
UNKNOWN • NA • Updated 2023-05-10
Conditions: Long COVID / PASC
AGENTS
Osteopathic Manipulative Treatment In Addition To PhysiotherapyPhysiotherapy
Background: Fatigue is among the most common symptoms of the long-term effects of coronavirus (long COVID). This study aims to compare the effectiveness of osteopathic manipulative treatment (OMT) combined with physiotherapy treatment (PT) compared to PT alone on fatigue and functional limitations after two months post randomization in adults with long COVID. Methods: This is ...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Biosound Therapy as a Treatment for Long COVID Patients
NCT05848401
COMPLETED • NA • Updated 2023-05-08
Conditions: Long COVID / PASC
AGENTS
Biosound Therapy System
This study aimed to explore the impact of the Biosound Therapy Systerm on long COVID symptoms while determining feasibility of a future full-scale Randomized Controlled Trial. It was hypothesized that Biosound treatment would significantly improve long COVID. The goal of this clinical trial is to learn about Biosound Therapy System's impact on long COVID symptoms. The main que...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Effect of Telerehabilitation Practice in Long COVID-19 Patients
NCT05817032
UNKNOWN • NA • Updated 2023-04-18
Conditions: Long COVID / PASC
AGENTS
TelerehabilitationStandard Rehabilitation Care
The goal of this clinical trial is to test the efficacy of telerehabilitation practice in Long COVID-19 patients. The main question\[s\] it aims to answer are whether telerehabilitation practice in Long COVID-19 patients help to reduce stress oxidative, reduce inflammation, improve functional capacity and improve quality of life. Participants will receive 12 weeks of telerehab...
View on ClinicalTrials.gov →
Anti-inflammatory NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Exosomes in Treating Chronic Cough After COVID-19
NCT05808400
UNKNOWN • EARLY_PHASE1 • Updated 2023-04-14
Conditions: Long COVID / PASC
AGENTS
Msc-Derived Exosomes
This clinical trial aims to evaluate the safety and effectiveness of umbilical cord mesenchymal stem cell (UCMSC)-derived extracellular vesicle nebulization inhalation therapy for the treatment of chronic cough after COVID-19 infection. The main objective is to assess whether UCMSC-derived exosome nebulization inhalation therapy alleviates chronic cough after COVID-19. Partici...
View on ClinicalTrials.gov →
General EARLY_Phase 1 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Inspiratory Muscle Training in ME/CFS and COVID-19 Survivors
NCT05196529
COMPLETED • NA • Updated 2023-04-12
Conditions: Long COVID / PASC / ME/CFS
AGENTS
Inspiratory Muscle Training
Coronavirus-2019 (COVID-19) is a viral disease leading to respiratory dysfunction, but it may also affect the brain and result in the development of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This may be the result of the COVID-19 virus infecting regions of the brain responsible for respiratory control. The symptoms of COVID-19 long haulers and ME/CFS may be l...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Long COVID-19 Intervention Using Digital Health & Technology
NCT05616806
UNKNOWN • NA • Updated 2023-04-04
Conditions: Long COVID / PASC
AGENTS
Iendure
The current study seeks to pilot test the iENDURE (Enhancing Distress tolerance to Uplift motivation in Recovery) intervention among 10 participants with Long COVID (Coronavirus Disease) symptoms. Following informed consent procedures, participants will complete a brief baseline assessment of self-report measures. Participants will then engage in the iENDURE intervention (descr...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
TDCS-potentiated Generalization of Cognitive Training in the Rehabilitation of Long COVID Symptoms
NCT05589272
WITHDRAWN • NA • Updated 2023-03-13
Conditions: Long COVID / PASC
AGENTS
Active Tdcs
The overarching goals of this study are to employ cognitive testing to understand how transcranial direct current stimulation (tDCS), when used concurrently with cognitive training tasks, can affect cognitive impairment symptoms in individuals with long COVID, or post-acute sequelae SARS-CoV-2 infection (PASC), and to examine variability in response between active and sham tDCS...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Enrollment: Actual Sponsor Type: Other
COVID-19 Sequelae: Treatment and Monitoring. A Dietary Supplement Based on Sea Urchin Eggs With Echinochroma A
NCT05531019
COMPLETED • NA • Updated 2023-02-28
Conditions: Long COVID / PASC
AGENTS
Echinochrome A
The aim of this study is to assess the efficacy and efficiency of a nutraceutical from sea urchin eggs with Echinochrome A in the inflammation of tissues in subjects with long Corona Virus (COVID) syndome
View on ClinicalTrials.gov →
Anti-inflammatory NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
TaiChi-DTx for Treating Long Covid Symptoms
NCT05419219
UNKNOWN • NA • Updated 2023-02-15
Conditions: ME/CFS
AGENTS
The Multi-Domain Tai Chi Digital Therapy Software Application
The randomized controlled trial will be conducted to evaluate the effectiveness of a Multi-domain Tai Chi Digital Therapy for treating the individuals suffering from the long term COVID-19 syndrome (Long COVID).
View on ClinicalTrials.gov →
Neurological / Autonomic NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
Exercise Intervention Using mHealth in Patients With Post-Acute COVID-19 Syndrome: a Randomized Clinical Trial
NCT05725538
UNKNOWN • NA • Updated 2023-02-13
Conditions: Long COVID / PASC
AGENTS
Covidreapp Group
Post-Acute Syndrome COVID-19 is a disease resulting from infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is estimated that between 10 and 35% of infected persons suffer symptoms afterwards, and in hospitalized patients it can reach 85%. These sequelae have individual, social and economic repercussions, so effective rehabilitation alternatives a...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia
NCT05706454
UNKNOWN • PHASE2 • Updated 2023-01-31
Conditions: Long COVID / PASC
AGENTS
Ramatroban
Phase II/Phase III study to evaluate the safety and efficacy of Ramatroban 75 mg tablet against Placebo in subjects hospitalized for pneumonia due to SARS-CoV-2 infection. Approximately 324 eligible subjects will be randomized in a 1:1 ratio to one of the two treatment groups. Group I: Ramatroban 75 mg tablet + Standard of care; Group II: Placebo + Standard of care. Phase 2 ...
View on ClinicalTrials.gov →
General Phase 2 Large (200-999 participants) Enrollment: Estimated Sponsor Type: Industry
Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome
NCT04604704
COMPLETED • PHASE2 • Updated 2023-01-25
Conditions: Long COVID / PASC
AGENTS
NaltrexoneNad+
Pilot study into low dose naltrexone (LDN) and NAD+ for treatment of patients with post-COVID-19 syndrome.
View on ClinicalTrials.gov →
Immunomodulatory Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Industry
Acupressure and Qigong in Chronic Fatigue Post COVID-19.
NCT05289154
UNKNOWN • NA • Updated 2023-01-23
Conditions: Long COVID / PASC
AGENTS
Self- Applied Acupressure Plus Qigong Course Plus Advice LiteratureAdvice Literature With Naturopathy
International observational studies confirm the high incidence of post-infectious residual syndrome after infection with severe acute respiratory syndrome corona virus 2 (SARS-COV2), which can occur in 10-15% of all infected persons, regardless of the severity of the acute infection. Post corona virus disease 19 (postCOVID-19) patients suffer mostly from symptoms such as fatigu...
View on ClinicalTrials.gov →
Anti-inflammatory NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
Feasibility of Cannabidiol for the Treatment of Long COVID
NCT04997395
COMPLETED • PHASE2 • Updated 2023-01-19
Conditions: Long COVID / PASC
AGENTS
Medicabilis Cannabis Sativa 50
This is an open label, phase 2 clinical trial to assess the feasibility of a cannabidiol (CBD) dominant medicinal cannabis for the treatment of Long COVID. The primary aim is to assess the feasibility of recruiting and retaining individuals diagnosed with Long COVID into a treatment trial of medicinal cannabis, as well as assessing the safety and tolerability of a dominant medi...
View on ClinicalTrials.gov →
General Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Industry
BREATHE: Virtual Self-management for Long COVID-19
NCT05107440
COMPLETED • NA • Updated 2022-12-14
Conditions: Long COVID / PASC
AGENTS
Breathe
A mixed-methods evaluation of a virtual self-management program for people living with long COVID in Alberta.
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Effects of IMT on Functional Capacity in Patients With Chronic COVID After Hospital Discharge
NCT05279430
COMPLETED • NA • Updated 2022-12-13
Conditions: Long COVID / PASC
AGENTS
Inspiratory Muscle Training
Exercise intolerance and fatigue are the most common symptoms in patients with chronic COVID after hospital discharge. Muscle deconditioning, dysautonomia, and exercise hyperventilation have been proposed as potential mechanisms contributing to exercise functional capacity limitation in Long-COVID. Along this line, combined exercise training or inspiratory muscle training (IMT)...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Efficacy of a Physical and Respiratory Rehabilitation Program for Patients With Persistent COVID-19 (SARS-CoV-2).
NCT05629884
UNKNOWN • NA • Updated 2022-11-29
Conditions: Long COVID / PASC
AGENTS
Coperia-Rehab
The pandemic caused by SARS-CoV-2 infection has resulted, in addition to the well-known acute symptoms, in the emergence of a plethora of persistent, diffuse and heterogeneous symptoms such as fatigue, shortness of breath and cognitive dysfunction among others, that have come to be called persistent COVID. Patients have reported that physical activity, stress and sleep disturba...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Differential Diagnosis of Persistent COVID-19 by Artificial Intelligence
NCT05629793
UNKNOWN • NA • Updated 2022-11-29
Conditions: Long COVID / PASC
AGENTS
Experimental Tests
The pandemic caused by SARS-CoV-2 infection has resulted, in addition to the well-known acute symptoms, in the emergence of persistent, diffuse and heterogeneous symptoms referred to as persistent COVID. Common symptoms include fatigue, shortness of breath, and cognitive dysfunction, among others, and result in an impact on daily functioning. Symptoms may be new onset, appear ...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Digital Physiotherapy Practice in Long Covid-19 Patients
NCT04742946
UNKNOWN • NA • Updated 2022-11-18
Conditions: Long COVID / PASC
AGENTS
Digital Physiotherapy Practice
The COVID-19 can cause important sequels in the respiratory system by bilateral pneumonia and frequently presents loss of strength, dyspnea, polyneuropathies and multi-organic affectation. Long COVID-19 has been defined as the condition occurring in individuals with a history of probable or confirmed SARS-CoV-2 infection, with related symptoms lasting at least 2 months and not ...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome
NCT05597800
NOT_YET_RECRUITING • PHASE2 • Updated 2022-10-28
Conditions: Long COVID / PASC
AGENTS
Nivolumab And Ipilimumab
Study type: Phase 2 - Interventional Trial Number of patients to be enrolled: 105 Participating countries: Italy Study drugs: nivolumab and ipilimumab Cohort A: HBV and HCV patients Cohort B: HIV patients Cohort C: Long COVID syndrome The stratification factors are HBV/HCV positive (cohort A), HIV positive (cohort B), patients with Long Covid syndrome (Cohort C), histology (squ...
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
HEART Rate Variability Biofeedback in LOng COVID-19 (HEARTLOC)
NCT05228665
UNKNOWN • NA • Updated 2022-10-24
Conditions: Long COVID / PASC
AGENTS
Heart Rate Variability Biofeedback
Long COVID is a common but highly debilitating illness which develops after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19). It is thought to affect as many as 1 in 7 people following COVID-19 infection. It can produce a vast array of symptoms including fatigue, breathlessness, fast heart rate, blood pressure disturbance, temperature dist...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection
NCT05152849
COMPLETED • PHASE2 • Updated 2022-10-20
Conditions: Long COVID / PASC
AGENTS
Axa1125
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving muscle function (metabolism) following moderate exercise in subjects with fatigue-Predominant Post-Acute Sequelae of SARS-CoV-2 as well as the safety and tolerability of AXA1125. Subjects will take one dose of AXA1125 or a placebo twice daily for 28 days.
View on ClinicalTrials.gov →
General Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Industry
Safety and Dosage of a Computerized Cognitive Training Program for Cognitive Dysfunction After COVID-19
NCT05582603
UNKNOWN • PHASE1 • Updated 2022-10-18
Conditions: Long COVID / PASC
AGENTS
Cct Long Covid
The goal of this Phase I/II clinical trial is to assess the safety and maximum tolerated training time of a self-administered computerized cognitive training (CCT) in individuals with cognitive dysfunction as a consequence of COVID-19 infection.
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 1 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Telerehabilitation Program in Persistent COVID-19
NCT04996212
COMPLETED • NA • Updated 2022-10-17
Conditions: Unspecified / Overlap
AGENTS
Walking App GroupFunctional App Group
The syndrome characterized by the persistence of symptoms typical of COVID-19, beyond 4 weeks after discharge, is called long COVID. Long COVID affects a high percentage of patients who have suffered from COVID-19, regardless of its severity. The various symptoms present in that patients affect the functionality and physical, mental and psychological capacities of patients. The...
View on ClinicalTrials.gov →
Persistence / Antiviral NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Personalized Computerized Training Program for Cognitive Dysfunction After COVID-19
NCT05571852
COMPLETED • NA • Updated 2022-10-07
Conditions: Long COVID / PASC
AGENTS
Cognifit'S Cct Post Covid-19
This before-and-after study aims to evaluate the usefulness and efficacy of a personalized computerized cognitive training (CCT) to improve cognitive function among people with post-acute sequelae of COVID-19 (PASC).
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Long COVID-19 Syndrome in Primary Care: A Novel Protocol of Exercise Intervention "CON-VIDA Clinical Trial"
NCT05543408
UNKNOWN • NA • Updated 2022-09-22
Conditions: Long COVID / PASC
AGENTS
Exercise
This is a randomized controlled trial of the efficacy of an individualized, progressive, exercise program (strength, cardiovascular, and breathing exercises) in recovering people from the post-COVID-19 syndrome (i.e., patients who present symptoms \>12 weeks once the acute phase of the disease is over).
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Digital Health Intervention Based on Artificial Intelligence to Support the Personalized Recovery of Long COVID Patients Affected by Fatigue (AIDA)
NCT05483829
COMPLETED • NA • Updated 2022-09-22
Conditions: Long COVID / PASC
AGENTS
Adhera® Fatigue For Long Covid Program
The AIDA feasibility study builds upon mental health and technology acceptance theoretical frameworks. It examines the feasibility of a mobile-based digital program to support patients with long covid affected by fatigue. The program Adhera ® Fatigue Self-management is adapted for long covid patients.
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Industry
Rehabilitation Therapy for Post COVID 19 Chronic Fatigue Syndrome
NCT05534997
UNKNOWN • NA • Updated 2022-09-10
Conditions: Long COVID / PASC
AGENTS
Intensive Combined Rehabilitation Therapy
The aim of this study is to investigate the effect of intensive combined rehabilitation therapy in form of Graded Exercise Therapy (GET) , Cognitive Behavioral Therapy (CBT) to treat patients with post COVID19 chronic fatigue syndrome .
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Treatment for Post Acute COVID-19 Syndrome
NCT05507372
UNKNOWN • NA • Updated 2022-08-22
Conditions: Unspecified / Overlap
AGENTS
Pimozide 1 Mg
Post-acute COVID-19 tinnitus has not been treated successfully. As tinnitus may be related to SARS-CoV-2 neurological manifestations. This study aims to investigate if the dopamine receptor antagonists can be used effectively treat COVID-19 induced tinnitus.
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Industry
Long-term Effects of SARS-CoV-2 on the Central Nervous System and One-year Follow-up of "Long COVID-19" Patients
NCT05492292
UNKNOWN • NA • Updated 2022-08-08
Conditions: Long COVID / PASC
AGENTS
Perfusion Brain Scintigraphy Imaging
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the seventh coronavirus known to infect humans, and causing coronavirus disease 2019 (COVID-19). . Since its emergence in December 2019, in Wuhan, China, SARS-CoV-2 has led to a global pandemic with almost 188 million cases and 4 million COVID-19 related deaths reported. Although initially considered as a predomina...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain
NCT04827992
COMPLETED • NA • Updated 2026-06-24
Conditions: Unspecified / Overlap
AGENTS
CannabisPrescription Opioid Taper Support
This study will use a randomized controlled design to test whether medical marijuana use by adults on high-dose chronic opioid therapy (COT) for chronic non-cancer pain is associated with reduced opioid dose and improved pain intensity and interference when added to a 24-week behavioral intervention (POTS).
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)
NCT06593600
ACTIVE_NOT_RECRUITING • PHASE2 • Updated 2026-06-17
Conditions: Unspecified / Overlap
AGENTS
Regn7544
This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on participants with POTS. The aim of the study is to see how safe, tolerable, and effective the study drug is. The study is looking at several other research questions, including: * How the study drug changes heart rate and blood pressure in participants with POTS * Wh...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Industry
The Impact of Improved Vagal Function on Periaqueductal Gray Connectivity
NCT05618067
NOT_YET_RECRUITING • NA • Updated 2026-06-09
Conditions: Unspecified / Overlap
AGENTS
Breathing Exercise Training
This study is being to see if participating in breathing exercise training and practicing this training will help with Postural tachycardia syndrome (POTS). The information may help doctors to learn more about how the different parts of people's brains communicate.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Cervicothoracic Sympathetic Block Evaluation for Post COVID Condition
NCT07468604
RECRUITING • PHASE4 • Updated 2026-06-08
Conditions: Unspecified / Overlap
AGENTS
5 Ml Of 0.25% Bupivacaine With Epinephrine
Post-COVID Condition (PCC) affects roughly 2.1 million Canadians, carrying an annual economic burden of CAD $7.8-50.6 billion. It presents across multiple organ systems with symptoms including fatigue, brain fog, palpitations, and orthostatic intolerance, at an annual cost of CAD $1,675-$7,340 per case. A key mechanism underlying many treatment-resistant PCC symptoms appears t...
View on ClinicalTrials.gov →
Immunomodulatory Neurological / Autonomic Anti-inflammatory Phase 4 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Beta-3 Enhanced Autonomic Therapy for POTS
NCT07585513
NOT_YET_RECRUITING • PHASE2 • Updated 2026-05-13
Conditions: Unspecified / Overlap
AGENTS
Mirabegron
The study will test the hypothesis that mirabegron is more effective than a placebo in alleviating postural orthostatic tachycardia (POTS) symptoms.
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Effects of Breathing Retraining Exercises in Pregnant Females With Postural Orthostatic Tachycardia Syndrome.
NCT07579026
RECRUITING • NA • Updated 2026-05-11
Conditions: Unspecified / Overlap
AGENTS
Diaphragmatic Breathing Exercise
Postural orthostatic tachycardia POTS is characterized by excessive increase in heart rate when moving from lying to standing position, often accompanied by symptoms such as dizziness, fatigue, brain fog, lightheadedness, rapid heartbeat and palpitation.it most commonly effects the females of reproductive age and can be triggered by events like viral infections, trauma and horm...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Non-invasive Vagus Nerve Stimulation for Chronic Musculoskeletal Pain
NCT07409363
NOT_YET_RECRUITING • NA • Updated 2026-05-11
Conditions: Unspecified / Overlap
AGENTS
Active Vagus Nerve Stimulation
Chronic musculoskeletal (MSK) pain affects an estimated 20-33% of the global population and is frequently associated with autonomic nervous system dysfunction, characterised by symptoms such as orthostatic intolerance, palpitations, gastrointestinal dysmotility, and fatigue. Conventional treatments often fail to address this autonomic component, limiting their effectiveness. Th...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
The Effects of Chiropractic in a Population With High Central Adiposity
NCT06208163
COMPLETED • NA • Updated 2026-05-08
Conditions: Unspecified / Overlap
AGENTS
Chiropractic
Since 1980, the global prevalence of obesity, commonly defined as a body mass index (BMI) of 30 or higher, has doubled. Importantly, high levels of central adiposity (i.e., abdominal fat) is associated with numerous PNI-related sequelae, including increased levels of psychological distress, cognitive deficits, ANS dysfunction, and immune marker abnormalities. To our knowledge, ...
View on ClinicalTrials.gov →
Immunomodulatory Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
CAlgary SAlt for POTS
NCT05924646
RECRUITING • NA • Updated 2026-05-07
Conditions: Unspecified / Overlap
AGENTS
Microcystalline Cellulose Capsules
Many patients with postural orthostatic tachycardia syndrome (POTS) have decreased plasma volume. Current POTS guidelines recommend \~10 g of salt and 2-3 L of fluid per day. Despite this recommendation, there is no long term data evaluating the use of salt in POTS. This randomized, placebo-controlled cross-over trial will evaluate a high salt diet, compared to a normal salt di...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Compression Garments in the Community With POTS
NCT04881318
RECRUITING • NA • Updated 2026-05-07
Conditions: Unspecified / Overlap
AGENTS
Waist-High Compression TightsAbdominal Compression GarmentsMedications That Modulate Heart Rate And Blood Pressure
Compression Garments are a commonly prescribed treatment in Postural Orthostatic Tachycardia Syndrome (POTS). The effectiveness of a proof-of-concept compression garment has been demonstrated in an acute laboratory setting. It is not known if commercially available compression garments that participants wear in their every day lives are effective at improving heart rate and red...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Hypercapnia and Orthostatic Tolerance in Postural Orthostatic Tachycardia Syndrome
NCT04271878
RECRUITING • NA • Updated 2026-05-07
Conditions: Unspecified / Overlap
AGENTS
Respiract™ System
The mechanism behind postural orthostatic tachycardia syndrome (POTS) involves many causes including a sympathetic nervous system problem. Blood gases, like carbon dioxide (CO2), have an important effect on sympathetic activation. The purpose of this research study is to determine if higher CO2 levels have any effect in lowering heart rate and reducing POTS symptoms when uprig...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Low Dose Naltrexone Use in Patients With POTS
NCT05363514
NOT_YET_RECRUITING • PHASE4 • Updated 2026-05-01
Conditions: Unspecified / Overlap
AGENTS
Low Dose NaltrexoneMicrocrystalline Cellulose
Many patients with Postural Orthostatic Tachycardia Syndrome (POTS) experience debilitating fatigue and this significantly impacts their daily lives. Unfortunately, there are no treatments to help POTS patients with their fatigue. One medication, called low dose naltrexone (LDN), has been tested as a treatment for fatigue in other medical conditions. In this other research, LDN...
View on ClinicalTrials.gov →
Immunomodulatory Neurological / Autonomic Anti-inflammatory Phase 4 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Blood Pressure Effects on Cognition and Brain Blood Flow in PD
NCT05400174
RECRUITING • NA • Updated 2026-04-27
Conditions: Unspecified / Overlap
AGENTS
Tilt Table
Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide. Besides causing symptoms that impair movement, PD also causes non-motor symptoms, such as problems thinking and orthostatic hypotension (OH), i.e., low blood pressure (BP) when standing. About one-third of people with PD have OH, which can cause sudden, temporary symptoms while upright, inc...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Paediatric Syncope in the Emergency Department
NCT05555771
RECRUITING • NA • Updated 2026-04-23
Conditions: Unspecified / Overlap
AGENTS
Counterpressure Maneuvers
The investigators will assess the efficacy of clinically recommended counterpressure maneuvers (CPM) in preventing syncope for paediatric patients. Participants presenting to the emergency department (ED) will first provide written informed consent. In stage I, they will be asked to complete a brief survey documenting the presentation of their syncopal episode, and any prodroma...
View on ClinicalTrials.gov →
General NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
Postural Sway and Counterpressure Maneuvers for Pediatric Syncope
NCT05633693
RECRUITING • NA • Updated 2026-04-23
Conditions: Unspecified / Overlap
AGENTS
Counterpressure ManeuversBaseline Stand
The investigators are interested in whether discrete counterpressure maneuvers, or muscle movements in the lower body, will boost blood pressure and cardiovascular control in children who faint. We will record cardiovascular responses to maneuvers of exaggerated sway, leg crossing, crouching, and gluteal muscle tensing in children who faint (N=20), as well as their height, weig...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Natural History With Its Numerous Co-morbidities?
NCT05618054
RECRUITING • NA • Updated 2026-04-21
Conditions: Unspecified / Overlap
AGENTS
Looming Task
This study is being conducted to see how people with Postural tachycardia syndrome (POTS) make sense of the things they see. The information may help doctors to learn more about how the different parts of people's brains communicate.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Definition of Autonomic Nervous System Involvement in Patients With Multiple Sclerosis
NCT05748015
RECRUITING • NA • Updated 2026-04-17
Conditions: Unspecified / Overlap
AGENTS
Quantification Of Sensory And Autonomic Small Nerve Fibers By Punch Skin BiopsyCardiovascular Reflexes TestingAdministration Of Clinical Scales Evaluating Autonomic Symptoms, Pain Small Fiber Neuropathy Symptoms
The goal of this interventional non-pharmacological study is to evaluate the involvement of the autonomic nervous system in patients with relapsing-remitting and primary progressive multiple sclerosis. The main questions it aims to answer are: * Is it possible to define the characteristics of dysautonomia to improve treatment on patients with multiple sclerosis through the ma...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Dexmedetomidine Sublingual Film for the Ambulatory Treatment of Hyperadrenergic Autonomic Crisis in Patients With Familial Dysautonomia
NCT06148311
ENROLLING_BY_INVITATION • PHASE2 • Updated 2026-04-13
Conditions: Unspecified / Overlap
AGENTS
Dexmedetomidine
The purpose of this placebo controlled interventional study is to collect preliminary data on administering dexmedetomidine in patients with Familial Dysautonomia (FD) during a rapid cessation of autonomic crisis. The primary aims are to assess the feasibility and evaluate if measurements of heart rate, blood pressure and oxygen saturation can predict the start of an autonomic ...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
NCT06524739
TERMINATED • PHASE3 • Updated 2026-04-13
Conditions: Long COVID / PASC
AGENTS
Igpro20
This is a prospective, phase 3, multicenter, double-blind, randomized placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics (PK) of repeat doses of IgPro20 in participants with post SARS-CoV-2 infection 2019 postural orthostatic tachycardia syndrome (post-Coronavirus Disease 2019 \[COVID-19\] POTS \[post-COVID-POTS\]).
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 3 Small (<50 participants) Enrollment: Actual Sponsor Type: Industry
NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome
NCT04977388
COMPLETED • PHASE1 • Updated 2026-04-13
Conditions: Unspecified / Overlap
AGENTS
Droxidopa
The purpose of this study is to evaluate whether Northera (Droxidopa) is safe and effective in young adults with Menkes disease who survived the most severe complications of their illness or adults with occipital horn syndrome (OHS), who have trouble with intermittent low blood pressure and other symptoms of dysautonomia. The outcomes and information from this study may help ad...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 1 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Autoimmune Basis for Postural Tachycardia Syndrome
NCT05043051
ACTIVE_NOT_RECRUITING • NA • Updated 2026-04-08
Conditions: Unspecified / Overlap
AGENTS
Vagal Stimulation
The purpose of this study is to test the hypothesis that an antibody-mediated autoimmune reaction will cause symptoms of autonomic dysfunction in some patients with postural tachycardia syndrome (POTS). The investigators further hypothesize that electrical stimulation of the vagus nerve will improve POTS symptoms, autoimmunity and inflammation.
View on ClinicalTrials.gov →
Immunomodulatory Neurological / Autonomic Anti-inflammatory NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Using Mirabegron to Increase BP in Patients With POTS
NCT06133075
COMPLETED • PHASE2 • Updated 2026-04-08
Conditions: Unspecified / Overlap
AGENTS
Mirabegron 50 MgMirabegron 25 Mg
This is a pilot dose-finding study to test the hypothesis that mirabegron increases systolic blood pressure (BP), prevents syncope/presyncope, and improves the quality of life (QOL), functional capacity, chest pain, and overactive bladder (OAB) symptoms in patients with postural orthostatic tachycardia syndrome (POTS) who have a documented history of hypotension inadequately re...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Programming Aquatic Therapy for POTS
NCT07182578
COMPLETED • NA • Updated 2026-04-03
Conditions: Unspecified / Overlap
AGENTS
Aquatic Occupational Therapy
The goal of this pilot study is to create, implement, and evaluate an aquatic therapy for Postural Orthostatic Tachycardia Syndrome (POTS) program feasibility and ability to improve quality of life as determined by reduced orthostatic tachycardia, reduced POTS symptoms, and improved quality of life measures. The main questions it aims to answer are: Does aquatic occupational ...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Better Understanding of Fatigue After STroke
NCT06292377
RECRUITING • NA • Updated 2026-03-30
Conditions: Unspecified / Overlap
AGENTS
EcgTransthoracic EchographyBlood Sampling
Stroke is worldwide the second most common cause of death following heart attack and the leading cause of disability. Post-stroke fatigue (PSF) is a common complication after stroke and can be defined as 'an overwhelming exhaustion or tiredness, not related to exertion, which does not typically improve with rest'. Fatigue following stroke can be divided into early (\< 3 months)...
View on ClinicalTrials.gov →
Neurological / Autonomic Anti-inflammatory NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
Autonomic Determinants of POTS - Pilot 2
NCT04140721
ACTIVE_NOT_RECRUITING • EARLY_PHASE1 • Updated 2026-03-27
Conditions: Unspecified / Overlap
AGENTS
Moxonidine Pill
Postural tachycardia syndrome (POTS) is a relatively common condition affecting mostly otherwise healthy young women. These patients have high heart rate and disabling symptoms during standing. Quality of life may be poor. The sympathetic nerves in the autonomic nervous system help to maintain normal blood pressures and heart rates during activities of daily life. The purpose ...
View on ClinicalTrials.gov →
Neurological / Autonomic EARLY_Phase 1 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Transdermal Vagal Stimulation for POTS
NCT02281097
ACTIVE_NOT_RECRUITING • NA • Updated 2026-03-27
Conditions: Unspecified / Overlap
AGENTS
Stimulation
Some patients experience high heart rates and symptoms of light-headedness, fatigue, headache during standing despite well maintained blood pressure. These patient are disabled and can't be in upright position for a longer time. The purpose of this study is to test whether electrical stimulation of a nerve through a skin of the ear may improve heart rate response and reduce di...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Autonomic Determinants of POTS - Pilot1
NCT04050410
ACTIVE_NOT_RECRUITING • EARLY_PHASE1 • Updated 2026-03-27
Conditions: Unspecified / Overlap
AGENTS
Moxonidine
Postural tachycardia syndrome (POTS) is a relatively common condition affecting mostly otherwise healthy young women. It is the cause of significant disability and an impairment in quality of life. These patients have high heart rate and symptoms during standing. Many of these patients are disabled and have a poor quality of life. The sympathetic nerves are part of the nervous ...
View on ClinicalTrials.gov →
Neurological / Autonomic EARLY_Phase 1 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
NCT07478172
RECRUITING • NA • Updated 2026-03-17
Conditions: Unspecified / Overlap
AGENTS
Whole-Body Electrical Muscle Stimulation Exercise
This single-arm pilot study evaluates the effects of whole-body electrical muscle stimulation (WB-EMS) exercise on neuromuscular and physical function in adults with neuromuscular disease (NMD). Due to motor unit impairments, NMD patients often cannot tolerate traditional exercise. WB-EMS bypasses voluntary activation limits by directly stimulating muscle contractions. Up to 50...
View on ClinicalTrials.gov →
Metabolic Mitochondrial Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Dysautonomia in Children With Type 1 Diabetes
NCT07455994
RECRUITING • NA • Updated 2026-03-06
Conditions: Unspecified / Overlap
AGENTS
Neurocoach® And Sudoscan®
Some physiological factors, such as physical activity, or pathological factors, such as sepsis or diabetes, are known to modulate the overall autonomic activity and the individual's intrinsic capacity to regulate their sympathetic and parasympathetic balance. These conditions can alter the physiological autonomic balance, sometimes with positive consequences on the FC-breathing...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
A Study of Pyridostigmine in Postural Tachycardia Syndrome
NCT00409435
RECRUITING • PHASE2 • Updated 2026-03-05
Conditions: Unspecified / Overlap
AGENTS
Pyridostigmine
This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Pilot Study of Dexmedetomidine Sublingual Film for the Ambulatory Treatment of Hyperadrenergic Autonomic Crisis in Patients With Familial Dysautonomia
NCT06128356
ACTIVE_NOT_RECRUITING • PHASE2 • Updated 2026-03-04
Conditions: Unspecified / Overlap
AGENTS
Dexmedetomidine Sublingual
This is a pilot open-label study to evaluate the feasibility of conducting a clinical trial using sublingual dexmedetomidine sublingual film to treat hyperadrenergic autonomic crises in patients with Familial Dysautonomia at home. The primary aims are to examine the feasibility of performing a clinical trial using dexmedetomidine at home to terminate autonomic crisis, and refin...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Personalized Brain Stimulation to Treat Chronic Concussive Symptoms
NCT06073886
RECRUITING • PHASE2 • Updated 2026-02-24
Conditions: Unspecified / Overlap
AGENTS
Active CtbsImaginal Exposure
The goal of this study is to investigate a new treatment for chronic symptoms after concussion or mild traumatic brain injury in people aged 18-65 years old. Chronic symptoms could include dizziness, headache, fatigue, brain fog, memory difficulty, sleep disruption, irritability, or anxiety that occurred or worsened after the injury. These symptoms can interfere with daily func...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Autonomic Reactivity and Personalized Neurostimulation
NCT06863207
RECRUITING • NA • Updated 2026-02-13
Conditions: Unspecified / Overlap
AGENTS
Percutaneous Electrical Nerve Field StimulationHypnotherapy
Disorders of gut-brain interaction (DGBI) affect up to 25% of U.S. children. Patients often suffer from disabling, multisystem comorbidities that suggest a common root (sleep disturbances, fatigue, anxiety, etc). Yet, DGBI are defined and treated based on GI symptom origin (cyclic vomiting, dyspepsia, irritable bowel) rather than underlying pathophysiology. Many patients manife...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Auricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome
NCT05212129
RECRUITING • NA • Updated 2026-02-13
Conditions: Unspecified / Overlap
AGENTS
Percutaneous Vagal Nerve Stimulation (Pvns) DeviceAcoustic Vagal Nerve Stimulation (Avns) Treatment
Hypermobile Ehlers-Danlos Syndrome (hEDS) is a connective tissue disorder characterized by hyperextensible skin, joint hypermobility and additional connective tissue manifestations. For unclear reasons, hEDS is associated with many gastrointestinal (GI) and autonomic nervous system (ANS) complaints such as postural orthostatic tachycardia syndrome (POTS). This study will addres...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease.
NCT07398508
RECRUITING • PHASE1 • Updated 2026-02-10
Conditions: Unspecified / Overlap
AGENTS
Droxidopa Oral Product
This clinical trial will evaluate the safety, tolerability, dosing, and efficacy of Northera (Droxidopa) in children with Menkes disease aged 7 to 17 years who survived the major neurodegenerative and neurocognitive effects of Menkes disease through early Copper Histidinate treatment. The investigator hypothesizes that Northera (Droxidopa) treatment in pediatric Menkes disease ...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 1 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Modafinil and Cognitive Function in POTS
NCT01988883
ACTIVE_NOT_RECRUITING • EARLY_PHASE1 • Updated 2026-01-15
Conditions: Unspecified / Overlap
AGENTS
ModafinilPropranolol
A common complaint among patients with Postural Tachycardia Syndrome (POTS) is "brain fog" or difficulty concentrating. This problem is poorly understood. The purpose of this study is to better understand the cognitive dysfunction associated POTS, and to determine optimal treatment strategies for this condition. In this study, the investigators will test the hypothesis that ac...
View on ClinicalTrials.gov →
Neurological / Autonomic EARLY_Phase 1 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Aldosterone & Sodium Regulation in Postural Tachycardia Syndrome - Screening
NCT01783288
ACTIVE_NOT_RECRUITING • NA • Updated 2026-01-13
Conditions: Unspecified / Overlap
AGENTS
Autonomic Function TestingPosture StudyMeasurement Of Total Blood VolumeExercise Capacity Test
The purpose of the study is to determine whether patients meet criteria for Postural Tachycardia Syndrome (or not) and have reduced blood volume (or not). Both of these are important screening elements to Aim 3 of a National Institutes of Health Grant. The purposes of Aim 3 are to determine 1. whether a high dietary sodium level appropriately expands plasma volume in Postural O...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Screening for Alterations in the Autonomic Nervous System
NCT07029191
COMPLETED • NA • Updated 2025-12-24
Conditions: Unspecified / Overlap
AGENTS
Progressive Standing Test
Dysautonomia is an alteration of the autonomic nervous system that manifests itself in different forms, some of which are very disabling. Dysautonomia accompanies many pathologies. Its importance in public health is illustrated by an incidence of 20-70% in diabetes. It affects between 400,000 and 1.4 million patients in the French diabetic population alone. Dysautonomia is main...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other Gov
Breathing Device in Postural Orthostatic Tachycardia Syndrome (POTS)
NCT00962728
ACTIVE_NOT_RECRUITING • NA • Updated 2025-12-22
Conditions: Unspecified / Overlap
AGENTS
Inspiratory Threshold Device
The investigators will test whether breathing through an inspiratory resistance device will improve the ability to be upright and decrease heart rate increases on standing in patients with postural tachycardia syndrome.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Cardiac Involvement in Wilson's Disease
NCT05493605
RECRUITING • NA • Updated 2025-12-17
Conditions: Unspecified / Overlap
AGENTS
Delivery Of A Long-Term Holter 21 Days Or Placement Of An Implantable Holter From The Outset So Syncope
Heart damage by copper accumulation has been reported in Wilson's Disease. However, the disease epidemiology is still poorly understood. A number of studies on pediatric populations have not shown any significant cardiac involvement apart from early dysautonomia. This could suggest that the clinical manifestations related to the copper accumulation in the heart appears with the...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Network
Restoring Iron Deficiency in POTS
NCT07197905
RECRUITING • PHASE2 • Updated 2025-12-11
Conditions: Unspecified / Overlap
AGENTS
Intravenous Iron
People with postural orthostatic tachycardia syndrome (POTS) often have low red blood cell volumes and low ferritin in their blood (a marker of iron storage in the body). The purpose of this pilot study is to investigate whether giving iron to people with POTS who have low ferritin levels will increase the red blood cell volume and improve POTS symptoms.
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Splanchnic Venous Capacitance in Postural Tachycardia Syndrome
NCT05375968
RECRUITING • PHASE2 • Updated 2025-12-05
Conditions: Unspecified / Overlap
AGENTS
Compare Change Is Svc And Sma Flow Due To Gip Antagonist Gip(3-30)Nh2Compare Change Is Svc And Sma Flow Due To Saline
Postural tachycardia syndrome (POTS) affects ≈3 million young people, characterized by chronic presyncopal symptoms characterized by dizziness, lightheadedness, and orthostatic tachycardia that occur while standing. Across-sectional survey found that 25% of these patients complains that meals rich in carbohydrates are among the factors that further exacerbate POTS's symptoms an...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Autoimmune Basis for Postural Tachycardia Syndrome
NCT02725060
ENROLLING_BY_INVITATION • NA • Updated 2025-11-12
Conditions: Unspecified / Overlap
AGENTS
PhenylephrineIsoproterenol25 Micro-Ci Of Radiation24-Hour Heart Rhythm And Blood Pressure MonitoringQuantitative Axonal Sudomotor Reflex TestingAutonomic Function TestsRebreathing TestAssessment Of Splanchnic CapacitanceMicroneurography
The purpose of this study is to see if some people with postural tachycardia syndrome (POTS) have higher levels of immune proteins (autoantibodies) directed against receptors of the autonomic nervous system, and if these autoantibodies make a difference in their POTS symptoms. The investigators also want to see if the levels of these autoantibodies stay the same over time.
View on ClinicalTrials.gov →
Immunomodulatory Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Non-invasive Vagal Neurostimulation (nVNS) in Adolescents With Postural Orthostatic Tachycardia Syndrome (POTS)
NCT06268288
COMPLETED • NA • Updated 2025-10-31
Conditions: Unspecified / Overlap
AGENTS
Gammacore InterventionSteps Management Protocol
The purpose of this study is to determine if nVNS will decrease autonomic symptom intensity (COMPASS-31 and Child Functional Disability Inventory) in adolescent patients with postural orthostatic tachycardia syndrome (POTS) in comparison to standard recovery STEPS management.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Ultrasound Guided Stellate Ganglion Block in Postural Tachycardia Syndrome
NCT06953661
NOT_YET_RECRUITING • NA • Updated 2025-10-15
Conditions: Unspecified / Overlap
AGENTS
Stellate Ganglion BlockRopivacaineNormal Saline
This single-center study aims to evaluate both immediate and long-term outcomes of stellate ganglion block (SGB) in a cohort of rigorously phenotyped patients with Postural Tachycardia Syndrome (POTS). By assessing the effects of SGB, this study seeks to determine its viability as an intervention for symptom control in POTS.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Pathophysiology of Orthostatic Intolerance
NCT00608725
ACTIVE_NOT_RECRUITING • NA • Updated 2025-10-08
Conditions: Unspecified / Overlap
AGENTS
DaxorQsweatIntrinsic Heart Rate
The purpose of this study is to describe the mechanism of orthostatic intolerance, relying on cardiovascular physiological studies. The syndrome is of undetermined etiology, but the syndrome causes impairment of a number of young adults, females more than males, with symptoms of tachycardia, fatigue, lightheadedness, palpitations, blurred vision, chest discomfort, difficulty co...
View on ClinicalTrials.gov →
General NA Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Intravenous (IV) Saline and Exercise in Postural Tachycardia Syndrome (POTS)
NCT01000350
ACTIVE_NOT_RECRUITING • NA • Updated 2025-10-08
Conditions: Unspecified / Overlap
AGENTS
Saline
The investigators will test whether an intravenous infusion of saline (salt water) will improve the exercise capacity in patients with postural tachycardia syndrome (POTS).
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
fMRI in Postural Tachycardia Syndrome
NCT04137757
ACTIVE_NOT_RECRUITING • NA • Updated 2025-09-19
Conditions: Unspecified / Overlap
AGENTS
Lower Body Negative Pressure
Postural tachycardia syndrome (POTS) is one of the most common forms of chronic orthostatic intolerance in the United States. This is a disabling disorder characterized by an excessive increase in heart rate upon standing that is accompanied by symptoms such as dizziness and fatigue. One of the most under appreciated and bothersome symptoms of POTS is impaired cognition or "bra...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
The Renin-Aldosterone Axis in Postural Tachycardia Syndrome
NCT00962949
COMPLETED • PHASE1 • Updated 2025-09-16
Conditions: Unspecified / Overlap
AGENTS
Angiotensin Ii
The purpose of this study is to determine the role of the renin-angiotensin-aldosterone in the pathophysiology of postural tachycardia syndrome, and to provide an insight about the disease process in this disorder.
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 1 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Vagal Stimulation in POTS
NCT03124355
ACTIVE_NOT_RECRUITING • PHASE1 • Updated 2025-08-05
Conditions: Unspecified / Overlap
AGENTS
Pyridostigmine PillGalantamine PillVagal Stimulation
The purpose of this study is to investigate how the electrical stimulation of a nerve in the skin of the earlobe (transcutaneous vagal nerve stimulation), alone or in combination with two medications (galantamine and pyridostigmine), affects the way the autonomic (involuntary) nervous system controls heart rhythm, symptoms on standing, and inflammatory markers in female patient...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 1 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Effect of Low Sodium Oxybate (LXB) on Autonomic Symptom Burden in Idiopathic Hypersomnia Patients With Postural Tachycardia Syndrome
NCT07077278
NOT_YET_RECRUITING • PHASE4 • Updated 2025-07-25
Conditions: Unspecified / Overlap
AGENTS
Low Sodium Oxybate
The investigators hope to learn if low sodium oxybate (LXB) is an effective treatment for symptoms of idiopathic hypersomnia (IH) and postural tachycardia syndrome (POTS). Previous research has shown that patients with IH also report having symptoms associated with POTS. The researchers have observed that in patients with both IH and POTS, when patients' sleep quality improves,...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 4 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
POTS-FLOW: Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS
NCT07019519
RECRUITING • NA • Updated 2025-06-13
Conditions: Unspecified / Overlap
AGENTS
Gipr AntagonistGlp-1R AntagonistCck Agonist
This study will describe the interplay between the gut hormones GIP and CCK and their regulation of blood flow to the large vessels in patients with Postural Orthostatic Tachycardia Syndrome (POTS) and GIP, CCK and GLP-1 in healthy. This is addressed by hormone infusions during MR-scans of the abdomen and intake of oral glucose.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
The Effect of Physical Activity on Postural Orthostatic Tachycardia Syndrome
NCT05554107
RECRUITING • NA • Updated 2025-05-30
Conditions: Unspecified / Overlap
AGENTS
Training Program
Postural orthostatic tachycardia syndrome (POTS) is a disorder of unknown origin characterized by orthostatic intolerance and increased heart rate (HR) of ≥ 30 beats/minute during orthostasis in the absence of orthostatic hypotension. In addition to the orthostatic intolerance and tachycardia, patients with POTS experience several debilitating symptoms including light-headednes...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
Mechanisms of Vasovagal Syncope
NCT01791816
COMPLETED • EARLY_PHASE1 • Updated 2025-05-23
Conditions: Unspecified / Overlap
AGENTS
PhenylephrineL-Ng-Monomethyl Arginine
Vasovagal Syncope (simple postural faint) is the most common cause of acute loss of consciousness. Postural tachycardia syndrome(POTS) is the most common chronic form of postural lightheadedness. Together they afflict many Americans, mostly young women, who are prevented from gainful employ or school attendance. The underlying mechanism is not known. Our past work suggests that...
View on ClinicalTrials.gov →
Neurological / Autonomic EARLY_Phase 1 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)
NCT02558972
TERMINATED • PHASE2 • Updated 2025-05-23
Conditions: Unspecified / Overlap
AGENTS
Northera
Vasovagal syncope (VVS, simple faint) is the most common cause of transient loss of consciousness and represents the acute episodic form of orthostatic intolerance (OI). Postural tachycardia syndrome (POTS) is the common chronic form of OI. Both are defined by debilitating symptoms and signs while upright relieved by recumbency. Northera should therefore improve both sympatheti...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Counterpressure Maneuvers in Postural Orthostatic Tachycardia Syndrome
NCT06936319
RECRUITING • NA • Updated 2025-05-02
Conditions: Unspecified / Overlap
AGENTS
Best Clinical Practice Plus Cpm-Biofeedback TrainingBest Clinical Practice
The present study evaluates whether performing a 14-days counter pressure maneuvers (CPM)-biofeedback training improves the symptomatic burden (primary objective) and secondarily the interference of POTS symptoms with daily activities, fatigue, and health-related quality of life of individuals with POTS compared to best clinical practice non-pharmacological measures. Secondary ...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Evaluation of Urinary Dysfunction in CANVAS Patients
NCT06817707
RECRUITING • NA • Updated 2025-03-26
Conditions: Unspecified / Overlap
AGENTS
Evaluation Of Urinary Dysfunction In Patients With Canvas
The investigator wishes to evaluate the prevalence of urinary symptoms in patients diagnosed with Cerebellar Ataxia, Neuropathy, Vestibular Areflexia Syndrome (CANVAS). As much as one third of patients living with CANVAS experience symptoms of urinary system dysfunction. The primary objective of this study is to evaluate the incidence of urinary symptoms in these patients, as ...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Muscular and Cutaneous Dysfunction in POTS
NCT04170725
COMPLETED • NA • Updated 2025-03-10
Conditions: Unspecified / Overlap
AGENTS
Patient And Healthy Volunteers Training Protocol
POTS patients seem to experience orthostasis-dependent muscle weakness and pain as well as increased muscle fatigue upon physical activity, which can be improved by regular aerobic exercise. However, reduced sweat production of the extremities with limited control of the body temperature leads to exercise intolerance, so that sticking to a training program becomes a challenge f...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
A Shared Medical Appointment Intervention for Quality of Life Improvement in POTS
NCT05454137
COMPLETED • NA • Updated 2025-03-05
Conditions: Unspecified / Overlap
AGENTS
Shared Medical Appointment
Postural orthostatic tachycardia syndrome (POTS) is a clinical syndrome encompassing a myriad of debilitating symptoms that does not have any FDA approved drug therapies. We propose a shared medical appointment intervention where participants will learn lifestyle management therapies and integrative practices that may improve quality of life.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
The Effect of Neural Therapy on Heart Rate Recovery, Cardiac Parameters and Pain in Fibromyalgia
NCT06795750
COMPLETED • NA • Updated 2025-01-28
Conditions: Unspecified / Overlap
AGENTS
Neural TherapyExercise
Background: Autonomic dysfunction has been observed in patients with fibromyalgia and is associated with symptoms and arrhythmia development in such patients.The investigators can analyze dysautonomia using heart rate recovery (HRR). Studies have reported that impaired HRR improves after exercise in fibromyalgia patients. Although previous theories have suggested that neural th...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
POTS Stroke Volume
NCT05796154
NOT_YET_RECRUITING • NA • Updated 2024-12-19
Conditions: Unspecified / Overlap
AGENTS
Ear Blood Pressure Monitor
the investigators propose studies of a tiny, wearable, wireless, beat-to-beat blood pressure monitor that will be both a transformative research platform and an enabler of patient self-care in the diagnosis, investigation, and management of POTS.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Effect of Stellate Ganglion Block on ME/CFS
NCT05664711
COMPLETED • PHASE1 • Updated 2024-12-06
Conditions: ME/CFS
AGENTS
Bupivacaine Injection
The goal of this clinical trial is to study the effects of stellate ganglion block (SGB) in participants with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The main questions it aims to answer are: Does SGB treatment improve symptoms of ME/CFS (e.g. brain fog, fatigue)? Do changes in symptoms go along with changes in blood or saliva? Participants will receive a...
View on ClinicalTrials.gov →
Immunomodulatory Neurological / Autonomic Phase 1 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
A Novel Noninvasive Thermoregulatory Device for Postural Tachycardia Syndrome
NCT04943276
COMPLETED • NA • Updated 2024-10-08
Conditions: Unspecified / Overlap
AGENTS
Embr Device
The investigators hope to learn the feasibility and preliminary efficacy of the Embr device for improving thermal comfort in individuals with POTS and impaired thermoregulation. Feasibility will be assessed via usage of the Embr device and participant feedback. Preliminary efficacy measures will include temperature-related symptoms and temperature- related quality of life in in...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
IVIG (Gamunex-C) Treatment Study for POTS Subjects
NCT03919773
COMPLETED • PHASE1 • Updated 2024-09-19
Conditions: Unspecified / Overlap
AGENTS
IVIG (Intravenous Immunoglobulin)Albumin
The purpose of this trial is to evaluate the symptomatic benefits of immunomodulatory treatment with IVIG for POTS (postural tachycardia syndrome) patients with evidence of autoimmunity.
View on ClinicalTrials.gov →
Immunomodulatory Neurological / Autonomic Phase 1 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
A Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe POTS
NCT03365414
WITHDRAWN • PHASE3 • Updated 2024-09-19
Conditions: Unspecified / Overlap
AGENTS
Albumin (Human) 5%, Usp
POTS is a relatively common condition that affects millions of patients around the globe. It has an estimated prevalence of 170/100,000 with approximately 80% of patients being women of childbearing age. POTS is characterized by an excessive heart rate increase on assuming an upright posture, either standing or even sitting and leading to disabling palpitations, light-headednes...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 3 Enrollment: Actual Sponsor Type: Other
Phenotyping Mitochondrial and Immune Dysfunction in POTS With Targeted Clinical Intervention.
NCT05409651
ACTIVE_NOT_RECRUITING • NA • Updated 2024-08-20
Conditions: Unspecified / Overlap
AGENTS
Time Restricted Eating
The mechanisms underlying POTS are not well understood. Though heterogeneous in nature, patients often present with symptoms that include fatigue, orthostatic lightheadedness and tachycardia, "brain fog", shortness of breath, and sleep disruption. The central mediator that links observations in disease entities similar to POTS is energy use and balance driven by mitochondrial h...
View on ClinicalTrials.gov →
Metabolic Immunomodulatory Mitochondrial Neurological / Autonomic Anti-inflammatory NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Effects of Osteopathic Technique on Autonomic Nervous System Activity
NCT06554834
RECRUITING • NA • Updated 2024-08-16
Conditions: Unspecified / Overlap
AGENTS
Cv4 + RrCv4Eeg/Hrv/Rsa (Electroencephalography, Heart Rate Variability, Respiratory Sinus Arrhythmia) Monitoring Using Infiniti System
Cranial osteopathic manipulation technique for brain and cranial nerve function, known as the fourth ventricle compression (CV4), has been recognized. Rib raising (RR), aimed at reducing rib restriction and conditions associated with sympathetic hypertonia, is also employed. This study aimed to assess, in about 109 healthy individuals, the effects of osteopathic techniques (CV4...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Telerehabilitation for Dysautonomia in Parkinson's Disease
NCT06017232
COMPLETED • NA • Updated 2024-05-23
Conditions: Unspecified / Overlap
AGENTS
Hybrid Telerehabilitation Program
People diagnosed with Parkinson's Disease (PD) exhibit a combination of motor and non-motor symptoms, with the latter posing challenges in terms of identification and management. These non-motor symptoms tend to manifest before the motor symptoms and progressively worsen over time, significantly impacting the symptoms and everyday life activities of those affected. However, the...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Crossover Study of Propranolol vs Ivabradine in POTS
NCT04186286
RECRUITING • PHASE2 • Updated 2024-05-09
Conditions: Unspecified / Overlap
AGENTS
Ivabradine 4-Week CoursePropranolol 4-Week Course
1.0 BACKGROUND Postural tachycardia syndrome (POTS) is a disorder of chronic orthostatic intolerance characterized by symptoms of palpitations, lightheadedness, chest discomfort, shortness of breath, blurred vision, and mental clouding. These symptoms occur during standing and are associated with a marked increase in heart rate (HR) in the absence of hypotension, which typicall...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Single-center Pathophysiological Study of the Role of Inflammation, Changes in the Intestinal Epithelial Barrier and the Intestinal Microbiota in Parkinson's Disease
NCT04652843
TERMINATED • NA • Updated 2024-02-01
Conditions: Unspecified / Overlap
AGENTS
RectosignoidoscopyColoscopy
Converging evidence from the literature suggests that digestive inflammation may play a role in the development of Parkinson's disease (PD). The investigators showed in the laboratory in a pilot study that PD patients have digestive inflammation and that the level of inflammation was inversely related to the length of the disease course. This digestive inflammation could be at ...
View on ClinicalTrials.gov →
Neurological / Autonomic Anti-inflammatory NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Vagus Nerve Stimulation in Treatment of Postural Orthostatic Tachycardia Syndrome
NCT03930914
COMPLETED • NA • Updated 2023-12-18
Conditions: Unspecified / Overlap
AGENTS
Parasym (Tm) Transcutaneous Electrical Nerve Stimulation (Tens) Device
Postural orthostatic tachycardia (POTS) is characterized by abnormalities in the autonomic nervous system in the body. The autonomic nervous system controls and regulates body functions such as heart rate, breathing, digestion, and more. The investigator has shown that patients with POTS have higher cardiovascular and adrenergic activating autoantibodies (AAb), which likely ch...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Increasing Seat Belt Wearing and Decreasing Handheld Phone Use While Driving
NCT05469477
COMPLETED • NA • Updated 2023-10-03
Conditions: Unspecified / Overlap
AGENTS
WoopCustomized Habit TipsRaffle Financial IncentiveShared Pot Financial IncentiveWeekly Sms Support TextWeekly Sms Encouragement
The study team is proposing to conduct a randomized controlled trial to determine the effectiveness of behavioral and financial incentives on phone use while driving and seat belt adherence. Each arm will receive a support text if their app is not collecting data. The behavioral engagement intervention includes persuasive education, mental contrasting with implementation intent...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Very Large (1000+ participants) Enrollment: Actual Sponsor Type: Other
Chemoreflex and Baroreflex Alterations Causing Postural Tachycardia Syndrome With Orthostatic Hyperpnea and Hypocapnia
NCT05923840
UNKNOWN • NA • Updated 2023-06-28
Conditions: Unspecified / Overlap
AGENTS
Chemoreflex TestingBaroreflex TestingOrthostatic Stress Testing
Postural tachycardia syndrome (POTS) is the most common chronic cause of postural lightheadedness, and upright confusion afflicting many Americans, mostly young women. Many POTS patients hyperventilate by increasing their depth of breathing that produces tachycardia, alters blood flow and blood pooling in the body and importantly reduces brain blood flow causing "brain fog". In...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Concentration and Attentional Deficits in POTS and Other Autonomic Neuropathies
NCT03681080
COMPLETED • NA • Updated 2023-06-26
Conditions: Unspecified / Overlap
AGENTS
Leg Crossing
People with POTS, autoimmune autonomic neuropathy (AAN), pure autonomic failure (PAF), SFN and Ehlers Danlos Syndrome (EDS) do not only suffer from orthostatic symptoms such as dizziness, headache, neck pain, blurred vision or (pre-) syncope. They also experience deficits in attention and concentration (more precisely deficits in selective perspective, operating speed, executiv...
View on ClinicalTrials.gov →
Immunomodulatory Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Iron Sucrose in Patients With Iron Deficiency and POTS
NCT04855266
WITHDRAWN • PHASE2 • Updated 2023-06-13
Conditions: Unspecified / Overlap
AGENTS
SucroseTilt Table Test
This study aims to investigate whether the treatment of non-anemic iron deficiency with intravenous iron sucrose will result in decreased symptom reporting and improved cardiovascular indices in patients with Postural Orthostatic Tachycardia syndrome (POTS).
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Enrollment: Actual Sponsor Type: Other
Brainstem and Prematurity
NCT02669056
COMPLETED • NA • Updated 2023-05-16
Conditions: Unspecified / Overlap
AGENTS
5-Ht MeasurementCerebral MriVideo RecordingEegGrowth Curves
Although significant advances in neonatal care have increased survival rates of preterm infants born before 28 weeks gestation, a concomitant decrease in neuro developmental disorders has not been achieved. Cerebral injuries, well documented during the previous years, in preterm babies are particularly deleterious since they occur in a developing brain. They affect both white a...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health
NCT02669212
COMPLETED • NA • Updated 2023-04-18
Conditions: ME/CFS
AGENTS
Cardiopulmonary Exercise Test
Background: Post-Infectious Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (PI-ME/CFS) refers to long-lasting and disabling fatigue or malaise, inability to recover after exercise, and physical and emotional discomfort that may occur after a person has an infection. Researchers want to learn more about its causes. Objective: To learn more about PI-ME/CFS. Eligibility: ...
View on ClinicalTrials.gov →
Metabolic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Nih
Anomalies of Nocturnal Gaz Exchanges in Patients With Down Syndrome
NCT03903666
COMPLETED • NA • Updated 2023-03-02
Conditions: Unspecified / Overlap
AGENTS
Nocturnal Gaz Exchanges Measurement
Recently, retrospective studies have shown that Down Syndrome children have a higher CO2 (carbone dioxide) sleep pressure than the general pediatric population. This increase does not seem to be always related to sleep apnea. The Investigators wish to confirm these results prospectively. The investigators hypothesize that this alveolar hypoventilation may be due to ventilatory ...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Vitamin D Deficiency and Dysautonomia
NCT03032328
COMPLETED • NA • Updated 2023-01-27
Conditions: Unspecified / Overlap
AGENTS
Vitamin D Supplement
In previous work the investigator identified a group of children between the ages of 10-18 years whose diagnostic workup for chronic nausea unexplained by conventional diagnostic tests has unexpectedly revealed underlying cardiovascular instability manifesting as orthostatic intolerance, primary defined as postural orthostatic tachycardia syndrome (POTS) (88%). While this is an...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Breathing Exercises With And Without Aerobic Training In Patients With Postural Orthostatic Tachycardia Syndrome
NCT05404672
COMPLETED • NA • Updated 2023-01-25
Conditions: Unspecified / Overlap
AGENTS
Aerobic TrainingConventional Treatment
Postural orthostatic tachycardia syndrome (POTS) is a chronic, multifactorial syndrome with complex symptoms of orthostatic intolerance. Of the major complaints are breathlessness and exercise intolerance. The aim is to explore the potential impact of a physiotherapy intervention involving education and breathing control on dysfunctional breathing and improving exercise intoler...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome
NCT03674541
COMPLETED • PHASE2 • Updated 2022-11-08
Conditions: ME/CFS
AGENTS
Pyridostigmine Bromide
Myalgic encephalomyelitis/Chronic fatigue syndrome (ME/CFS), otherwise known as Chronic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME), is an under-recognized disorder whose cause is not yet understood. Suggested theories behind the pathophysiology of this condition include autoimmune causes, an inciting viral illness, and a dysfunctional autonomic nervous system caus...
View on ClinicalTrials.gov →
Immunomodulatory Repurposed Neurological / Autonomic Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Electrophysiological Findings in Fibromyalgia Patients
NCT04845737
COMPLETED • NA • Updated 2022-10-13
Conditions: Unspecified / Overlap
AGENTS
Sympathetic Skin Response Measurement
Fibromyalgia Syndrome (FMS); It is a chronic condition characterized by widespread body pain, sleep disturbance, fatigue, impaired cognitive functions, and anxiety (1). FMS; chronic fatigue syndrome, interstitial cystitis, irritable bowel syndrome, temperomandibular joint dysfunction, myofascial pain, functional dyspepsia, restless leg syndrome and posttraumatic stress disorder...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS
NCT03261570
COMPLETED • EARLY_PHASE1 • Updated 2022-09-28
Conditions: Unspecified / Overlap
AGENTS
PyridostigmineDigoxin
Postural tachycardia syndrome (POTS), is the chronic form of orthostatic intolerance associated with excessive upright tachycardia, and occurs predominantly in young females (\>85%). Among its most troubling symptoms are lightheadedness, fatigue, and decreased memory often called "brain fog" by patients. Task-related neurovascular coupling (NVC) links neural activity to an incr...
View on ClinicalTrials.gov →
Neurological / Autonomic EARLY_Phase 1 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Coenzyme Q10 Plus NADH Supplementation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis
NCT03186027
COMPLETED • NA • Updated 2022-09-21
Conditions: ME/CFS
AGENTS
Coenzyme Q10 Plus NadhPhosphoserine Plus Vitamin C
The main aim of the study is to examine the effect of oral CoQ10 plus NADH (Reconnect®) supplementation twice daily for 8-weeks on the changes in fatigue perception, sleep disturbances, autonomic dysfunction and HRQoL assessed by patient-reported outcome measures in CFS/ME.
View on ClinicalTrials.gov →
Mitochondrial Neurological / Autonomic NA Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Phlebotomy and Polycystic Ovary Syndrome
NCT02460445
COMPLETED • NA • Updated 2022-07-27
Conditions: Unspecified / Overlap
AGENTS
PhlebotomyCyproterone Acetate
AIMS To study the effects of the decrease in iron tissue depots after scheduled bloodletting on insulin sensitivity, carbohydrate metabolism, classic and non-classic cardiovascular risk factors in patients with functional hyperandrogenism (polycystic ovary syndrome \& idiopathic hyperandrogenism) on standard treatment with combined oral contraceptives (COC) according to usual c...
View on ClinicalTrials.gov →
Metabolic Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
NCT05454683
UNKNOWN • NA • Updated 2022-07-12
Conditions: ME/CFS
AGENTS
Melatonin Plus ZincIsomaltose And Magnesium Stearate
The aim of the study is to investigate the effects of oral melatonin and zinc supplementation on core features in individuals with ME/CFS
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Industry
Alterations of Attention in POTS Depending on Body Position and Hydration
NCT03253120
COMPLETED • NA • Updated 2022-07-06
Conditions: Unspecified / Overlap
AGENTS
Water
The Postural Tachycardia-Syndrome (POTS) is a form of autonomic dysregulation, typically accompanied by symptoms of orthostatic intolerance (OI). OI is defined by the inability to tolerate the upright position and is improved by lying down. POTS is considered a syndrome that may include a number of several disorders. Symptoms should be persistent for at least 6 months to reach ...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Long-term Effects of Transcutaneous Vagal Nerve Stimulation on Postural Orthostatic Tachycardia Syndrome (POTS)
NCT04632134
UNKNOWN • NA • Updated 2022-06-30
Conditions: Unspecified / Overlap
AGENTS
Transcutaneous Vagal Nerve StimulationHome Daily Transcutaneous Vagal Nerve Stimulation
Postural Orthostatic Tachycardia Syndrome (POTS) is characterized by symptoms of chronic orthostatic intolerance such as fatigue, lightheadedness, dizziness, palpitations and by pronounced tachycardia upon standing. The aims of the present research study are to test whether a daily transcutaneous vagal nerve stimulation (tVNS) performed for 14 consecutive days may improve hear...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Using Telehealth to Improve Outcomes in Veterans at Risk for Suicide
NCT03724370
UNKNOWN • NA • Updated 2022-05-06
Conditions: Unspecified / Overlap
AGENTS
Telehealth Monitoring SystemVha-Srm
Overview. The investigators will randomize 120 Veterans in this 3-site trial over 16 months. Eligible Veterans will include those to be discharged for a hospitalization for suicidal ideation. Baseline data collection and randomization will occur at discharge. The 3 month intervention will have study assessments at 2, 4, 8, and 12 weeks post-discharge. The study's primary outcom...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Fed
Adrenocorticotropic Hormone Stimulation in Postural Orthostatic Tachycardia Syndrome (POTS)
NCT01764711
COMPLETED • NA • Updated 2022-03-31
Conditions: Unspecified / Overlap
AGENTS
Cosyntropin Administration
This study is to determine different chemical levels in the blood during a low salt diet. This study will compare normal volunteers to those with Postural Tachycardia Syndrome (POTS)
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Remote Self-training Program for Patients With Postural Orthostatic Tachycardia Syndrome
NCT04603157
COMPLETED • NA • Updated 2022-03-15
Conditions: Unspecified / Overlap
AGENTS
Hybrid Exercise Training
The purpose of this research is to evaluate if a hybrid semi-supervised remote exercise training program can reduce symptoms and improve quality of life and physical fitness in individuals with postural orthostatic tachycardia syndrome (POTS) and determine if this program is more effective than current standard of care.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Dietary Salt in Postural Tachycardia Syndrome
NCT01547117
COMPLETED • NA • Updated 2022-02-22
Conditions: Unspecified / Overlap
AGENTS
Blood VolumeTotal Blood VolumeExercise Capacity Test - BicyclePosture Study
Patients with POTS may not adequately expand their plasma volume in response to a high-sodium (Na+) diet. Mechanisms involved in the regulation of plasma volume, such as the renin-angiotensin-aldosterone system and renal dopamine, may be impaired in POTS and may respond inappropriately to changes in dietary sodium.The purpose of this study is to determine (1) whether a high die...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Carbidopa for the Treatment of Excessive Blood Pressure Variability
NCT02553265
COMPLETED • PHASE2 • Updated 2022-02-09
Conditions: Unspecified / Overlap
AGENTS
Carbidopa Low-DoseCarbidopa High-Dose
The overall study objectives are to determine whether carbidopa (Lodosyn®) is safe and well tolerated and to assess whether it can inhibit catecholamine-induced paroxysmal hypertension and normalize or reduce the exaggerated blood pressure variability in patients with familial dysautonomia (FD, also called hereditary sensory and autonomic neuropathy type III or Riley-Day syndro...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome
NCT01563107
COMPLETED • NA • Updated 2022-01-25
Conditions: Unspecified / Overlap
AGENTS
Plasma VolumeExercise Capacity Test - BicyclePosture Study
Patients with Postural Tachycardia Syndrome (POTS) may not adequately expand their plasma volume in response to a high sodium diet. Mechanisms involved in the regulation of plasma volume, such as the renin-angiotensin-aldosterone system and renal dopamine (DA), may be impaired in POTS and may respond inappropriately to changes in dietary sodium. The investigators propose that t...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Peripheral Dopamine in Postural Tachycardia Syndrome
NCT00685919
COMPLETED • PHASE2 • Updated 2022-01-24
Conditions: Unspecified / Overlap
AGENTS
Carbidopa
The purpose of the proposed research is to determine how changes in kidney dopamine (DA) activity influence urinary sodium excretion. We will decrease DA activity in the kidney by inhibiting DA synthesis via carbidopa administration. We want to compare findings in normal volunteers and in patients with postural tachycardia syndrome (POTS). We will test the null hypothesis (Ho) ...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Effect of Dietary Sodium Intake on Vascular Endothelium
NCT01550315
COMPLETED • NA • Updated 2022-01-05
Conditions: Unspecified / Overlap
AGENTS
Pulsitile Arterial Tonometry (Pat) ProtocolCalf Blood Flow In Reactive HyperemiaEvaluation Of Forearm-Mediated Dilation
The investigators will test the hypothesis that markers of vascular endothelial dysfunction will be exaggerated acutely with an extreme high sodium diet compared to an extreme low-sodium diet. The investigators will compare patients with postural orthostatic tachycardia (POTS) to healthy control subjects.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Physical Activity as a Complementary Treatment in POTS
NCT04702217
WITHDRAWN • NA • Updated 2021-12-06
Conditions: Unspecified / Overlap
AGENTS
Training Program
Postural orthostatic tachycardia syndrome (POTS) is a disorder of unknown origin characterized by orthostatic intolerance and increased heart rate (HR) of ≥ 30 beats/minute during orthostasis in the absence of orthostatic hypotension. In addition to the orthostatic intolerance and tachycardia, patients with POTS experience several debilitating symptoms including light-headednes...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Enrollment: Actual Sponsor Type: Other
Hemodynamic Effects of Compression in POTS
NCT03484273
COMPLETED • NA • Updated 2021-10-22
Conditions: Unspecified / Overlap
AGENTS
Lifewrap Compression Garment
When an individual with Postural Tachycardia Syndrome (POTS) stands up, their heart rate increases significantly (\>30BPM) and they may experience symptoms such as lightheadedness, dizziness, shortness of breath, nausea and mental confusion. One commonly prescribed treatment for POTS is compression garments. Compression garments squeeze veins to help return blood back to the h...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome
NCT03182725
COMPLETED • PHASE3 • Updated 2021-06-29
Conditions: Unspecified / Overlap
AGENTS
Ivabradine
Postural orthostatic tachycardia syndrome (POTS) occurs in approximately 500,000 Americans, but predominates in women with a 5:1 ratio. Patients with POTS experience debilitating tachycardia upon postural changes such as standing that impairs their quality of life. Tachycardia is clinically defined as a heart rate greater than 100 beats/min; and in POTS patients, the prolonged ...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 3 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Local Vasoconstriction in Postural Tachycardia Syndrome
NCT01210430
COMPLETED • EARLY_PHASE1 • Updated 2021-06-10
Conditions: Unspecified / Overlap
AGENTS
LosartanAscorbic AcidNormal Saline
The investigators study will determine how often blood flow regulation abnormalities and abnormalities of sympathetic regulation produced by nitric oxide, angiotensin-II, and oxidative stress occur in POTS and the mechanism(s) of POTS in individual patients. Specific causes for POTS may vary from patient to patient. Patients will be compared to healthy control subjects. There i...
View on ClinicalTrials.gov →
Neurological / Autonomic EARLY_Phase 1 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Reducing Orthostatic Intolerance With Oral Rehydration in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients
NCT02854683
UNKNOWN • PHASE1 • Updated 2021-06-10
Conditions: ME/CFS
AGENTS
Normal SalineOral Rehydration Solution
We and others have shown that many younger patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) have orthostatic intolerance (OI), i.e., they can't tolerate prolonged standing. OI in ME/CFS is often accompanied by either postural tachycardia syndrome (POTS) in which standing results in an excessive heart rate, and neurally mediated hypotension (NMH) in whic...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 1 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Study of Abnormalities of the Nervous System in the Occurrence of Intradialytic Arterial Hypotension
NCT03990142
COMPLETED • NA • Updated 2021-06-02
Conditions: Unspecified / Overlap
AGENTS
Cutaneous Conductance To Chlorine By Sudoscan
Intradialytic hypotension is a common complication of hemodialysis sessions in patients with chronic renal failure, with an estimated prevalence of 10 to 30%. This hypotensopn is classically defined by a decrease in systolic blood pressure greater than 30 mmHg associated with clinical signs (cramps, abdominal pain, unconsciousness, convulsions). Its repetition is correlated wit...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Temporary Celiac Ganglion Block as a Test Before Celiac Ganglion Resection for Dysautonomia-Related Bowel Dysmotility
NCT04121338
COMPLETED • PHASE1 • Updated 2021-05-19
Conditions: Unspecified / Overlap
AGENTS
Celiac Ganglion BlockLiposomal Bupivacaine
Dysautonomia is malfunction of the autonomic nervous system. It usually results from overactivity of the sympathetic portion and over-secretion of acetylcholine. Symptoms depend on the organ involved by this sympathetic overstimulation. Involvement of the gastrointestinal system results in chronic dysmotility, nausea, vomiting, food intolerance, weight loss and need for feeding...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 1 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Anti-Cholinergic Receptors Antibodies, Autonomic Profile and Dysautonomia Symptoms in PAF, ALS and POTS (DISAUT-AB)
NCT04875949
COMPLETED • NA • Updated 2021-05-06
Conditions: Unspecified / Overlap
AGENTS
Immunoabsorption/Plasmapheresis Procedure
Anti alfa-3 and alfa-7 ganglionic cholinergic receptors (anti-AChRs) antibodies (Abs) plasma removal by plasmapheresis (1,2) acutely improved dysautonomia symptoms in case reports with Pure Autonomic Failure (PAF) (3). We shall assess the prevalence of anti-AChRs Ab and the relationship among Ab titer, cardiovascular autonomic profile and symptoms in neurodegenerative diseases ...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Standing Cognition and Co-morbidities of POTS Evaluation
NCT03602482
COMPLETED • NA • Updated 2021-04-14
Conditions: Unspecified / Overlap
AGENTS
StandingSupine
The purpose of this study is to evaluate cognition in patients with postural tachycardia syndrome (POTS) while lying down and standing and to assess the prevalence of hypermobile Ehlers-Danlos Syndrome in POTS.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome
NCT01607073
COMPLETED • PHASE2 • Updated 2021-04-13
Conditions: Unspecified / Overlap
AGENTS
Verapamil
This study will assess how well the drug verapamil can improve control of seizures and dysautonomia symptoms in children and young adults diagnosed with Dravet syndrome. The safety of verapamil when given with all concomitant medications will also be assessed.
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
The Nutritional Supplement Phosphatidylserine in Patients With Familial Dysautonomia
NCT02276716
COMPLETED • PHASE2 • Updated 2021-02-21
Conditions: Unspecified / Overlap
AGENTS
Phosphatidylserine
Familial dysautonomia (FD) is a devastating hereditary disease in which the development of selective neuronal populations is impaired because of a deficiency of the protein IKAP (Slaugenhaupt, 2002). There is no known cure. Treatments are supportive, often ineffective and around half of all patients die before reaching age 40 (Axelrod et al., 2002). Phosphatidylserine is an FD...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Use of Cast Iron Pots to Improve Maternal Anemia
NCT02341300
TERMINATED • NA • Updated 2020-07-30
Conditions: Unspecified / Overlap
AGENTS
Cast Iron PotAlumnium Pot
Anemia of pregnancy is defined as a hemoglobin concentration of less than 11 g/dL in the first and third trimesters, and less than 10.5 g/dL in the second trimester. The rates of anemia are variable and depend largely on preexisting iron stores and supplementation. Estimates from the World Health Organization report that 35% to 75% of pregnant women in developing countries and ...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Telemedicine Clinical Trial for Cognitive Behavioral Therapy in Familial Dysautonomia
NCT03911063
WITHDRAWN • NA • Updated 2020-04-28
Conditions: Unspecified / Overlap
AGENTS
Cbt SessionsTalking Sessions
This is a single-blind, placebo-controlled, telemedicine clinical trial to assess the efficacy of cognitive behavioral therapy (CBT) in adult patients 18 years and older with familial dysautonomia (FD) and anxiety and/or depression and/or obsessive compulsive or related disorders. The trial will enroll 20 adult patients each with FD who have anxiety and/or depression and/or obs...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Enrollment: Actual Sponsor Type: Other
Gabapentin Treatment of Postural Tachycardia Syndrome (PoTS)
NCT04345432
COMPLETED • NA • Updated 2020-04-14
Conditions: Unspecified / Overlap
AGENTS
Gabapentin
In this pilot study, the investigator will test the usefulness of gabapentin in treating some of the symptoms associated with POTS. Gabapentin is FDA-approved to treat epilepsy and nerve pain and works by reducing excessive activity in the nervous system. This medication has also been shown to be effective in reducing bowel discomfort in patients with irritable bowel syndrome, ...
View on ClinicalTrials.gov →
Repurposed Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer
NCT07675876
NOT_YET_RECRUITING • PHASE1 • Updated 2026-07-01
Conditions: Unspecified / Overlap
AGENTS
Cromolyn Sodium
Brief Summary This prospective, open-label pilot study is designed to evaluate the safety, tolerability, feasibility, and preliminary clinical activity of inhaled cromolyn sodium administered by dry powder inhalation in participants with locally advanced lung cancer. Cromolyn sodium is an FDA-approved mast cell stabilizer with an established safety profile in respiratory dise...
View on ClinicalTrials.gov →
Immunomodulatory Phase 1 Small (<50 participants) Enrollment: Estimated Sponsor Type: Industry
Study Evaluating the Effect of UCB8600 on Mast Cell Activation in the Human Gut
NCT07655375
NOT_YET_RECRUITING • NA • Updated 2026-06-22
Conditions: Unspecified / Overlap
AGENTS
Sample Collection
Study evaluating the effect of UCB8600 on mast cell activation in the human gut: IBS is a disease characterized by abdominal pain and a change in stool. Treatment is limited to an adapted life style, dietary changes and medication to lessen cramps (spasmolytica), all of which have seen limited to no clinical success. Recently, we were able to demonstrate that mast cells play ...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
NCT05652907
TERMINATED • PHASE2 • Updated 2026-04-21
Conditions: Unspecified / Overlap
AGENTS
Fsd201
This study will determine if FSD201 reduces the average daily 24-hour recall pain intensity after 28 and 56 days of treatment in adults with chronic widespread musculoskeletal nociplastic pain.
View on ClinicalTrials.gov →
General Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Industry
Mast Cell Treatment in Post-tick Bite Illness (PTBI)
NCT07526558
NOT_YET_RECRUITING • PHASE2 • Updated 2026-04-13
Conditions: Unspecified / Overlap
AGENTS
KetotifenFexofenadineCromolyn Sodium
This is a Phase II double-blinded study to assess the safety, tolerability, and feasibility of the mast cell stabilizing medications ketotifen and cromolyn compared to participants receiving standard of care treatment with fexofenadine alone in participants who have persistent symptoms of mast cell activation following a documented tick-borne illness (Ehrlichiosis, Rocky Mounta...
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Measuring Nerve Activity in Small Human Intestinal Biopsies in IBS (Irritable Bowel Syndrome)
NCT01912313
RECRUITING • NA • Updated 2026-03-20
Conditions: Unspecified / Overlap
AGENTS
Rectal Biopsies From Ibs Patients Or Healthy Subjects Will Be Taken During Proctoscopy
Rectal biopsies from IBS patients or healthy subjects will be taken. Biopsies will be used for: 1. the isolation of submucosal plexus to perform: 1.1 live nerve recordings and Calcium imaging; 1.2 immunohistochemistry; 1.3 mRNA (Messenger ribonucleic acids) isolation and real time PCR (Polymerase chain reaction); 2. culturing biopsies On the basis of these observations, the ...
View on ClinicalTrials.gov →
Metabolic NA Very Large (1000+ participants) Enrollment: Estimated Sponsor Type: Other
Improved Diagnostics in Food Allergy Study
NCT06097572
UNKNOWN • NA • Updated 2024-03-28
Conditions: Unspecified / Overlap
AGENTS
Intranasal Food ChallengeMast Cell Activation Test
The investigators will conduct low-dose intranasal allergen challenges on children and young people with an indeterminate diagnosis of food allergy to cow's milk or peanut. Blood samples will also be taken, for conventional blood allergy diagnostics (allergy-specific Immunoglobulin E) and mast cell activation test (MAT). The data will be used to determine the diagnostic accurac...
View on ClinicalTrials.gov →
Immunomodulatory NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
The Clinical Impact of the Basophil Activation Test to Diagnose Food Allergy
NCT05309772
UNKNOWN • NA • Updated 2023-09-06
Conditions: Unspecified / Overlap
AGENTS
Basophil Activation TestOral Food Challenge
The BAT Impact study is a prospective multicentre study in the UK using a biomarker-led study design to compare the incidence of adverse events (defined as allergic reactions during oral food challenges) in a randomized-controlled trial. Patients will either follow the standard-of-care (i.e. an oral food challenge in case of equivocal SPT/sIgE) or follow a basophil activation t...
View on ClinicalTrials.gov →
General NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
Masitinib for the Treatment of Severe Mast Cell Activation Syndrome
NCT05449444
UNKNOWN • PHASE2 • Updated 2023-02-06
Conditions: Unspecified / Overlap
AGENTS
Masitinib 4.5 Mg/Kg/DayBest Supportive CareMasitinib 6.0 Mg/Kg/Day
To evaluate the efficacy and safety of two dosing schemes of oral masitinib versus matching placebo in the treatment of patients suffering from severe MCAS with handicap unresponsive to optimal symptomatic treatment.
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Industry
Ocular and Palpebral Manifestations of Mastocytosis (MOOMA)
NCT04978740
COMPLETED • NA • Updated 2022-12-01
Conditions: Unspecified / Overlap
AGENTS
Ophthalmological Examination
Mastocytosis is a rare condition characterized by an accumulation of mast cell cells in one or more organs such as the liver, bone marrow, spleen and intestines. Its prevalence in the general population is 1 in 10,000. This pathology is due to the proliferation of a mast cell clone and the excessive release of inflammatory mediators which lead to abnormal tissue infiltration. ...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Confocal Laser Endomicroscopy, IBS and Stress
NCT02316132
WITHDRAWN • NA • Updated 2022-07-06
Conditions: Unspecified / Overlap
AGENTS
Stress
After standard endomicroscopy with fluorescein to investigate for dysplasia in Barrett's esophagus the endoscope will be forwarded into the 2nd part of the duodenum. Fluorescein is needed for CLE but is not part of the investigation. Initial CLE baseline images will be taken to assure intact mucosa and allow later detailed baseline counts of intraepithelial lymphocytes (IEL) a...
View on ClinicalTrials.gov →
General NA Enrollment: Actual Sponsor Type: Other
Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients
NCT05084872
UNKNOWN • PHASE2 • Updated 2021-10-20
Conditions: Unspecified / Overlap
AGENTS
Hydroxychloroquine
The treatment of systemic mastocytosis has two main axes: * Control of mast cell activation symptoms and * The control of proliferation (accumulation) of mast cells. There is no standard treatment and no treatment has a marketing authorization for the treatment of monoclonal indolent mastocytosis.
View on ClinicalTrials.gov →
General Phase 2 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Tranexamic Acid and Spontaneous Chronic Urticaria
NCT03789422
UNKNOWN • PHASE4 • Updated 2021-04-28
Conditions: Unspecified / Overlap
AGENTS
Association Of Levocetirizine And Tranexamic AcidLevocetirizine Only
Spontaneous chronic urticaria (UCS) is a disease that affects 1% of the general population with a potentially severe impact on quality of life. Most patients respond favorably to long-term antihistamine treatment, but sometimes it is necessary to give a high dose (4 times the formal dose, Berlin consensus 2016). These high doses are often accompanied by side effects requiring c...
View on ClinicalTrials.gov →
General Phase 4 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Intravesical Injection of Dextrose to Improve Lower Urinary Tract Symptoms Caused by Chronic Cystitis
NCT04821882
COMPLETED • NA • Updated 2021-04-05
Conditions: Unspecified / Overlap
AGENTS
Dextrose
The pathogenesis of bladder pain syndrome/interstitial cystitis (BPS/IC) is currently unclear. Scholars have put forward different hypotheses, including the function of the extracellular matrix surface of the glycosaminoglycan (GAG) layer, downregulation of tight junction protein, increased urothelial permeability, mast cell activation, neurogenic inflammation, and psychosomati...
View on ClinicalTrials.gov →
Anti-inflammatory NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Effect of Designated Education Session on Patellofemoral Pain
NCT03784339
COMPLETED • NA • Updated 2020-02-26
Conditions: Unspecified / Overlap
AGENTS
Physiotherapy
Feasibility study: Does a designated education session change levels of catastrophizing, kinesiophobia and pain beliefs in patients with patellofemoral pain? Design: Single site feasibility Study Aim: Aims are to identify if a formal education session (intervention) improves patient outcomes and to assess if it is possible to test the intervention for efficacy in a larger study...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria
NCT01713725
COMPLETED • PHASE2 • Updated 2017-10-24
Conditions: Unspecified / Overlap
AGENTS
Omalizumab
Chronic urticaria can be defined as the occurrence of widespread daily or almost daily wheals for at least 6 weeks, which may be accompanied by angioedema. While the wheals are transient, the resolution of angioedema is slower than wheals and could take up to 72 hours. The natural course of chronic urticaria is self-limited, with spontaneous remissions and occasional relapses. ...
View on ClinicalTrials.gov →
Immunomodulatory Repurposed Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)
NCT01316718
COMPLETED • PHASE4 • Updated 2014-01-17
Conditions: Unspecified / Overlap
AGENTS
Mesalazine
The purpose of the trial is to define the clinical benefit and possible mediators of the benefit of mesalazine in Irritable Bowel Syndrome (IBS) with diarrhoea. The investigators will therefore evaluate symptoms (primarily bowel frequency) and markers reflecting mast cell activation and small bowel tone.
View on ClinicalTrials.gov →
General Phase 4 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Photobiomodulation in Chronic Fatigue Syndrome
NCT07546539
RECRUITING • NA • Updated 2026-06-24
Conditions: ME/CFS
AGENTS
Photobiomodulation
The goal of this clinical trial is to evaluate whether photobiomodulation therapy (low-level laser therapy) can reduce fatigue and improve quality of life in patients with chronic fatigue syndrome (CFS). The study will include adults aged 18-60 years diagnosed with chronic fatigue syndrome. The main questions it aims to answer are: Does photobiomodulation therapy significantl...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
NCT04542161
ACTIVE_NOT_RECRUITING • PHASE2 • Updated 2026-06-22
Conditions: ME/CFS
AGENTS
N-Acetylcysteine (NAC)
Chronic fatigue syndrome/myalgic encephalomyelitis (ME/CFS) is an unexplained multisymptom/multisystem disorder for which there are currently no validated treatments. The present exploratory clinical trial aims to advance our understand of the mechanisms of in situ GSH synthesis control through assessment of the response of brain GSH and plasma markers of oxidative stress to di...
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.
NCT05947136
RECRUITING • NA • Updated 2026-06-11
Conditions: Unspecified / Overlap
AGENTS
Interpretation Of The Results From The Detection VisitExplaining Detection Results And Referrals To The PatientEarly Medical Care Through The Network
This is a prospective, multicentre, phase III, randomised, controlled intervention study. Two groups of patients with equal numbers will be studied and each patient will be allocated to one of the two groups described below by randomisation (ratio 1:1). Each patient will be allocated to one of the two groups described below by randomisation (ratio 1:1). \- PASCA intervention...
View on ClinicalTrials.gov →
General NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
Is Post-exertional Symptom Exacerbation Specific to Patients With Myalgic Encephalomyelitis / Chronic Fatigue Syndrome? A Study Comparing Patients With Myalgic Encephalomyelitis / Chronic Fatigue Syndrome and Patients With Cardiac Diseases Who Underwent an Exercise Test.
NCT07491315
RECRUITING • NA • Updated 2026-06-08
Conditions: ME/CFS
AGENTS
Exercise Test On ErgocycleNear Infrared Spectroscopy
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) is a disease characterized by persistent and unexplained fatigue associated with diffuse pain, sleep disorders, neurocognitive and autonomic symptoms, musculoskeletal manifestations and digestive symptoms. A central feature of this disease is post-exertional symptom exacerbation, also referred to as post-exertional m...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
ME/CFS Brain Fog: Cognitive Rehabilitation Trial
NCT07523113
NOT_YET_RECRUITING • NA • Updated 2026-06-08
Conditions: ME/CFS
AGENTS
Processing Speed TrainingIn-Session Instrumental Activities Of Daily Living TrainingTransfer PackageFollow Up Phone CallsTrans-Auricular Vagus Nerve Stimulation: High IntensityIn-Session Brain Health TrainingReaction Time TrainingTrans-Auricular Vagus Nerve Stimulation: Low Intensity
The purpose of this study is to compare two approaches to cognitive rehabilitation in adults with post-viral cognitive syndrome, which resulted in brain fog. All participants will be screened for eligibility prior to participation. Most of the procedures will take place over a phone call or secure telehealth platform (i.e., Zoom). However, participants will be asked to visit UA...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
NCT03759522
RECRUITING • PHASE1 • Updated 2026-06-02
Conditions: ME/CFS
AGENTS
Dpa-714 Pet/Mri
The primary objective of this study is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET radiopharmaceutical \[F-18\]DPA-714 in individuals with chronic pain and fatigue suspected to be associated with neuroinflammation. The PET tracer \[F-18\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known...
View on ClinicalTrials.gov →
Metabolic Mitochondrial Anti-inflammatory Phase 1 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.
NCT03807973
SUSPENDED • PHASE1 • Updated 2026-06-02
Conditions: ME/CFS
AGENTS
[Zr-89]Oxine-Labeled Leukocytes Pet/Mri
This study will use brain Positron Emission Tomography/ Magnetic Resonance Imaging (PET/MRI) and an investigational radioactive drug called \[Zr-89\]oxine to track the location of white blood cells (also called leukocytes) in the body. PET/MRI will be used to visualize labeled white blood cells and determine if they enter the central nervous system in conditions associated with...
View on ClinicalTrials.gov →
Immunomodulatory Anti-inflammatory Phase 1 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Hyperbaric Oxygen Therapy for Chronic Fatigue Syndrome (CFS)
NCT07621068
NOT_YET_RECRUITING • NA • Updated 2026-06-02
Conditions: ME/CFS
AGENTS
Hyperbaric Oxygen Therapy (HBOT)
This study evaluates the effects of hyperbaric oxygen therapy (HBOT) in patients with mild to moderate CFS/ME. Participants will undergo 60 HBOT sessions over 3 months with a 3-month follow-up, including physical, cognitive, imaging, and laboratory assessments.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other Gov
Low-Dose Naltrexone For ME/CFS: Dose-Finding
NCT07285473
NOT_YET_RECRUITING • PHASE2 • Updated 2026-05-14
Conditions: ME/CFS
AGENTS
Low-Dose Naltrexone (LDN)
This exploratory clinical trial tests low-dose naltrexone (LDN) for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). A remote trial approach is used, with eligibility open to the state of Alabama.
View on ClinicalTrials.gov →
Immunomodulatory Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Functional Neuroimaging to Detect the Neural Signatures of the Unpleasantness of Pain and Effort
NCT06472622
RECRUITING • EARLY_PHASE1 • Updated 2026-05-13
Conditions: ME/CFS
AGENTS
Thermal Pain StimulationPhysical Effort Stimulation
Background: The way the brain processes rewards and punishments may play a role in some disorders of the nervous system. People with chronic overlapping pain conditions (such as myalgic encephalomyelitis/chronic fatigue syndrome \[ME/CFS\]) may have heightened responses to unpleasant, punishing sensations. Some of these conditions may also cause heightened responses to effort;...
View on ClinicalTrials.gov →
General EARLY_Phase 1 Small (<50 participants) Enrollment: Estimated Sponsor Type: Nih
Functional and Affective Effects of a Brief tDCS Intervention in Fibromyalgia and Chronic Fatigue Syndrome
NCT07573709
TERMINATED • NA • Updated 2026-05-07
Conditions: ME/CFS
AGENTS
Transcraneal Direct Current Electric StimulationTranscranial Direct Current Electric Stimulation
Functional and Affective Effects of a brief tDCS Intervention in Fibromyalgia and Chronic Fatigue Syndrome Fibromyalgia (FM) and chronic fatigue syndrome (CFS) are characterized by persistent, multidimensional symptoms arising from complex brain-body interactions that impair functioning and quality of life. Noninvasive neuromodulation techniques such as transcranial direct curr...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Effectiveness and Safety of a Tele-Rehabilitation Program on Fatigue and Related Variables in Chronic Fatigue Syndrome and Post COVID Syndrome
NCT06978582
ACTIVE_NOT_RECRUITING • NA • Updated 2026-04-28
Conditions: Long COVID / PASC / ME/CFS
AGENTS
Mindful And Conscious Movement-Based ExerciseConventional Exercise
This is a randomized, single-blind clinical trial that aims to evaluate the effectiveness of a tele-rehabilitation program based on mindful and conscious movement-based exercise (including adapted yoga, breathing exercises, and body awareness) compared to conventional exercise (low-intensity strength and aerobic training) and usual medical care (control group) over twelve weeks...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments
NCT03844412
COMPLETED • PHASE2 • Updated 2026-03-19
Conditions: ME/CFS
AGENTS
Nortriptyline
Vestibulodynia (VBD) is a complex chronic vulvar pain condition that impairs the psychological, physical, and sexual health of 1 in 6 reproductive aged women in the United States. Here, the investigators plan to conduct a randomized, double-blinded, placebo-controlled clinical trial to 1) compare the efficacy of peripheral (lidocaine/estradiol cream), centrally-targeted (nortri...
View on ClinicalTrials.gov →
General Phase 2 Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Effect of Physical Exercise and Neuromodulation on Pain, Sleep and Fatigue in Patients With Fibromyalgia
NCT07242573
RECRUITING • NA • Updated 2026-02-24
Conditions: ME/CFS
AGENTS
Physical Training ProgramNesa X-SignalConventional Physiotherapy
Fibromyalgia (FMS) is a chronic, multifactorial syndrome characterized by widespread pain, fatigue, and cognitive disturbances. This interventional study evaluates the impact of structured physical training using diagnostic-training devices (Zebris treadmill and Alfa balance platform) and transcutaneous neuromodulation (NESA X-Signal) on pain, sleep quality, and overall health ...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Network
Effects of a Rehabilitation Programme Focused on Energy Management in People With Myalgic Encephalomyelitis / Chronic Fatigue Syndrome
NCT07363655
COMPLETED • NA • Updated 2026-01-28
Conditions: ME/CFS
AGENTS
Intervention Group
The study focuses on rehabilitation nursing care for adults diagnosed with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in a home setting. The objective is to evaluate the effects of an individualised rehabilitation programme, which aims to empower participants to manage their energy effectively, observing the impacts on functionality and fatigue.
View on ClinicalTrials.gov →
Metabolic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
The Effect of Acupuncture Therapy on Cognitive Function in Post-COVID-19 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
NCT07357688
NOT_YET_RECRUITING • NA • Updated 2026-01-22
Conditions: ME/CFS
AGENTS
Acupuncture
Background of study: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a common sequela after SARS-CoV-2 infection(COVID-19). Cognitive dysfunction is one of the most common debilitating symptoms in ME/CFS. Currently, standardized therapy for ME/CFS has not been established. Some treatments, such as cognitive behavioral therapy (CBT) and graded exercise therapy (G...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
OutreAch MediCal Care for HousEbound Patients With Post-COVID-19 Syndrome or ME/CFS of Any Cause (ACCESS)
NCT07352254
RECRUITING • NA • Updated 2026-01-21
Conditions: ME/CFS
AGENTS
Online Visit
The significance of the Post-COVID Syndrome (PCS) has been widely acknowledged. Various efforts are made to find out about the pathomechanisms behind PCS and to establish therapies. One sub-group of PCS-patients, however, is generally excluded from any studies, and that are those who are unable to visit outpatient clinics or hospitals for diagnostic work up or participation in ...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Effects of Yiqi Fuyuan Paste Formula in Chronic Fatigue Syndrome: A Randomized Double-Blind Controlled Clinical Trial.
NCT07320937
ENROLLING_BY_INVITATION • NA • Updated 2026-01-06
Conditions: Unspecified / Overlap
AGENTS
"Yiqi Fuyuan Paste Formula" Test Group
The goal of this clinical trial is to learn if "Yiqi Fuyuan Paste Formula" (a traditional Chinese medicinal paste made from medicinal and edible Chinese medicines and health food like Ginseng Radix et Rhizoma, Astragali Radix et Rhizoma, Codonopsis Radix, Atractylodis Macrocephalae Rhizoma, Poria Cocos, Coicis Semen, Dioscoreae Rhizoma, Nelumbinis Semen, Angelicae Sinensis Radi...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Cardiovascular Analysis of PEM
NCT04740736
COMPLETED • NA • Updated 2025-12-18
Conditions: ME/CFS
AGENTS
Saline Infusion
The purpose of this study is to examine cardiopulmonary function in Chronic Fatigue Syndrome (CFS) patients and determine how it relates to the common symptom of Post-exertional malaise (PEM). Subjects will complete a maximal exercise test on 2 subsequent days. Total blood volume will be measured prior to each exercise test, and patient with hypovolemia on day 1, will be random...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
FMRI Study on DC/TMD Patients
NCT07259902
NOT_YET_RECRUITING • NA • Updated 2025-12-02
Conditions: Unspecified / Overlap
AGENTS
Fmri
Temporomandibular disorders (TMD) are among the most common causes of chronic pain worldwide. It is estimated that about 5-12% of the global population is affected, and some conditions, such as arthritis, may be causative factors. Depending on severity, the joints involved can affect multiple functions of the masticatory system, such as the ability to speak, chew, swallow, limi...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
A 3-day Course for CFS/ME
NCT05236465
RECRUITING • NA • Updated 2025-11-26
Conditions: ME/CFS
AGENTS
A 3-Day CourseWaiting List
Chronic fatigue syndrome/Myalgic encephalomyelitis (CFS/ME) can be a serious and disabling condition with a heavy symptom burden and low function. Work disability is common, and social life dramatically affected. CFS/ME is a challenging health problem as well as a societal problem. In recent years, a doubling of the number of patients with a CFS/ME diagnoses has been reported ...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Compound Ciwujia Granules Treat Chronic Fatigue Syndrome
NCT06245642
COMPLETED • PHASE4 • Updated 2025-09-23
Conditions: ME/CFS
AGENTS
Compound Ciwujia Granules, Guipi Granules
To observe the improvement of Chalder scale score in patients with chronic fatigue syndrome treated by Compound Ciwujia Granules. Improvement =\[(baseline score - post-treatment score)/baseline score\]\*100%
View on ClinicalTrials.gov →
General Phase 4 Large (200-999 participants) Enrollment: Actual Sponsor Type: Industry
Application of Direct Current Transcranial stImulation, Remotely superVised in Chronic fATiguE
NCT05791812
ACTIVE_NOT_RECRUITING • NA • Updated 2025-09-19
Conditions: ME/CFS
AGENTS
Home-Based Transcranial Direct Current Stimulation
It is a one-arm open-label interventional study with transcranial direct current stimulation in an remote home-based setting with the aims to evaluate the feasibility (usability of the device, compliance of patients, usability of the teletherapy), the effectiveness (clinical ratings) and the compatability of this intervention in 20 patients with myalgic encephalomyelitis/chroni...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Retraining of the Amygdala and Insula for the Treatment of Persistent Covid
NCT05956405
COMPLETED • NA • Updated 2025-09-16
Conditions: Unspecified / Overlap
AGENTS
Air + MindfulnessRelaxation Condition
Prolonged COVID, also known as post-COVID or Sar-CoV-2 infection with post-acute sequelae, refers to a set of multi-organ symptoms that persist in patients who have suffered SARS-CoV-2 infection, even after of the acute phase of the disease. Approximately 10% of people experience this set of symptoms after their acute COVID has resolved. Such symptoms may include respiratory pr...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome
NCT01071044
COMPLETED • PHASE4 • Updated 2025-09-09
Conditions: ME/CFS
AGENTS
Lisdexamfetamine Dimesylate
Over the past decade, the Rochester Center for Behavioral Medicine (RCBM) has evaluated many patients with attention deficit hyperactivity disorder (ADHD). A recurrent finding in these patients is a history of unexplained fatigue and musculoskeletal pain. Treatment of these patients in our clinic has revealed that when their underlying ADHD is treated with psychostimulant medi...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 4 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Hydrogen Water Intervention With Heart Rate Variability as an Outcome Biomarker in ME/CFS
NCT07009691
RECRUITING • NA • Updated 2025-06-08
Conditions: ME/CFS
AGENTS
Hydrogen Water Which Is Prepared From An Otc Supplement.
The goal of this clinical trial is to learn if the OTC supplement, hydrogen water, works to treat the fatigue-related symptoms and functional limitations in adults with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). It will also examine if heart rate variability (HRV) can be used to predict who will benefit from the hydrogen water treatment. The main questions it ...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue
NCT00518869
TERMINATED • PHASE2 • Updated 2025-06-04
Conditions: ME/CFS
AGENTS
Pg2
The objective of this study is to evaluate the efficacy and safety of PG2 as a complementary treatment to conventional chemotherapy among NSCLC patients. In reference to previous studies, "Clinical Benefit Response" and "Incidence of Grade III plus VI Neutropenia" will be used as the primary endpoints in this study. Clinical Benefit Response is a metric measurement including ch...
View on ClinicalTrials.gov →
General Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Industry
Research for Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue (CFS/ME)
NCT03773003
RECRUITING • NA • Updated 2025-05-29
Conditions: ME/CFS
AGENTS
Probiotics
Research for Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue Syndrome (CFS/ME) by Lipidomics, Metabolomics, Intestinal and Peritoneal Microbiome Analysis and Exome Analysis and Investigation of a Possible Benefit of Probiotics.
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Creatine Supplementation in Chronic Fatigue Syndrome
NCT02374112
ACTIVE_NOT_RECRUITING • NA • Updated 2025-05-23
Conditions: ME/CFS
AGENTS
Creatine
This study evaluates the effectiveness of medium-term supplementation with creatine to improve clinical outcomes in well-defined adult CFS population. Half of the participants will receive creatine while the other half will receive placebo.
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
NCT06952413
RECRUITING • PHASE2 • Updated 2025-04-30
Conditions: ME/CFS
AGENTS
Rituximab
The efficacy and safety of rituximab on ME/CFS symptoms after administration to patients with myalgic encephalomyelitis/chronic fatigue syndrome will be compared in an exploratory, placebo-controlled, double-blind fashion. In the subsequent secondary evaluation period, subjects who received rituximab in the primary evaluation period will receive placebo, and the timing and dura...
View on ClinicalTrials.gov →
General Phase 2 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue
NCT04141696
COMPLETED • PHASE1 • Updated 2025-04-15
Conditions: ME/CFS
AGENTS
KetamineMidazolam
Background: Many people experience fatigue as a side effect of their illnesses and treatments. There are no medicines to treat fatigue, but a drug called ketamine has reduced fatigue in depressed people. Researchers hope that ketamine, compared to a drug called midazolam, can reduce fatigue in people with illnesses. Objective: To test whether ketamine reduces fatigue in canc...
View on ClinicalTrials.gov →
General Phase 1 Small (<50 participants) Enrollment: Actual Sponsor Type: Nih
Breathing Therapy for Patients in General Practice
NCT06575920
COMPLETED • NA • Updated 2025-04-06
Conditions: Unspecified / Overlap
AGENTS
Breathing Excercizes
Medically unexplained physical symptoms (MUPS) capture conditions characterized by symptoms without corresponding objective findings, such as asthenia, low back pain, fibromyalgia, irritable bowel syndrome, or chronic fatigue syndrome. In order to establish the grounds for a RCT. this pilot study aims to investigate the effectiveness and feasibility of a 5-week breathing retrai...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
NCT04622293
COMPLETED • PHASE4 • Updated 2025-04-06
Conditions: ME/CFS
AGENTS
Solriamfetol Oral Tablet [Sunosi]
This study is an 8-week single center, randomized, double-blind, placebo-controlled, flexible titration trial evaluating the efficacy of solriamfetol in the treatment of fatigue symptoms in adult patients with chronic fatigue syndrome. Subjects will be randomized to a solriamfetol group or placebo group. The investigators will utilize an intent to treat model and impute data. T...
View on ClinicalTrials.gov →
General Phase 4 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
e-COGRAT: A Blended eHealth Intervention for Fatigue Following Acquired Brain Injury
NCT05863897
ENROLLING_BY_INVITATION • NA • Updated 2025-04-03
Conditions: ME/CFS
AGENTS
E-Cograt
Fatigue is a common, persistent consequence of acquired brain injury (ABI). Research into treatments that may alleviate post-ABI fatigue is been limited. Pharmacological treatment (methylphenidate) has shown the greatest scientific effects, but is complicated because the risk of adverse side effects and its potential for abuse. COGRAT, an evidence-based treatment combining cogn...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability
NCT04363606
TERMINATED • NA • Updated 2025-03-25
Conditions: ME/CFS
AGENTS
Blood TestMaximal Effort TestActigraphyNeuromuscular EvaluationStool AnalysisFood Diary
Chronic fatigue is the most common and debilitating symptom in intensive care unit (ICU) survivors. Indeed, it has been widely reported that patients who stayed in ICU for prolonged periods report a feeling of tiredness for months to years after ICU discharge. This symptom seems particularly pronounced in Covid-19 patients and may affect their quality of life by decreasing thei...
View on ClinicalTrials.gov →
Persistence / Antiviral NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone
NCT04313972
TERMINATED • PHASE4 • Updated 2025-03-07
Conditions: Unspecified / Overlap
AGENTS
Low-Dose Naltrexone (LDN)
Interstitial cystitis/painful bladder syndrome (IC/PBS) is a debilitating condition with symptoms of urinary urgency, frequency, nocturia (waking up at night to void), and pain, without evidence of urinary tract infection or other identifiable causes. IC/PBS often coexists with other chronic pain syndromes, such as irritable bowel syndrome, chronic fatigue syndrome, and fibromy...
View on ClinicalTrials.gov →
Immunomodulatory Phase 4 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
NCT06211062
RECRUITING • PHASE2 • Updated 2025-03-04
Conditions: ME/CFS
AGENTS
Floradapt Intensive Gi
This clinical study aims to evaluate the use of i3.1 probiotic in participants who meet the Institute of Medicine (Canadian Consensus Criteria) case definition for ME/CFS and who may or may not be diagnosed with irritable bowel syndrome (IBS). The main questions it aims to answer are: * how effective is the usage of the i3.1 probiotic to reduce gastrointestinal (GI) inflammati...
View on ClinicalTrials.gov →
Anti-inflammatory Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Strength Training Protocol in Fibromyalgia Women
NCT06393790
COMPLETED • NA • Updated 2025-02-13
Conditions: ME/CFS
AGENTS
FmgHg
Physical exercise is an effective tool for the prevention of various chronic diseases. Fibromyalgia (FM) is a common chronic pain condition, in which patients may also experience a variety of other symptoms, including sleep disturbances, fatigue, stiffness, frequent episodes of pain and mental health problems, as well as possible gastrointestinal disorders. Furthermore, accordi...
View on ClinicalTrials.gov →
Immunomodulatory NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
RESTORE ME -- RCT of Oxaloacetate on Improving Fatigue in ME/CFS
NCT05273372
COMPLETED • NA • Updated 2025-02-04
Conditions: ME/CFS
AGENTS
Medical Food - Anhydrous Enol-Oxaloacetate
There is no approved treatment for fatigue in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a condition with as many as 2.5 million people in the US. Initial case studies have shown an improvement in fatigue in ME/CFS with anhydrous enol-oxaloacetate (AEO). This randomized, double blinded, placebo controlled trial will seek to further evaluate the efficacy of AE...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Industry
Effectiveness and Health Benefits of a Nutritional, Chronobiological and Physical Exercise Intervention in Fibromyalgia and Chronic Fatigue Syndrome (SYNCHRONIZE +)
NCT05719493
ACTIVE_NOT_RECRUITING • NA • Updated 2024-12-18
Conditions: ME/CFS
AGENTS
Multicomponent Treatment
Chronic pain, fatigue and insomnia are classical symptoms of Fibromyalgia and Chronic Fatigue Syndrome, affecting seriously life quality. Non-pharmacological multicomponent approach is gaining relevance in Fibromyalgia treatment. However, nutrition and chronobiology are often not approached in-depth despite their potential. Furthermore, programs addressed to Chronic Fatigue Syn...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
RCT of Efficacy and Safety of CP003 on CFS/ME or Post-COVID Fatigue
NCT06739720
NOT_YET_RECRUITING • PHASE2 • Updated 2024-12-18
Conditions: ME/CFS
AGENTS
Lingzhi Capsule
The goal of this clinical trial is to test if a Lingzhi supplement (CP003) helps people with chronic fatigue or post-COVID fatigue feel better. It will also check if the supplement is safe to use. The main questions it aims to answer are: Does the Lingzhi supplement reduce fatigue symptoms? Is it safe to take? How does it affect the body's immune system and inflammation? Rese...
View on ClinicalTrials.gov →
Immunomodulatory Anti-inflammatory Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Effectiveness of Acceptance Commitment Therapy or Micro Breaks in Patients with Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis
NCT05168124
RECRUITING • NA • Updated 2024-12-16
Conditions: ME/CFS
AGENTS
Acceptance Commitment Therapy For Chronic FatigueMicro Breaks In Everyday Life For Chronic Fatigue
Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a distinct disease entity with an estimated prevalence of 0.3-0.7% and more common in women (3:1 ratio). It can be diagnosed according to the Institute of Medicine (IOM) 2015 consensus definition using 3 major criteria and one of 2 minor criteria. Diagnosis requires that the patient have the following three symptom...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Qigong Exercise on Fatigue and Postural Imbalance in Lower Limb Burn Injury
NCT05803824
COMPLETED • NA • Updated 2024-11-19
Conditions: Unspecified / Overlap
AGENTS
Exercise Therapy Program
90 patients who suffer from chronic fatigue syndrome and postural imbalance following Lower Limb Burn Injury. will be selected from outpatient clinic, faculty of physical therapy, Cairo university. Patients will be assigned randomly into 3 groups of equal numbers, group A: (Study group A) will receive Baduanjin Qigong exercise plus selected exercise program. group B:(Study grou...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection
NCT04308278
RECRUITING • PHASE4 • Updated 2024-10-30
Conditions: Unspecified / Overlap
AGENTS
2Lebv® / 2Lxfs®
Worldwide, 95% of adults are infected with Epstein-Barr Virus (EBV). These infections may cause different diseases. In most cases, EBV infection is asymptomatic because of a highly effective host immune response. Some individuals develop infectious mononucleosis (a self-limiting lymphoproliferative disorder in adolescents and young adults that is considered to be the primary in...
View on ClinicalTrials.gov →
Immunomodulatory Phase 4 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Industry
Bright Light Therapy in ME/CFS Patients
NCT06635928
COMPLETED • NA • Updated 2024-10-10
Conditions: ME/CFS
AGENTS
Bright Light Therapy
In this study patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) will receive bright light therapy through portable lamps for 2 weeks. They will either start with this treatment and then go through a wash-out period of two weeks followed by a wait period of two weeks or they will start with the wait period, followed by a wash-out period, followed by the t...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Psychoneuromentalism Disorder: A Medical Condition That Affects People With Psychological Impairments From Health Issues
NCT06235177
NOT_YET_RECRUITING • EARLY_PHASE1 • Updated 2024-08-12
Conditions: ME/CFS
AGENTS
Decompartmentalization FrameworkLiquid Herbal TincturesMental ImageryClinical YogaDietary SupplementsApplied RelaxationPain Relaxation TechniquesComprehensive Theocentric Psychological Assessment
Psychoneuromentalism Disorder is a disorder arising in the mind; that is related to the mental and emotional state of a person. It is the science of mental life. The body has a natural design to heal itself. This is a mental phenomena that cannot be explained, until now. Psychoneuromentalism Disorder is a new condition resulting from behavioral impairments, neurodiversity, and...
View on ClinicalTrials.gov →
General EARLY_Phase 1 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
A Feasibility Study: Assessing Photobiomodulation in Myalgic Encephalomyelitis
NCT06145867
UNKNOWN • NA • Updated 2024-04-29
Conditions: ME/CFS
AGENTS
Photobiomodulation Therapy
There is no cure or approved treatments for ME. Several causes have been implicated in ME, including poor mitochondrial function. Mitochondria are the powerhouse of cells, producing energy. Therefore, loss of mitochondrial function and reduced energy production could be an explanation for the debilitating chronic fatigue that defines ME. The primary site of red light absorptio...
View on ClinicalTrials.gov →
Metabolic Mitochondrial Neurological / Autonomic NA Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
A Complex Intervention for Chronically Fatigued Lymphoma Survivors
NCT05130099
UNKNOWN • NA • Updated 2024-04-08
Conditions: ME/CFS
AGENTS
Interdisciplinary Complex Intervention
The present study is a randomized controlled trial (RCT) with an overall objective to examine the effect of an interdisciplinary complex intervention on the level of fatigue in lymphoma survivors with chronic fatigue. Secondary aims are to examine the effects of the intervention on daily functioning, work status/ability, physical fitness and QoL among the survivors, on QoL of t...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Health Psychological Group Rehabilitation for Patients With Chronic Fatigue Syndrome (ME/CFS)
NCT04151693
RECRUITING • NA • Updated 2024-04-03
Conditions: Unspecified / Overlap
AGENTS
Health Psychological Group Rehabilitation For Patients With Chronic Fatigue Syndrome
Chronic fatigue syndrome (ME/CFS) is a severe medical condition. It is characterized by long term fatique and other persisted symptoms, such as a cognitive disabilities and orthostatic intolerance. Symptoms limit a persons ability to carry out ordinary daily activities. In ICD- 10, disease is known as G93.3, postviral fatigue syndrome. The purpose of this research (doctoral st...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome
NCT01156922
TERMINATED • PHASE2 • Updated 2024-03-04
Conditions: ME/CFS
AGENTS
Rituximab
Based on pilot patient observations, and experience from the prior study KTS-1-2008, the investigators anticipate that severely affected chronic fatigue syndrome patients may benefit from B-cell depletion therapy using Rituximab induction with maintenance treatment. The hypothesis is that at least a subset of chronic fatigue syndrome (CFS) patients have an activated immune sys...
View on ClinicalTrials.gov →
Immunomodulatory Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
The Comeback Study
NCT03691987
COMPLETED • PHASE2 • Updated 2024-02-23
Conditions: ME/CFS
AGENTS
Preprocessed Thawed Donor FmtPreprocessed Thawed Autologous Fmt
This is a single-center stratified (on gender and donor), block randomized, placebo-controlled, parallel group trial with 12-months follow-up of 80 chronic fatigue syndrome/encephalomyelitis (CFS/ME) participants. Participants will be randomized to treatment by preprocessed thawed donor fecal microbiota transplant or preprocessed thawed autologous fecal microbiota transplant. P...
View on ClinicalTrials.gov →
Metabolic Immunomodulatory Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Hydrogen Water Dosing Study for ME/CFS
NCT06227273
UNKNOWN • NA • Updated 2024-01-26
Conditions: ME/CFS
AGENTS
Hydrogen Water
The aim of this 16-week pilot randomized trial is to explore the potential benefit of the OTC supplement hydrogen water, for the symptoms of chronic fatigue syndrome (CFS). Methods: This 16-week home-based trial will compare two groups: (1) low dose hydrogen water (2-3 glasses/day) for all 16 weeks; and (2) low dose followed by high dose hydrogen water (up to 5 glasses/day). Co...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Evaluation of an Integrative Medicine Outpatient Clinical Setting for Post-COVID-19 Patients
NCT05630378
COMPLETED • NA • Updated 2023-12-04
Conditions: Long COVID / PASC
AGENTS
Outpatient Clinic With Multimodal Integrative Medicine And Naturopathy For Post-Covid-19 PatientsWaiting Group
The study aims to identify whether a multimodal integrative naturopathy outpatient clinical concept can improve the symptoms of patients suffering from post-COVID-Syndrome. Main outcome is fatigue. The outpatient clinical programme consists of 11 weeks wherein patients visit the clinic one day per week. The pillars of classical naturopathy are combined with extended naturopathy...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Epigenetics of Post-exertional Malaise in Patients With ME/CFS
NCT04378634
COMPLETED • NA • Updated 2023-11-07
Conditions: ME/CFS
AGENTS
ExerciseMental Stress Test
Exploring epigenetic mechanisms of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) is crucial to understand the mechanisms underlying its pathophysiology. Three potential candidates have been selected (BDNF, COMT, and HDAC genes). DNA methylation in the promoter regions of those genes will be explored. The investigators designed a randomised controlled trial and ...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fog Symptoms in Patients After COVID-19.
NCT06012552
RECRUITING • PHASE2 • Updated 2023-08-25
Conditions: Unspecified / Overlap
AGENTS
Tianeptine
COVID-19 is associated with a high risk of complications from the central nervous system. Syndrome of cognitive disorders- in terms of memory, attention or executive functions among COVID-19 convalescents is often called brain fog (covid fog - CF). CF leads to psychomotor retardation and chronic fatigue syndrome, resulting in poor functioning and low quality of life. CF may aff...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Analysis of Post-exertional Malaise Using a Two-day CPET in People With ME/CFS
NCT04026425
COMPLETED • NA • Updated 2023-07-07
Conditions: ME/CFS
AGENTS
Two-Day Cardiopulmonary Exercise Test
This study aims to collect and identify key outcome measures or disease parameters in ME/CFS that are altered during elevated symptoms relative to baseline by gathering information before and after symptom provocation using a two-day cardiopulmonary exercise test.
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Chronic Fatigue Etiology in Intensive Care Unit Survivors: the Role of Neuromuscular Function
NCT03849326
WITHDRAWN • NA • Updated 2023-04-26
Conditions: ME/CFS
AGENTS
Blood TestMaximal Effort TestActigraphyNeuromuscular Evaluation
Chronic fatigue is the most common and debilitating symptom in intensive care unit (ICU) survivors. Indeed, it has been widely reported that patients who stayed in ICU for prolonged periods report a feeling of tiredness for months to years after ICU discharge. This chronic fatigue affects their quality of life by decreasing their capacity to perform simple tasks of daily life. ...
View on ClinicalTrials.gov →
Persistence / Antiviral NA Enrollment: Actual Sponsor Type: Other
Clinical Trial to Assess the Improvement of Fatigue, Sleep Problems, Anxiety / Depression, Neurovegetatives Alterations and Quality of Life After the Administration of ImmunoVita® in Chronic Fatigue Syndrome Patients
NCT04301609
COMPLETED • NA • Updated 2023-03-15
Conditions: ME/CFS
AGENTS
Active
Chronic Fatigue Syndrome, also known as Myalgic Encephalomyelitis (CFS / MS) is a medical entity characterized mainly by debilitating and prolonged fatigue lasting more than 6 months, post-exertion fatigue (physical and / or mental), non-sleep restorative, cognitive impairment and orthostatic intolerance with prolonged recovery that is not relieved by rest. Currently, the etiop...
View on ClinicalTrials.gov →
Metabolic Immunomodulatory Mitochondrial Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Industry
'Activity Pacing' in PLWH With Fatigue Symptoms.
NCT05194059
COMPLETED • NA • Updated 2023-01-18
Conditions: Unspecified / Overlap
AGENTS
Home-Based Physical Activity
Physical activity helps to improve health and prevent chronic diseases. However, the fatigue usually hampers the training and execution of physical exercises, especially in people with chronic fatigue syndromes (CFCs), such as persons living with HIV (PLWH). We hypothesize that the "activity pacing", i.e. the strategy to optimize daily physical activity into manageable exercise...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Web-based Rehabilitation for Persistent Physical Symptoms.
NCT04532827
UNKNOWN • NA • Updated 2023-01-04
Conditions: ME/CFS
AGENTS
Case Formulation With Web-Program
Persistent physical symptoms (PPS) might diminish studying or workability and daily functioning without a clear medical or environment-related explanation. Psychosocial, patient-involving treatments that support individuals' abilities managing with the PPS and health behaviours have shown promising effects in treating PPS but the acceptability of these treatments among symptoma...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Sodium Oxybate in Patients With Chronic Fatigue Syndrome.
NCT01584934
WITHDRAWN • PHASE4 • Updated 2022-12-15
Conditions: ME/CFS
AGENTS
Sodium Oxybate
Chronic fatigue syndrome (CFS) is a disabling, unexplained disorder characterized by physical and mental exhaustion. Complaints of disturbed and unrefreshing sleep are very common in CFS patients, however, the relationship between (disturbed) sleep quality and fatigue is still not fully elucidated. To evaluate the effect of sodium oxybate on fatigue and to explore the interdepe...
View on ClinicalTrials.gov →
General Phase 4 Enrollment: Actual Sponsor Type: Other
Immune Effects of Low-dose Naltrexone in ME/CFS
NCT02965768
WITHDRAWN • NA • Updated 2022-09-02
Conditions: ME/CFS
AGENTS
Naltrexone Hcl
The main objective of this study is to test if naltrexone, when taken in low doses, has an anti-inflammatory effect that may be associated with positive clinical outcomes in people with chronic fatigue syndrome (CFS). In part, the present study, is a continuation of prior work in which we showed that chronic fatigue symptoms are associated with immune activity, and that low-dos...
View on ClinicalTrials.gov →
Immunomodulatory Anti-inflammatory NA Enrollment: Actual Sponsor Type: Other
Biofeedback and Hydrogen Water as Treatments for Chronic Fatigue Syndrome
NCT05397626
UNKNOWN • PHASE1 • Updated 2022-05-31
Conditions: ME/CFS
AGENTS
Heart Rhythm BiofeedbackHydrogen WaterCombined Treatment: Heart Rhythm Biofeedback Plus Hydrogen Water
The aim of this 10-week pilot study is to explore the potential benefit of two recently developed non-invasive interventions, heart rate variability biofeedback (HRV-BF) and OTC supplement hydrogen water, for the symptoms of chronic fatigue syndrome (CFS). Symptom measures and heart monitoring information will be generated by this study. Given the lack of effective treatments i...
View on ClinicalTrials.gov →
General Phase 1 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)
NCT00478465
COMPLETED • PHASE1 • Updated 2022-05-27
Conditions: ME/CFS
AGENTS
Valganciclovir
The purpose of this study determine whether the drug valganciclovir has a significant and real benefit on the central core of symptoms experienced by patients who have high titers to EBV and HHV-6 and are experiencing long-standing fatigue and cognitive impairment (CFS). In addition, to characterize a quantifiable biological marker in these patients that will facilitate the id...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 1 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Evaluation of the Effects of Treatment With Bioarginin C in Adult Subjects Belonging to the Post-Covid Day Hospital
NCT04947488
UNKNOWN • NA • Updated 2022-05-17
Conditions: ME/CFS
AGENTS
Bioarginina C
Long Covid could be much more frequent than it is thought to be. Few dwell on the great problem represented by the post covid syndrome. The virus often leaves important marks on our body, and those who recover face problems of various kinds: chronic fatigue, shortness of breath, dry cough, headache, cognitive difficulties. On the duration and resolution of this syndrome, now r...
View on ClinicalTrials.gov →
Neurological / Autonomic Anti-inflammatory NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Intestinal Microbiota and Chronic Fatigue Syndrome
NCT04158427
COMPLETED • NA • Updated 2022-04-28
Conditions: ME/CFS
AGENTS
Faecal Transplantation
Gut microbiota of 1) patients with chronic fatigue syndrome and 2) their healthy family members are analyzed. Up to 40 patients with chronic fatigue syndrome are randomized to receive either 1) a faecal transplant from a healthty donor or 2) their own feces via colonoscopy. Patient's health related quality and ability to work are assessed (baseline, 1 and 6 months after the pr...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Reconditioning Exercise for COVID-19 Patients Experiencing Residual sYmptoms
NCT04958161
WITHDRAWN • NA • Updated 2022-02-24
Conditions: Long COVID / PASC
AGENTS
Exercise Therapy
Individuals who had COVID-19 and are thought to have recovered from the disease often experience long-term symptoms such as fatigue, extreme tiredness and shortness of breath, a condition referred to as Long COVID. Previous studies have shown that regular exercise is beneficial for individuals suffering similar symptoms as a result of other diseases such as Chronic Fatigue Synd...
View on ClinicalTrials.gov →
General NA Enrollment: Actual Sponsor Type: Other
Mental Training for CFS Following EBV Infection in Adolescents
NCT02499302
COMPLETED • NA • Updated 2022-02-16
Conditions: ME/CFS
AGENTS
Mental Training
The general aim of this study is to investigate the effect of an individually tailored mental training program in adolescents developing chronic fatigue syndrome (CFS) after an acute Epstein Barr-virus (EBV) infection. Endpoints include physical activity (primary endpoint), symptoms (fatigue, pain, insomnia), cognitive function (executive functions) and markers of disease mecha...
View on ClinicalTrials.gov →
Immunomodulatory Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Chinese Medicine for Patients With LCOVID-19 Symptoms
NCT04924881
UNKNOWN • PHASE2 • Updated 2022-01-28
Conditions: Long COVID / PASC
AGENTS
Covid Rehab Formula Granules
COVID-19 has spread rapidly and now affects all over the world. On 11 March 2020, coronavirus disease 2019 (COVID-19) was declared a global pandemic by the World Health Organization (WHO). Most of the infected people will develop mild to moderate illness, for example fever, cough, tiredness and joint pain etc. For some older people, and those with comorbidities like cardiovasc...
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Effectiveness of VIRTUAL SFCAMINA STUDY
NCT04593225
UNKNOWN • NA • Updated 2021-12-30
Conditions: ME/CFS
AGENTS
Tau + Multicomponent Treatment Virtual SfcaminaTreatment As Usual
The main objective of this study is to analyse the effectiveness of the VIRTUAL SFCAMINA multicomponent treatment program as coadjuvant of treatmentas- usual (TAU) compared to TAU alone. In this Randomized Controlled Trial (RCT), in addition to evaluating the clinical effects of VIRTUAL SFCAMINA treatment in the short- and long term.
View on ClinicalTrials.gov →
General NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
Effect of CoQ10 Plus Selenium Supplementation on Clinical Outcomes and Biochemical Markers in ME/CFS (CoSeME Study)
NCT05128292
COMPLETED • NA • Updated 2021-11-19
Conditions: ME/CFS
AGENTS
Coenzyme Q10 (CoQ10)
In recent years, it has been suggested that nutritional deficiencies may be of causal relevance in individuals with ME/CFS. These include deficiencies of vitamins and trace elements. It is likely that the observed nutritional deficiencies contribute to the core symptoms of the disease. Coenzyme Q10 (CoQ10) has been studied as an alternative and complementary therapy in ME/CFS f...
View on ClinicalTrials.gov →
Metabolic Immunomodulatory Mitochondrial Neurological / Autonomic Anti-inflammatory NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Effect of Probiotics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
NCT04741841
COMPLETED • NA • Updated 2021-10-14
Conditions: ME/CFS
AGENTS
Gutmagnific™ H.Gutmagnific™ L.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a neurological disease. Currently there is no effective treatment for ME/CFS due to unclear etiology of the disease. The aim of this randomized double-blind placebo-control clinical trial is to study the efficacy of the probiotic food supplement "GutMagnific™" in ME/CFS and comorbid gastrointestinal complications. T...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Industry
Treatment of Fibromyalgia With Recovery Factors
NCT04381780
COMPLETED • NA • Updated 2021-10-11
Conditions: ME/CFS
AGENTS
Recovery Factors
Treatment of Fibromyalgia and CFS with Recovery Factors
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
SingStrong: Strong Lungs Through Song - Long COVID-19 Study
NCT04810065
COMPLETED • NA • Updated 2021-09-28
Conditions: Long COVID / PASC
AGENTS
Singstrong: Strong Lungs Through Song
Evidence is emerging that many individuals who recover from Covid-19 are experiencing a range of residual problems. These include fatigue, pain, reduced exercise tolerance and breathing issues. This study includes participants who are experiencing problems with their lungs such as breathing difficulties, shortness of breath, and/or reduced exercise tolerance. The intervention i...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Hydrogen Water Treatment for Chronic Fatigue Syndrome
NCT05013606
COMPLETED • NA • Updated 2021-08-19
Conditions: ME/CFS
AGENTS
Hydrogen Water
The proposed placebo-controlled pilot study will examine hydrogen water as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). 25 subjects who meet strict criteria for ME/CFS will be recruited. The 30 day trial will involve subjects ingesting 1-5 8 oz. glasses of hydrogen-dissolved water per day. The placebo condition will involve the same daily ingesti...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
The Effect of Acupressure on Fatigue in Individuals With Chronic Fatigue Syndrome
NCT04435002
COMPLETED • NA • Updated 2021-08-11
Conditions: ME/CFS
AGENTS
Acupressure
Chronic fatigue syndrome is a common problem in society. The treatment of this problem is limited. Acupressure is a treatment method that has become widespread and promising in recent years. For this purpose, the effect of acupressure treatment on chronic fatigue syndrome was investigated.
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Drug Intervention in Chronic Fatigue Syndrome
NCT00848692
COMPLETED • PHASE2 • Updated 2021-05-11
Conditions: ME/CFS
AGENTS
Rituximab
Based on pilot patient observations,the investigators anticipate that chronic fatigue syndrome (CFS) patients may benefit from B-cell depletion therapy. The hypothesis is that at least a subset of CFS patients have an activated immune system involving B-lymphocytes, and that B-cell depletion may alleviate symptoms.
View on ClinicalTrials.gov →
Immunomodulatory Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study.
NCT02229942
COMPLETED • PHASE3 • Updated 2021-05-11
Conditions: ME/CFS
AGENTS
Rituximab
The hypothesis is that a subgroup of patients with Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME) have a chronically activated immune system and may benefit from B-lymphocyte treatment using the monoclonal anti-CD20 antibody rituximab with induction and maintenance treatment.
View on ClinicalTrials.gov →
Immunomodulatory Phase 3 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS)
NCT02444091
COMPLETED • PHASE2 • Updated 2021-05-11
Conditions: ME/CFS
AGENTS
Cyclophosphamide
Significant clinical improvements of ME/CFS symptoms were observed in two patients with long-standing ME/CFS who received adjuvant chemotherapy including cyclophosphamide for breast cancer, also in one ME/CFS patient who received chemotherapy including iphosphamide for Hodgkin lymphoma. Three pilot ME/CFS patients were thereafter treated with six intravenous infusions four wee...
View on ClinicalTrials.gov →
Immunomodulatory Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Yan Nian Jiu Zhuan Fa Improve Chronic Fatigue Syndromes
NCT03496961
UNKNOWN • NA • Updated 2021-03-17
Conditions: ME/CFS
AGENTS
Yan Nian Jiu Zhuan Fa
This study is to disclose the mechanism of characteristic Tao yin exercises regulate Chronic Fatigue Syndromes based on Brain-Gut Axis.Explore the clinical manifestation of Chronic Fatigue Syndromes, changes of neurotransmitter and central brain function. Then provide some new methods of treating Chronic Fatigue Syndromes.
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE)
NCT02055898
COMPLETED • PHASE4 • Updated 2020-11-18
Conditions: ME/CFS
AGENTS
Sodium Oxybate
The investigators wish to investigate whether enhancement of SWS, which is seen after a drug called sodium oxybate, reduces the impact of sleep disruption in CFS on daytime function, specifically sleepiness and mental performance. This is a safe and well-tolerated drug that is licensed for excessive daytime sleepiness (EDS) and cataplexy associated with narcolepsy. The investi...
View on ClinicalTrials.gov →
General Phase 4 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Treatment of CFS and Fibromyalgia With HRG 80 Red Ginseng
NCT04599348
UNKNOWN • EARLY_PHASE1 • Updated 2020-10-22
Conditions: Unspecified / Overlap
AGENTS
Hrg 80 Red Ginseng
Will a unique form of ginseng be clinically helpful in those with chronic fatigue syndrome and fibromyalgia?
View on ClinicalTrials.gov →
General EARLY_Phase 1 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Treatment of CFS & Fibromyalgia With Recovery Factors
NCT04381793
COMPLETED • NA • Updated 2020-10-19
Conditions: ME/CFS
AGENTS
Recovery Factors
The study will explore if Recovery Factors improve symptoms in fibromyalgia and chronic fatigue syndrome
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Molecular Response to Custom Manual Physiotherapy Treatment of Fibromyalgia & Chronic Fatigue Syndrome (CFS)
NCT04174300
COMPLETED • NA • Updated 2020-08-27
Conditions: ME/CFS
AGENTS
Manual Therapy
Fibromyalgia (FM)and Chronic Fatigue Syndrome (CFS) are complex diseases often presenting overlapping symptomatology. Manual therapy (MT) protocols report benefits for pain treatment of FM, but the underlying mechanisms for patient improvement remain unknown. The main goal of this study is to assess the molecular changes associating to mechanical and additional MT triggers, po...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Rehabilitation of Adolescents Living With Chronic Fatigue
NCT04177459
TERMINATED • NA • Updated 2020-06-25
Conditions: ME/CFS
AGENTS
Health Promoting DialogueStandard Treatment / Treatment As Usual
Previous studies have shown that health-related quality of life (HRQoL) in adolescents living with chronic fatigue syndrome (CFS/ME) is low if compared with healthy adolescents and adolescents living with other chronic diseases. Effective strategies to improve HRQoL in this group are still lacking. Recently we have observed HRQoL in a group of Norwegian adolescents with CFS/ME ...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Survey and Cognitive Behavior Therapy for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis
NCT00920777
COMPLETED • NA • Updated 2020-06-09
Conditions: ME/CFS
AGENTS
Cbt
The purpose of this study is to analyze income variables in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis, and to analyze the effect of short vs. long Cognitive Behaviour Therapy.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome
NCT03613129
COMPLETED • PHASE1 • Updated 2020-05-12
Conditions: ME/CFS
AGENTS
Ct38
This study seeks to investigate the safety, tolerability and efficacy of CT38, an experimental peptide administered by subcutaneous infusion, in the treatment of ME/CFS patients.
View on ClinicalTrials.gov →
General Phase 1 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
A Double Blind Randomised Placebo-controlled Trial to Assess the Role of Iron Repletion in Glucose Homeostasis.
NCT03191201
TERMINATED • PHASE4 • Updated 2020-03-26
Conditions: Unspecified / Overlap
AGENTS
Ferric Carboxymaltose
In this study the investigators aim at addressing potential relationships between iron stores and glucose homeostasis. Iron (i.e. Ferric Carboxymaltose) will be perfused to pre-menopausal, iron-deficient non-anaemic women suffering from a chronic fatigue syndrome and parameters related to glucose homeostasis, parameters related to metabolic syndrome and inflammation will be mea...
View on ClinicalTrials.gov →
Metabolic Anti-inflammatory Phase 4 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Acupuncture for the Sleep Disorder of Chronic Fatigue Syndrome
NCT01534130
COMPLETED • NA • Updated 2020-02-17
Conditions: ME/CFS
AGENTS
Acupuncture
The investigators will conduct acupuncture for participants with chronic fatigue syndrome(CFS). Firstly the investigators aim to figure out the characteristic of sleep structure of CFS and the changes caused by acupuncture. Secondly the investigators seek to investigate the characteristic of sleep-wake rhythm, slow wave sleep(SWS)-rapid eye movement(REM)sleep rhythm, and REM sl...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Efficacy and Safety of Fermented Velvet Antler Extract on Fatigue Recovery After Exercise
NCT01689467
COMPLETED • NA • Updated 2019-08-26
Conditions: ME/CFS
AGENTS
Fermented Velvet Antler Extract
The investigators performed a 12-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Fermented Velvet Antler extract on fatigue recovery after exercise. The investigators measured fatigue recovery parameters , including lactate, ammonia, inorganic phosphorus, creatine kinase and LDH, and monitored their blood pressure.
View on ClinicalTrials.gov →
Metabolic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Exertional Exhaustion in Chronic Fatigue Syndrome
NCT03567811
COMPLETED • NA • Updated 2019-06-20
Conditions: ME/CFS
AGENTS
Submaximal Bicycle Exercise Stress Test On Days 1 And 2
Post-exertional malaise was modeled by having Chronic Fatigue Syndrome (CFS) and sedentary control subjects perform submaximal exercise on 2 consecutive days with objective changes in brain function measured by magnetic resonance imaging (MRI) during cognitive tests before and after the 2 exercise sessions.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process
NCT01650636
COMPLETED • NA • Updated 2018-12-10
Conditions: ME/CFS
AGENTS
Patient-Partner Videotelephone-Delivered Health InformationPatient-Partner Videotelephone-Delivered Cognitive Behavioral Stress Management Intervention
The purpose of this study is to test the effects of a videotelephone-delivered patient-partner dual-focused cognitive behavioral stress management intervention on chronic fatigue syndrome (CFS) symptoms and related psychosocial and neuroimmune processes in patients diagnosed with chronic fatigue syndrome. Study tests the hypothesis that videophone-delivered patient-partner cogn...
View on ClinicalTrials.gov →
Immunomodulatory Neurological / Autonomic NA Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
The Feasibility, Acceptability and Clinical Utility of a New Remote-mobile Technology Intervention (ASARM) for CFS/ME in a Paediatric Population
NCT02082730
COMPLETED • NA • Updated 2018-12-04
Conditions: ME/CFS
AGENTS
Asarm
This study aims to improve on the delivery of treatment for people with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME). People with CFS/ME have low energy. This interferes with doing everyday activities and has a major impact on quality of life. Energy management is a key aspect of treatment and involves patients building up their energy levels gradually. Their hea...
View on ClinicalTrials.gov →
Metabolic Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other Gov
Oral Melatonin Plus Zinc Supplementation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)
NCT03000777
COMPLETED • NA • Updated 2018-08-09
Conditions: ME/CFS
AGENTS
Melatonin Plus Zinc
The purpose of this study is to evaluate the effects of oral melatonin plus zinc supplementation in relieving self-reported fatigue in CFS/ME
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Industry
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects
NCT02955420
COMPLETED • PHASE1 • Updated 2018-07-18
Conditions: Unspecified / Overlap
AGENTS
BC 007 (Aptamer)N-Acetylcysteine (NAC)
Berlin Cures develops BC 007 to treat patients suffering from diseases (chronic heart failure, pulmonary hypertension, chronic fatigue syndrome etc.) which are associated with functional autoantibodies (AAB) directed against G-protein coupled receptors (GPCR). The first part of the study (part A) is designed to evaluate the safety and tolerability of ascending doses of BC 007....
View on ClinicalTrials.gov →
General Phase 1 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Industry
ACT for ME/CFS - an Open Case Trial
NCT03562325
COMPLETED • NA • Updated 2018-06-19
Conditions: ME/CFS
AGENTS
Acceptance And Commitment Therapy
The goal of this research project is to evaluate if our well-researched behavior medicine treatment model for chronic pain, based on Acceptance and Commitment Therapy, is safe and effective in increasing quality of life and functioning also in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). To date there are no effective treatments for ME/CFS as the ethology and pa...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Noradrenergic and Stress-Related Etiologies of Chronic Fatigue Syndrome
NCT03029377
COMPLETED • NA • Updated 2018-04-26
Conditions: ME/CFS
AGENTS
Posture Study, Autonomic Function Tests, And A Stress Test
The objective of this study is to measure sympathetic nervous system function and stress responses in patients with clinically documented and self-reported chronic fatigue that is worsened by stress, compared to healthy controls. Baseline norepinephrine (NE) levels and stress-induced NE levels in patients who fulfill criteria for Chronic Fatigue Syndrome (CFS) and who self-iden...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
New MRT Imaging Biomarkers and Treatment With Kinetic Oscillatory Stimulation (KOS) in Nasal Cavity for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
NCT03502044
UNKNOWN • NA • Updated 2018-04-19
Conditions: ME/CFS
AGENTS
N-Acetylcysteine (NAC)Active Kinetic Oscillation Stimulation
Placebo controlled trial study of efficacy of Kinetic Oscillation Stimulation (KOS) in nasal cavity will be conducted in patients with myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The outcome of the treatment will be assessed with clinical evaluation of patients, cognitive tests, structural and functional MRI of the brain.
View on ClinicalTrials.gov →
Neurological / Autonomic NA Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans
NCT02075489
COMPLETED • NA • Updated 2017-10-10
Conditions: ME/CFS
AGENTS
Acupressure Treatment.Reiki
This study will provide symptomatic veterans with acupressure treatment and determine its effectiveness in fatigue relief and pain management for Gulf War Illness (GWI). Investigators plan to recruit patients reporting symptoms of GWI through the Department of Veterans Affairs (VA), and randomize them into acupressure group (to receive acupressure treatment) and control group (...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Efficacy of Amygdala Retraining With Mindfulness (ART+MF) vs Compassion Therapy (CT) for the Treatment of Patients With Fibromyalgia
NCT02454244
COMPLETED • NA • Updated 2017-08-10
Conditions: Unspecified / Overlap
AGENTS
Art With MindfulnessMindfulness CompassionRelaxation
Amygdala Retraining Treatment (ART) is a new and promising therapy for patients with Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FM), however, randomized controlled trials (RCT) are scarce. The investigators have added mindfulness to this therapy, based on preliminary reports of its efficacy on patients, obtaining Amygdala Retraining Treatment with Mindfulness (ART+MF). O...
View on ClinicalTrials.gov →
Anti-inflammatory NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFS
NCT00598585
COMPLETED • PHASE4 • Updated 2017-06-27
Conditions: ME/CFS
AGENTS
Sildenafil
Use of Viagra to Alter Symptoms in Patients with Chronic Fatigue Syndrome (CFS)
View on ClinicalTrials.gov →
General Phase 4 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Neural Tensioner Exercise on Conditioned Pain Modulation
NCT02816060
COMPLETED • NA • Updated 2017-03-09
Conditions: Unspecified / Overlap
AGENTS
Manual Therapy
Background: There is evidence linking conditioned pain modulation (CPM) deficiency with musculoskeletal pain syndromes such as fibromyalgia, migraine, tension-type headaches and irritable bowel syndrome, as well as with temporomandibular disorders, idiopathic facial pain and chronic fatigue syndrome. Evidence shows that in pre-surgical situations of chronic pain there is no act...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Giardia Induced Fatigue and Functional Gastrointestinal Diseases
NCT00860236
COMPLETED • PHASE4 • Updated 2017-03-03
Conditions: ME/CFS
AGENTS
Cognitive Behavioural Therapy
A giardiasis outbreak in Bergen has given us the opportunity to approach two basic research questions of national and global importance: * Studying the pathoimmunology of giardiasis in a natural setting, and following the genetic and immunological responses leading to recovery or persistent disease and sequelae. * Studying the two disease entities FGID and CFS when induced by ...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 4 Small (<50 participants) Enrollment: Estimated Sponsor Type: Other
Guanidinoacetic Acid Loading for Chronic Fatigue Syndrome
NCT02213679
COMPLETED • NA • Updated 2017-02-01
Conditions: ME/CFS
AGENTS
Guanidinoacetic Acid
Chronic fatigue syndrome (CFS) is a debilitating condition of unknown etiology. Recent studies have shown that CFS is associated with impaired cellular energetics and low levels of phosphocreatine. Since guanidinoacetic acid (GAA) acts as a highly bioavailable precursor of creatine it may provide an ideal dietary supplement to facilitate treatment and perhaps prevention of CFS....
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Autonomic Nervous System and Chronic Fatigue Syndrome
NCT00580619
COMPLETED • PHASE1 • Updated 2017-01-18
Conditions: ME/CFS
AGENTS
Autonomic Function TestingSaline InfusionsL-Nmma TrimethaphanMethyldopa
The investigators propose to test the hypothesis that the sympathetic nervous system contributes to the cardiovascular and inflammatory abnormalities present in the chronic fatigue syndrome (CFS) and, in particular in the subset of patients characterized by postural tachycardia syndrome (POTS). CFS and POTS are seen mostly in otherwise normal young women, and are the cause of s...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 1 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Thunder-Fire Moxibustion Therapy for Chronic Fatigue Syndrome on Shenque Acupoint: a Randomized Controlled Trial
NCT02964533
UNKNOWN • NA • Updated 2016-11-16
Conditions: ME/CFS
AGENTS
Thunder-Fire Moxibustion TherapyCommon Moxa-Stick Moxibustion
Chronic fatigue syndrome is a group of syndrome and is prevalent in adult. Thunder-fire moxibustion is a commentary therapy belonged to acupuncture therapy. To evaluate the effect and safety of thunder-fire moxibustion therapy for chronic fatigue syndrome, we apply a randomized controlled trial by recruiting chronic fatigue syndrome patient as subject, applying thunder-fire mox...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
High-tech Acupuncture for Treatment of Chronic Fatigue Syndrome
NCT02924831
UNKNOWN • PHASE2 • Updated 2016-10-05
Conditions: ME/CFS
AGENTS
AcupunctureMoxibustion
1. To study the relationship between Chronic Fatigue Syndrome (CFS) and heart rate (HR) and its variability (HRV). 2. To compare the curative effects and the HR/HRV indices between applicationa of different acupoints as well as different treatments (acupuncture and moxibustion).
View on ClinicalTrials.gov →
General Phase 2 Large (200-999 participants) Enrollment: Estimated Sponsor Type: Other
A Clinical Study About Improvement of Chronic Fatigue After Taking Red Ginseng
NCT02847845
UNKNOWN • NA • Updated 2016-07-28
Conditions: ME/CFS
AGENTS
Red Ginseng Powder Capsule
The purpose of this study is to verify the efficacy of taking red ginseng for chronic fatigue patient.
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Effect of Ginko and Cistanche Against Fatigue Symptoms
NCT02807649
COMPLETED • NA • Updated 2016-06-21
Conditions: ME/CFS
AGENTS
Experimental: Nutrilite® Low DoseExperimental: Nutrilite® High Dose
To evaluate the efficacy of Nutrilite® ginkgo biloba cistanche tablets in relieving the symptoms of chronic fatigue syndrome(CFS), the investigators randomly recruit189 subjects with CFS, aged 35-60 yrs. The relief of fatigue and improvement of sexual function are evaluated by World Health Organization Quality Of Life Brief (WHOQoL-Bref), Sexual Life Quality Questionnaire (SLQQ...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Industry
Cytokine Inhibition in Chronic Fatigue Syndrome Patients
NCT02108210
COMPLETED • PHASE2 • Updated 2016-05-25
Conditions: ME/CFS
AGENTS
Anakinra
Rationale: Chronic fatigue syndrome (CFS) is a medically unexplained syndrome for which no somatic or pharmacological treatment has been proven effective. Dysfunction of the cytokine network has been suspected to play a role in the pathophysiology of CFS. Although derangements of the cytokine network in CFS are controversial, a major problem is that many studies did not use ade...
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome
NCT00498485
TERMINATED • PHASE4 • Updated 2016-05-19
Conditions: ME/CFS
AGENTS
Sodium Oxybate
Chronic fatigue syndrome is a disabling illness for which there is no specific treatment. As a group, CFS patients have disturbed sleep with frequent arousals and the sense of not having slept upon awakening. Xyrem (Sodium oxybate) is known to improve deep sleep and so may reduce the sleep disturbances of CFS leading to better sleep with less fatigue. Its ability to produce the...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 4 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Biopsychological Intervention in Chronic Fatigue Syndrome - a Pilot Study
NCT02336126
COMPLETED • NA • Updated 2016-04-18
Conditions: ME/CFS
AGENTS
Biopsychological Intervention
This is a pilot study of a biopsychological intervention program for adolescent chronic fatigue syndrome. The program is related to cognitive behavioral therapy, which has been proven beneficial in this disorders, but includes other mental techniques, such as emotional control and metacognitive elaboration. The aim of this pilot study is to explore a) patients' experiences and...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Pacing Activity Self-management for Patients With Chronic Fatigue Syndrome
NCT01512342
COMPLETED • PHASE2 • Updated 2015-12-17
Conditions: ME/CFS
AGENTS
PacingRelaxation Therapy
Given the lack of evidence in support of pacing self-management for patients with chronic fatigue syndrome (CFS), it is examined whether physical behavior and health status of patients with CFS improve in response to a pacing self-management program. The effects of pacing will be compared with those observed when applying relaxation therapy to patients with CFS.
View on ClinicalTrials.gov →
General Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome
NCT01730495
TERMINATED • PHASE2 • Updated 2015-12-02
Conditions: ME/CFS
AGENTS
Etanercept
The hypothesis is that a subset of patients with chronic fatigue syndrome/ myalgic encephalomyelitis (CFS/ME), including also patients with no clinical response after B-cell depletion therapy using the anti-CD20 antibody Rituximab, may benefit from tumor necrosis factor-alpha inhibition using Etanercept as weekly subcutaneous injections.
View on ClinicalTrials.gov →
General Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
A Rehabilitation Program for Adolescents With Chronic Fatigue Syndrome
NCT01806246
COMPLETED • NA • Updated 2015-10-23
Conditions: ME/CFS
AGENTS
Integrative Rehabilitation Program
The aim of the programme is to develop a treatment model for adolescents with Chronic Fatigue Syndrome. The program consists of 4 elements lasting for 12 months, psychoeducation reflecting the current knowledge about the disease, Heart Rate Variability Coherence Biofeedback, pacing and activity planning and some principles of cognitive behaviour therapy. The study is designed a...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome
NCT00375973
COMPLETED • PHASE2 • Updated 2015-08-21
Conditions: ME/CFS
AGENTS
Duloxetine
The purpose of this study is to determine the safety and efficacy of duloxetine compared with placebo for reducing fatigue in patients diagnosed with Chronic Fatigue Syndrome (CFS).
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Exercise and Behavioral Therapy Trial (EBT).
NCT00007748
COMPLETED • PHASE3 • Updated 2015-06-26
Conditions: Unspecified / Overlap
AGENTS
Aerobic ExerciseCognitive Behavioral Therapy
This trial is a study of Gulf War era veterans who have unexplained chronic medical symptoms such as pain, fatigue, and/or cognitive difficulties. The treatments to be studied, cognitive behavior therapy (CBT) and aerobic exercise, have been shown to be effective in alleviating symptoms in individuals with other similar types of illnesses, such as chronic fatigue syndrome and f...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 3 Very Large (1000+ participants) Sponsor Type: Fed
Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder
NCT01471652
WITHDRAWN • PHASE2 • Updated 2015-04-13
Conditions: ME/CFS
AGENTS
Nutraceutical Supplements
The pathogenesis of chronic fatigue syndrome (CFS) is poorly understood and no effective therapy has been developed. Recent studies suggest that a preceding viral infection causes mitochondrial dysfunction of the brain and skeletal muscle of genetically susceptible individuals. There is no specific laboratory test to identify patients with CFS. However, certain clinical manifes...
View on ClinicalTrials.gov →
Metabolic Mitochondrial Phase 2 Enrollment: Actual Sponsor Type: Other
Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS.
NCT02063126
COMPLETED • PHASE2 • Updated 2015-02-19
Conditions: ME/CFS
AGENTS
Coenzyme Q10 (CoQ10)
The main objective is evaluate to safety and efficacy of oral Reconnect ® (food supplementation composed by Coenzyme Q10, NADH, phosphoserine y vitamin C) on the maximum HR during an exercise test in CFS
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
A Computer-Based Intervention for Medically Unexplained Physical Symptoms
NCT00468013
COMPLETED • NA • Updated 2015-02-09
Conditions: ME/CFS
AGENTS
Resilience Building ExercisesJournaling
In this study 60 people with medically unexplained physical symptoms (MUPS) will receive either a 6-session resilience skill building intervention provided fully online or a weekly computerized journaling assignment. Both programs can be completed from home. Participants will complete questionnaires both before and after the intervention and changes in symptoms, mood and satisf...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Sleep Disordered Breathing in Gulf War Illness and the Effect of Nasal CPAP Treatment
NCT00252629
COMPLETED • NA • Updated 2014-12-11
Conditions: ME/CFS
AGENTS
Nasal Cpap Treatment During Sleep
The purpose of this study is to determine any sleep disordered breathing in veterans with Gulf War Syndrome (GWS) and compare it to healthy normal asymptomatic Gulf War veterans. This study will also determine the effect of treatment with continuous positive airway pressure on veterans with Gulf War Syndrome. 1. The investigators hypothesize that sleep complaints (insomnia, un...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Fed
Traditional African Healing Ceremony in a U.S. Population
NCT01873482
COMPLETED • NA • Updated 2014-11-03
Conditions: ME/CFS
AGENTS
Movement To Rhythm
Pre-agricultural societies almost universally used healing ceremonies that involved reverence, rhythm and dance in the presence of a healer. It is believed that we are "wired" for such experiences and they foster an integrative mode of consciousness similar to that of mindfulness based stress reduction, which has been shown to have therapeutic effects in a variety of conditions...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
The Synergy Trial: Methylphenidate Plus a CFS-Specific Nutrient Formula as a Treatment for Chronic Fatigue Syndrome
NCT01966276
UNKNOWN • PHASE2 • Updated 2014-09-25
Conditions: ME/CFS
AGENTS
Methyl-P Plus Nutrient Formula
The Synergy Trial will evaluate the safety and efficacy of a currently available medication (methylphenidate hydrochloride) combined with a CFS-specific dietary supplement (CFS Nutrient Formula) to treat Chronic Fatigue Syndrome (CFS).
View on ClinicalTrials.gov →
General Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Industry
Neuroscience Education on Osteoarthritis
NCT02246088
UNKNOWN • NA • Updated 2014-09-22
Conditions: Unspecified / Overlap
AGENTS
Mt + NeMt + E
Osteoarthritis (OA) is a frequent chronic musculoskeletal pathology that usually causes great disability and significant healthcare costs. Substantial scientific evidence indicates a role for central sensitization in OA pain. Reconceptualization of pain through Neuroscience Education (NE) is an intervention that has already been used successfully in some chronic musculoskeletal...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome
NCT01156909
COMPLETED • PHASE2 • Updated 2014-09-01
Conditions: ME/CFS
AGENTS
Rituximab
Based on pilot patient observations, and experience from the prior study KTS-1-2008, the investigators anticipate that chronic fatigue syndrome patients may benefit from B-cell depletion therapy using Rituximab induction with maintenance treatment. The hypothesis is that at least a subset of CFS patients have an activated immune system involving B-lymphocytes, and that prolong...
View on ClinicalTrials.gov →
Immunomodulatory Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome
NCT00977171
TERMINATED • PHASE2 • Updated 2014-06-09
Conditions: ME/CFS
AGENTS
Droxidopa
A subset of patients suffering from chronic fatigue syndrome exhibit symptoms of neurally mediated hypotension. While the underlying pathophysiology of chronic fatigue syndrome is not precisely understood, a dysfunction of the autonomic nervous system is thought to play a role in this subset of patients. In several small studies, subjects within this subset have noted improveme...
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Industry
Investigator Initiated Clinical Study to Explore the Efficacy and Safety of Human Placenta Hydrolysate in the Chronic Fatigue Patients
NCT01742013
COMPLETED • PHASE3 • Updated 2013-09-26
Conditions: ME/CFS
AGENTS
Gcjbp Laennec Inj.
GCJBP Laennec Injection contains a variety of cytokines derived from human placenta, amino acids, peptides, nucleobases, and carbohydrates. This product is approved for improving liver function. Also, it has been prescribed for lots of diseases such as menopausal disorders, atopic dermatitis, skin cares as well as fatigue for long time. Although its action mechanism and clinica...
View on ClinicalTrials.gov →
General Phase 3 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Clinical Trial to Evaluate the Effectiveness of Acupuncture as a Treatment in Patients Diagnosed With CFS.
NCT01907711
UNKNOWN • PHASE2 • Updated 2013-08-29
Conditions: ME/CFS
AGENTS
Acupuncture.
background: The Chronic Fatigue Syndrome (CFS) presents many disturbances multidimensional affect holistically to people who have the disease and current management of fatigue, pain, anxiety, depression and sleep disturbances present in this clinical entity is unsatisfactory. Hypothesis: The hypothesis of this essay is to contrast that acupuncture is more useful than placebo....
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Efficacy of Web-based Cognitive Behavioural Treatment for Adolescents With Chronic Fatigue Syndrome
NCT00893438
COMPLETED • NA • Updated 2013-05-22
Conditions: ME/CFS
AGENTS
Fitnet Treatment
The aim of this study is to determine the efficacy of FITNET (web-based cognitive behavioural treatment) for adolescents with Chronic Fatigue Syndrome (CFS) in The Netherlands. The second goal of the study is to establish predictors of outcome. It is very important to know the characteristics of patients who will benefit from Cognitive Behavioural Treatment (CBT) and who will n...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome
NCT00215800
COMPLETED • PHASE3 • Updated 2013-04-17
Conditions: ME/CFS
AGENTS
Ampligen
multi-center, double-blind, randomized, placebo-controlled study of the safety and efficacy.
View on ClinicalTrials.gov →
General Phase 3 Large (200-999 participants) Sponsor Type: Industry
Behavioral Insomnia Therapy With Chronic Fatigue Syndrome
NCT00540254
COMPLETED • PHASE1 • Updated 2013-03-01
Conditions: ME/CFS
AGENTS
Cognitive Behavioral Therapy
The purpose of this study is to determine how best to manage the sleep problems of people with Chronic Fatigue Syndrome. This study is being conducted to determine how improvements in sleep affect other Chronic Fatigue symptoms including pain, fatigue, and mood as well as a person's sense of general well-being.
View on ClinicalTrials.gov →
General Phase 1 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Treatment of Chronic Fatigue Syndrome (CFS) With Iodinated Activated Charcoal (IodoCarb®)
NCT01793415
UNKNOWN • PHASE1 • Updated 2013-02-15
Conditions: ME/CFS
AGENTS
Iodocarb
Chronic fatigue syndrome (CFS) is a devastating and complex disorder. People with CFS experience overwhelming fatigue and a host of other symptoms that are not improved by bed rest. Interestingly, many of the symptoms experienced by people with CFS are identical to symptoms caused by long-term low-level exposure to mercury, which is called micromercurialism. This study will ex...
View on ClinicalTrials.gov →
General Phase 1 Small (<50 participants) Enrollment: Estimated Sponsor Type: Industry
The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial
NCT01040429
COMPLETED • PHASE2 • Updated 2012-11-20
Conditions: ME/CFS
AGENTS
ClonidineLactose Capsula
The purpose of this study IS to * explore the underlying pathophysiology of chronic fatigue syndrome (CFS) in adolescents, particularly focusing on genetics, infections/immunology, endocrinology, autonomic control and cognitions * to assess the effect of clonidine (a drug that attenuates sympathetic nervous activity) in adolescent CFS.
View on ClinicalTrials.gov →
Neurological / Autonomic Phase 2 Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain
NCT01417923
UNKNOWN • PHASE4 • Updated 2012-11-06
Conditions: Unspecified / Overlap
AGENTS
Vitamin D
Vitamin D3 is produced in the skin following exposure to UVB light from the sun or artificial sources, and occurs naturally in a small range of foods.More recently, several reports underlined the impact of vitamin D on the prevalence and consequences of inadequate vitamin D intake and the research supporting its benefits for alleviating chronic musculoskeletal pain and fatigue ...
View on ClinicalTrials.gov →
Immunomodulatory Phase 4 Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Fatigue Self-Management in Primary Care
NCT00997451
COMPLETED • NA • Updated 2012-10-01
Conditions: ME/CFS
AGENTS
Cognitive-Behavioral Self-ManagementSymptom Monitoring
This study will evaluate, in a primary care setting, the effectiveness of a brief self-management behavioral treatment in patients with medically unexplained chronic fatigue. The hypothesis will be tested that fatigue self-management will yield improvements in fatigue,functioning, and distress in comparison to the two control conditions: standard medical care alone or standard ...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue Syndrome
NCT01651754
COMPLETED • NA • Updated 2012-07-27
Conditions: ME/CFS
AGENTS
Seasonal Influenza Vaccination
Postcancer fatigue (PCF) is a frequently occurring, severe and invalidating problem, impairing quality of life. Patients with chronic fatigue syndrome (CFS) also suffer from severe fatigue symptoms. Although it is possible to effectively treat CFS, the nature of the underlying physiology remains unclear. The presence of an underlying immunological problem has been suggested as ...
View on ClinicalTrials.gov →
Immunomodulatory NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Acupressure for Post-Treatment Cancer Fatigue
NCT00959998
COMPLETED • PHASE2 • Updated 2012-06-26
Conditions: ME/CFS
AGENTS
Self-Administered Acupressure
Persistent cancer related fatigue (PCRF) is a common symptom experienced by many cancer survivors, which may last for as long as 10 years following treatment. PCRF is currently under diagnosed, with between 20% to \>60% of survivors experiencing this symptom. Currently there are few effective treatment options for these patients. Acupressure offers a potential low-toxicity self...
View on ClinicalTrials.gov →
General Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Other
An Explorative Study on Physiological and Neurophysiological Determinants of Fatigue in Cancer Survivors
NCT01096641
UNKNOWN • NA • Updated 2012-06-22
Conditions: ME/CFS
AGENTS
Immediate CbtDelayed Cbt
Postcancer fatigue is a severe and invalidating problem, impairing quality of life. About 20 to 40% of the patients remain fatigued, at least one year after successful cancer treatment. Fortunately, there is an effective treatment for postcancer fatigue; cognitive behavior therapy. However, no cause for postcancer fatigue has been identified yet. The aim of the study is to iden...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
A Pilot Study of Amygdala Retraining Program in Patients With Chronic Fatigue Syndrome, Chronic Fatigue and Fibromyalgia
NCT01046370
COMPLETED • NA • Updated 2012-05-03
Conditions: ME/CFS
AGENTS
Amygdala Retraining Program
The purpose of this pilot study is to gather preliminary data on the efficacy and feasibility of the Amygdala Retraining Program (ARP), a mind-body practice versus a control (C) on fatigue, quality of life and sleep in patients with Chronic Fatigue Syndrome (CFS), Chronic Fatigue (CF) and Fibromyalgia (FM). CFS, CF and FM are incapacitating disorders characterized by profound ...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Medium (50-199 participants) Enrollment: Actual Sponsor Type: Other
Pilot Study for the NorCAPITAL Trial
NCT01507701
COMPLETED • NA • Updated 2012-01-13
Conditions: ME/CFS
AGENTS
Clonidine
The aim of this pilot study for the NorCAPITAL trial is to investigate the feasibility and safety of the drug clonidine in adolescent chronic fatigue syndrome (CFS). Specifically, the investigators wanted to assess appropriate dosage in relation to a) plasma concentration levels of clonidine, b) orthostatic cardiovascular responses (the pulse and blood pressure responses when r...
View on ClinicalTrials.gov →
General NA Small (<50 participants) Enrollment: Actual Sponsor Type: Other
Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes
NCT01154647
UNKNOWN • NA • Updated 2010-07-01
Conditions: ME/CFS
AGENTS
CitalopramN-Acetylcysteine (NAC)
Both patients with peripheral structural pathologies, like rheumatoid arthritis (RA)-patients, or patients with central sensitivity syndromes (CSS) suffer chronic pain. CSS are characterized by an increased responsiveness of central pain neurons. An impaired endogenous pain inhibition is already demonstrated in CSS. In the present study the investigators want to evaluate the ef...
View on ClinicalTrials.gov →
General NA Medium (50-199 participants) Enrollment: Estimated Sponsor Type: Other
Treatment of Chronic Fatigue Syndrome and Fibromyalgia With D-ribose- a Multicenter Study
NCT01108549
COMPLETED • NA • Updated 2010-04-22
Conditions: ME/CFS
AGENTS
Ribose
To determine whether adding Ribose 5 grams 3 x day would improve quality of life, energy, sleep and cognitive function and decrease pain in patients with CFS and/or fibromyalgia (CFS/FMS).
View on ClinicalTrials.gov →
Metabolic Neurological / Autonomic NA Large (200-999 participants) Enrollment: Actual Sponsor Type: Other
Hyporeactivity and Gulf War Illness
NCT00100412
COMPLETED • NA • Updated 2009-01-21
Conditions: ME/CFS
AGENTS
Graded Dobutamine InfusionsGraded Phenylephrine InjectionsPsychosocial Challenge Involving Socioevaluative Public Speaking
This research project is a follow-up to the prior VA-funded study that found that chronic fatigue reported by many Gulf War veterans may be a symptom of dysfunctional cardiovascular stress response regulation. Specifically, ill veterans had diminished autonomic responses during demanding psychosocial tasks involving high level cognitive processing and emotional stress. There wa...
View on ClinicalTrials.gov →
Neurological / Autonomic NA Sponsor Type: Fed
Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.
NCT04871815
COMPLETED • PHASE2 • Updated 2022-03-09 NEW
Conditions: Long COVID / PASC
AGENTS
Sodium Pyruvate Nasal Spray
There are approximately 12 million Americans with COVID-19 Long Hauler Symptoms, including athletes. The symptoms include hypoxemia (low SaO2), fatigue, coughing/sneezing, dyspnea, trouble breathing, body aches, headaches. This chronic disease is referred to as COVID-19 Long Haulers. 7-10% of COVID-19 long haulers are also at serious risk of developing Pulmonary Fibrosis. Conve...
View on ClinicalTrials.gov →
Anti-inflammatory Phase 2 Small (<50 participants) Enrollment: Actual Sponsor Type: Industry